idiopath
hyperlipidemia
ih
common
condit
miniatur
schnauzer
ms
dog
year
old
affect
dog
moder
sever
fast
hypertriglyceridemia
htg
without
combin
hypercholesterolemia
hchol
sever
htg
pose
increas
risk
develop
sever
condit
eg
pancreat
insulin
resist
recent
studi
human
suggest
ih
associ
lowgrad
inflamm
involv
pathogenesi
diseas
associ
ih
risk
complic
decreas
medic
control
ih
given
biomark
inflamm
investig
ms
ih
aim
studi
evalu
serum
calprotectin
concentr
healthi
ms
ms
ih
ii
ms
ih
respons
dietari
intervent
manag
ih
serum
sampl
collect
clinic
healthi
ms
studi
questionnair
complet
dog
confirm
health
statu
medic
histori
serum
triglycerid
cholesterol
calprotectin
concentr
measur
sampl
pair
serum
sampl
obtain
ih
dog
place
commerci
ultralow
fat
diet
without
addit
lipidlow
medic
statist
analys
perform
use
nonparametr
pair
unpair
group
comparison
fisher
exact
likelihood
ratio
test
statist
signific
set
p
total
dog
isol
htg
hypercholesterolemia
hchol
combin
hyperlipidemia
respect
compar
ms
without
ih
htg
hchol
associ
increas
serum
calprotectin
p
odd
ratio
p
respect
concentr
p
signific
differ
serum
calprotectin
concentr
among
ms
isol
htg
hchol
combin
hyperlipidemia
presenc
sever
htg
decreas
ms
ih
within
week
place
ultralow
fat
diet
p
p
dietari
intervent
also
yield
signific
decreas
serum
cholesterol
p
neither
serum
calprotectin
concentr
chang
significantli
time
p
result
suggest
subclin
inflamm
present
ms
htg
due
ih
ultralow
fat
diet
reduc
concentr
inflammatori
protein
ms
htg
whether
presum
inflammatori
phenotyp
ms
ih
contribut
develop
pancreat
insulin
resist
condit
warrant
research
disclosur
disclosur
report
exocrin
pancreat
insuffici
epi
dog
diagnos
observ
serum
canin
trypsinlik
immunoreact
ctli
affect
dog
sever
fat
malabsorpt
dog
sign
epi
margin
subnorm
serum
ctli
l
respond
enzym
replac
therapi
subclin
epi
sepi
given
clinic
sign
abnorm
serum
cobalamin
folat
absenc
detect
nonenter
diseas
presum
idiopath
chronic
enteropathi
ice
unpublish
preliminari
data
indic
decreas
serum
tocopherol
concentr
dog
epi
resolv
pancreat
enzym
supplement
object
studi
measur
serum
tocopherol
retinol
dog
epi
subclin
epi
ice
sepiic
inclus
criteria
epi
group
n
clinic
sign
epi
serum
ctli
concentr
dog
sepiic
group
n
clinic
sign
ice
serum
ctli
concentr
rang
diet
dog
group
supplement
oral
pancreat
enzym
extract
control
sampl
collect
healthi
dog
day
pancreat
enzym
supplement
sampl
surplu
anoth
studi
approv
institut
ethic
committe
store
prior
assay
tocopherol
retinol
highperform
liquid
chromatographi
dog
epi
sepiic
significantli
lower
serum
concentr
tocopherol
mean
lgml
p
p
respect
retinol
mean
ngml
p
respect
enzymesuppl
control
dog
mean
lgml
ng
ml
respect
neither
tocopherol
retinol
concentr
significantli
differ
epi
sepiic
group
differ
control
dog
enzym
supplement
find
indic
dog
epi
sepiic
rel
defici
tocopherol
retinol
like
reflect
fat
malabsorpt
may
share
similar
enteropathi
may
preced
onset
epi
clinic
signific
decreas
fat
solubl
vitamin
concentr
unknown
though
retinol
shown
influenc
enter
mucos
immun
respons
though
effect
tcell
differenti
iga
secret
galt
home
innat
lymphoid
cell
gut
tocopherol
import
antioxid
studi
reveal
increas
reactiv
oxygen
speci
intestin
biopsi
human
ibd
clinic
trial
assess
valu
tocopherol
retinol
supplement
dog
epi
ice
warrant
disclosur
disclosur
report
david
william
consult
idexx
laboratori
gi
laboratori
texa
univers
involv
collabor
research
studi
nestlepurina
member
nestlepurina
advisori
board
escg
effect
mirtazapin
canin
gastric
empti
assess
acet
breath
test
n
schleifenbaum
salavati
r
neiger
small
anim
clinic
justusliebigunivers
giessen
giessen
germani
royal
dick
school
veterinari
studi
r
univers
edinburgh
edinburgh
uk
delay
gastric
empti
suspect
occur
sever
common
condit
dog
exampl
metabol
endocrin
disord
inflammatori
bowel
diseas
also
sequela
critic
care
patient
suffer
sepsi
periton
pancreat
treat
underli
caus
indic
addit
support
treatment
form
prokinet
drug
scarc
especi
receptor
agonist
wide
avail
antidepress
mirtazapin
routin
use
low
dosag
appetit
stimul
properti
small
anim
report
acceler
gastric
empti
peopl
high
dosag
experiment
healthi
dog
effect
mirtazapin
gastric
empti
time
use
noninvas
test
assess
henc
assess
effect
differ
dosag
drug
gastric
half
empti
time
healthi
dog
use
csabt
sought
six
healthi
beagl
dog
year
kg
bodi
weight
includ
mirtazapin
use
increas
dosag
mgkg
mlo
mgkg
mme
mgkg
mhi
initi
mlo
placebo
prucaloprid
mgkg
posit
control
administ
oral
crossov
design
subsequ
mme
mhi
administ
compar
second
third
placebo
treatment
approach
chosen
enabl
interim
analysi
data
ethic
approv
allow
progress
higher
mirtazapin
dose
effect
seen
lower
one
day
treatment
test
meal
consist
dog
half
daili
calori
requir
mg
csodium
acet
fed
overnight
fast
csabt
perform
breath
sampl
obtain
facial
mask
min
min
test
meal
ingest
co
co
ratio
breath
measur
nondispers
infrar
spectroscopi
deltaov
baselin
dob
valu
plot
time
calcul
treatment
base
cumul
nonlinear
curv
fit
dob
valu
median
min
rang
mlo
mmed
min
rang
mhi
median
prucaloprid
placebo
min
min
respect
mlo
p
mmed
p
effect
compar
placebo
unexpectedli
mhi
prolong
gastric
empti
p
significantli
differ
prucaloprid
placebo
p
conclus
mirtazapin
acceler
healthi
dog
high
dosag
might
prolong
gastric
empti
even
though
borderlin
signific
disclosur
disclosur
report
clostridium
difficil
cd
common
caus
hospitalacquir
diarrhea
human
associ
diarrhea
dog
salmonellosi
major
zoonot
diseas
transmiss
pathway
unclear
thu
import
evalu
risk
factor
increas
likelihood
infect
canin
parvoviru
cpv
preval
fatal
caus
canin
enter
often
exacerb
concurr
infect
enteropathogen
persist
isol
salmonella
spp
hospit
environment
survey
isol
ward
prompt
investig
studi
design
determin
compar
preval
cd
salmonella
spp
dog
cpv
healthi
dog
studi
approv
ethic
committe
univers
pretoria
conduct
octob
march
fresh
fecal
sampl
collect
dog
age
week
month
diagnos
admit
cpv
infect
healthi
dog
present
vaccin
routin
hospit
procedur
cpv
shed
confirm
use
neg
stain
electron
microscopi
cd
detect
via
commerci
fecal
antigen
enzym
immunoassay
glutam
dehydrogenas
gdh
tcda
tcdb
addit
fece
submit
isol
antimicrobi
suscept
serotyp
salmonella
spp
seventyf
dog
cpv
healthi
dog
compris
studi
preval
cd
cpv
healthi
dog
respect
wherea
preval
salmonella
spp
cpv
healthi
dog
respect
statist
signific
associ
salmonella
infect
statu
possibl
risk
factor
continu
variabl
age
weight
length
hospit
identifi
statist
analysi
perform
cd
posit
anim
two
anim
either
group
test
posit
moreov
salmonella
spp
isol
n
resist
penicillin
g
lincomycin
tylosin
nine
isol
resist
lincospectin
show
intermedi
n
complet
resist
n
doxycyclineoxytetracyclin
nine
differ
serotyp
salmonella
spp
identifi
conclus
preval
salmonella
spp
dog
cpv
infect
statist
differ
healthi
cohort
howev
preval
group
consider
higher
previous
report
yet
similar
report
shelter
dog
dog
fed
raw
diet
first
report
preval
cd
salmonella
spp
dog
south
africa
disclosur
disclosur
report
clostridium
difficil
common
caus
antimicrobi
hospitalassoci
diarrhea
human
sever
risk
factor
identifi
develop
communityassoci
c
difficil
infect
human
inform
preval
strain
type
risk
factor
c
difficil
carriag
dog
scarc
prospect
studi
aim
quantifi
preval
strain
type
c
difficil
dog
without
diarrhea
present
small
anim
teach
hospit
identifi
risk
factor
c
difficil
carriag
retrospect
analysi
clinic
histori
stool
sampl
collect
dog
within
h
admiss
hospit
includ
dog
present
investig
diarrhea
dog
present
reason
diarrhea
time
sampl
dog
present
reason
unrel
diarrhea
found
acut
diarrhea
move
diarrheal
cohort
preval
c
difficil
carriag
dog
diarrheal
cohort
ci
sampl
cultur
posit
nondiarrh
cohort
ci
sampl
cultur
posit
dog
present
chronic
diarrhea
preval
c
difficil
carriag
ci
sampl
cultur
posit
dog
acut
diarrhea
preval
ci
sampl
cultur
posit
number
ribotyp
detect
predomin
type
identifi
pcr
test
ribotyp
carri
detect
alpha
beta
toxin
associ
clinic
diseas
epidemiolog
risk
factor
assess
includ
associ
dog
household
environ
includ
number
pet
presenc
elderli
peopl
infant
individu
anim
inform
includ
age
gender
neuter
statu
clinic
inform
medic
treatment
includ
antibiot
administr
visit
veterinari
practic
previou
three
month
type
studi
power
provid
evidencebas
data
support
clinic
decis
make
evalu
signific
detect
c
difficil
fecal
sampl
dog
acut
chronic
diarrhea
also
inform
whether
dog
carri
similar
differ
ribotyp
c
difficil
human
potenti
signific
reservoir
human
infect
disclosur
disclosur
report
intestin
microbiota
thought
play
major
role
pathogenesi
intestin
diseas
antibiot
commonli
employ
treatment
acut
chronic
enteropathi
case
goal
erad
specif
pathogen
aim
studi
prospect
evalu
impact
tylosin
administr
specif
bacteri
compon
fecal
microbiota
sixteen
healthi
pet
dog
randomli
assign
one
two
group
doubleblind
fashion
dog
given
oral
tylosin
mgkg
dog
administ
placebo
capsul
given
hr
day
dog
maintain
usual
diet
standard
fecal
score
rang
note
daili
drug
administr
fecal
sampl
collect
day
prior
drug
administr
well
day
fecal
sampl
assess
use
quantit
pcr
bacteri
taxa
belong
firmicut
proteobacteria
fusobacteria
phyla
rel
abund
clostridium
perfringen
also
assess
pre
posttreat
via
qpcr
paramet
compar
use
friedman
test
follow
dunn
posttest
pvalu
consid
statist
signific
none
dog
either
group
develop
diarrhea
though
signific
chang
seen
abund
variou
bacteri
taxa
significantli
decreas
faecalibacterium
clostridium
hiranoni
turicibact
fusobacterium
observ
fecal
microbiota
dog
treat
tylosin
day
month
posttylosin
cessat
dog
fail
regain
pretreat
faecalibacterium
c
hiranoni
level
respect
tylosin
administr
associ
signific
decreas
c
perfringen
p
dog
placebo
group
signific
decreas
c
perfringen
p
signific
chang
rel
abund
e
coli
dog
treat
tylosin
p
placebo
p
tylosin
lead
alter
fecal
microbiota
without
predict
effect
potenti
enter
pathobiont
studi
warrant
determin
longterm
effect
antimicrobialinduc
chang
well
efficaci
recommend
therapi
bacteri
enter
disclosur
disclosur
report
author
employ
texa
gi
lab
offer
test
fee
basi
studi
fund
grant
compar
gastroenterolog
societi
nanibouj
research
legaci
previous
shown
dog
protein
lose
enteropathi
significantli
lower
concentr
major
vitamin
metabolit
hydroxyvitamin
oh
furthermor
shown
serum
oh
concentr
neg
correl
extent
inflamm
dog
chronic
enteropathi
ce
addit
low
vitamin
statu
found
neg
prognost
marker
dog
ce
vitamin
influenc
cellular
function
signal
vitamin
receptor
vdr
despit
grow
awar
potenti
impact
gastrointestin
diseas
vitamin
metabol
dog
littl
known
site
vdr
express
whether
intestin
inflamm
influenc
vdr
express
aim
studi
defin
nonskelet
tissu
express
vdr
dog
investig
extent
inflamm
correl
vdr
express
small
intestin
twelv
nonskelet
tissu
collect
prospect
dog
euthan
nonhealth
relat
problem
includ
stomach
duodenum
ileum
colon
skin
kidney
spleen
liver
mesenter
lymph
node
heart
lung
vdr
express
assess
immunohistochemistri
use
rat
igg
vdr
monoclon
antibodi
thirti
five
dog
diagnos
chronic
enteropathi
prospect
enrol
biopsi
taken
endoscopi
duodenum
evalu
vdr
express
immunohistochemistri
quantit
polymeras
chain
reaction
qpcr
twenti
three
control
dog
also
prospect
enrol
without
clinic
sign
gastrointestin
diseas
vdr
found
highli
express
duodenum
control
dog
also
found
skin
dog
major
kidney
sampl
occasion
spleen
ileum
statist
differ
rel
express
qpcr
vdr
dog
chronic
enteropathi
dog
clinic
affect
vdr
express
also
differ
healthi
ce
dog
assess
protein
express
via
immunohistochemistri
score
studi
defin
tissu
express
vdr
healthi
dog
lack
regul
vdr
express
intestin
inflamm
contrast
human
provid
support
futur
studi
aim
investig
whether
vitamin
analogu
use
modul
intestin
inflamm
dog
disclosur
disclosur
report
aim
current
studi
evalu
express
select
serum
circul
canin
lymphocyticplasmacyt
lp
ibd
base
publish
data
human
ibd
serum
sampl
collect
dog
diagnos
activ
lp
ibd
dog
undergon
upper
andor
lower
gi
endoscopi
accord
clinic
sign
diagnos
histopatholog
accord
guidelin
wsava
intern
gastrointestin
standard
group
washabau
et
al
clinic
exclus
diagnosi
addit
serum
sampl
avail
clinic
healthi
control
dog
comparison
total
rna
serum
isol
use
trizol
revers
transcrib
cdna
express
serum
mir
gene
measur
use
realtim
quantit
revers
transcriptas
polymeras
chain
reaction
realtim
qrtpcr
clinic
diseas
activ
record
dog
use
canin
chronic
enteropathi
clinic
activ
index
ccecai
allenspach
et
al
endoscopi
perform
grade
accord
canin
ibd
endoscop
index
slovak
et
al
compar
healthi
control
significantli
increas
express
follow
mir
serum
dog
ibd
median
rang
p
control
median
rang
ibd
median
rang
control
median
rang
p
ibd
median
rang
control
median
rang
p
ibd
median
rang
control
median
rang
p
ibd
median
rang
p
control
median
rang
p
well
significantli
decreas
express
ibd
median
rang
p
control
median
rang
p
ibd
median
rang
p
control
median
rang
p
ibd
median
rang
p
control
median
rang
p
studi
show
circul
mir
differenti
express
serum
dog
lp
ibd
versu
healthi
dog
studi
need
evalu
use
marker
diagnosi
treatment
canin
ibd
disclosur
disclosur
report
mucos
e
coli
harbor
expec
virul
gene
may
drive
inflamm
small
intestin
dog
lymphoplasmacyt
ibd
contribut
sever
clinic
present
comprehens
investig
virul
gene
ecoli
strain
dog
diagnos
ibd
perform
use
multiplex
pcr
target
gene
typic
human
ibdassoci
adher
invas
e
coli
group
gene
eaeh
fimh
rata
fepc
usp
colv
dsba
gene
typic
associ
expec
group
gene
cvac
omptp
hlyf
etab
iss
aerj
erea
papc
johnson
tj
jmicrobiol
cohort
german
shepherd
dog
gsd
nongsd
diagnos
lymphoplasmacyt
ibd
basi
clinic
sign
intestin
histopatholog
exclus
known
caus
chronic
gastrointestin
sign
enrol
e
coli
cultur
endoscop
collect
biopsi
use
macconkey
sheep
blood
agar
identifi
use
biom
erieux
statist
analysi
perform
use
univari
linear
mix
effect
model
fisher
exact
test
continu
categor
variabl
respect
follow
depend
variabl
consid
clinic
activ
diseas
ccecai
allenspach
k
ii
histolog
sever
score
wsava
index
day
iii
use
immunosuppress
agent
iv
euthanasia
due
intract
ibd
surviv
within
year
diagnosi
result
reveal
none
test
virul
factor
significantli
associ
ccecai
index
howev
one
virul
factor
group
colv
colicin
v
antimicrobi
peptid
p
signific
effect
wsava
index
two
virul
gene
typic
associ
expec
group
omptp
inactiv
antimicrobi
cvac
secret
toxin
result
cytolysi
significantli
associ
euthanasia
due
intract
ibd
omptp
cvac
p
well
increas
likelihood
treat
immunosuppress
p
data
reminisc
report
human
ulcer
coliti
case
harbor
mucos
e
coli
multipl
expec
virul
factor
associ
clinic
sever
similarli
data
indic
specif
microbi
factor
may
import
determin
predictor
diseas
progress
surviv
subgroup
dog
ibd
disclosur
disclosur
report
chronic
pancreat
cp
common
english
cocker
spaniel
ec
character
histolog
duct
destruct
interlobular
fibrosi
dens
periductular
periven
lymphocyt
aggreg
chang
characterist
human
autoimmun
pancreat
type
part
steroidrespons
multiorgan
syndrom
newli
recogn
diseas
human
affect
one
sever
organ
often
show
predomin
plasma
cell
histolog
igg
plasma
cell
ratio
studi
investig
whether
ecss
cp
inflammatori
diseas
sever
organ
show
increas
plasma
cell
within
affect
tissu
histolog
section
pancrea
n
liver
n
kidney
n
salivari
gland
n
anal
sac
n
conjunctiva
n
obtain
ecss
idiopath
chronic
inflammatori
diseas
affect
tissu
control
sampl
identifi
agematch
dog
breed
chronic
pancreat
n
chronic
idiopath
hepat
n
chronic
nephriti
n
anal
saccul
n
chronic
sialaden
n
chronic
conjunct
n
eleven
ecss
control
dog
present
diseas
one
organ
immunohistochemistri
perform
canin
total
igg
igg
subclass
normal
tissu
section
label
control
number
plasma
cell
count
three
high
power
field
number
cell
percentag
total
igg
plasma
cell
compar
group
use
mannwhitney
u
test
nineteen
section
ecss
section
control
show
elev
number
plasma
cell
igg
ratio
individu
dog
ecss
breed
show
mark
increas
cell
signific
differ
number
plasma
cell
ecss
control
affect
pancrea
liver
anal
sac
salivari
gland
conjunctiva
anal
sac
show
high
number
total
igg
plasma
cell
kidney
section
cell
case
control
organ
dog
breed
significantli
plasma
cell
affect
kidney
conclus
sever
ecss
dog
breed
fulfil
histolog
criteria
diagnosi
support
exist
multiorgan
immunemedi
diseas
ec
dog
strict
inclus
criteria
control
multiorgan
inflammatori
diseas
like
select
dog
breed
anal
saccul
show
histolog
chang
suggest
immunemedi
etiolog
futur
studi
focu
immunolog
treatment
diseas
disclosur
disclosur
report
studi
financi
support
kennel
club
chari
diagnosi
canin
inflammatori
bowel
diseas
ibd
requir
confirm
histopatholog
inflamm
intestin
biopsi
differ
studi
found
difficult
correl
histopatholog
find
clinic
diseas
sever
due
lack
consist
pathologist
describ
histopatholog
chang
question
qualiti
specimen
submit
diagnost
evalu
wsava
gi
standard
grade
scheme
day
attempt
rectifi
problem
even
associ
poor
agreement
among
pathologist
aim
present
studi
util
new
grade
scheme
improv
consist
evalu
gi
histopatholog
find
correl
featur
clinic
diseas
activ
dog
ibd
paraffinembed
tissu
stomach
duodenum
ileum
colon
healthi
dog
ibd
dog
evalu
histopatholog
lesion
use
simplifi
model
defin
gi
inflamm
jergen
morphologicinflammatori
featur
independ
score
pathologist
total
lesion
score
gi
organ
subscor
within
organ
clinic
diseas
activ
calcul
use
ccecaicibdai
score
pearson
correl
coeffici
use
evalu
associ
clinic
histopatholog
score
estim
correl
ccecaicibdai
total
histolog
score
found
signific
p
duodenum
r
ci
colon
r
ci
correl
borderlin
signific
ileum
p
r
ci
nonsignific
stomach
p
r
ci
evalu
relationship
histopatholog
subscor
diseas
activ
correl
signific
crypt
dilat
p
r
ii
lp
macrophag
p
r
iii
lp
neutrophil
p
r
iv
mucos
fibrosi
p
r
v
surfac
epithelium
p
r
vi
villu
stunt
p
r
correl
ccecaicibdai
colon
goblet
cell
intraepitheli
lymphocyt
lp
eosinophil
lp
lymphocyt
lacteal
dilat
nonsignific
agreement
pathologist
total
histolog
score
subscor
mucos
fibrosi
villu
stunt
differ
significantli
p
conclus
simplifi
model
gi
inflamm
show
util
correl
histolog
featur
clinic
diseas
activ
gastric
biopsi
would
appear
less
clinic
use
versu
duoden
colon
biopsi
defin
intestin
inflamm
canin
ibd
disclosur
disclosur
report
strictur
result
recent
anesthesia
case
caus
includ
foreign
bodi
toxic
ingest
acut
vomit
one
benign
neoplasia
clinic
sign
report
owner
regurgit
vomit
dysphagia
dysorexia
anorexia
ptyalism
cough
median
durat
clinic
sign
prior
endoscopi
day
thirtytwo
strictur
identifi
initi
esophagoscopi
seventeen
anim
one
strictur
six
two
strictur
one
three
strictur
seven
strictur
locat
within
cervic
esophagu
midesophagu
distal
esophagu
median
strictur
diamet
mm
annular
strictur
observ
stenosi
balloon
dilat
procedur
perform
anim
use
dilat
inflat
diamet
mm
median
number
dilat
clinic
improv
note
case
perfor
esophagu
complic
stent
consid
anim
boston
ultraflex
half
cover
stent
case
symphoni
nitinol
uncov
stent
case
stent
placement
consid
last
refractori
case
firstlin
treatment
case
clinic
improv
observ
case
complic
includ
discomfort
stent
migrat
longterm
follow
avail
anim
median
surviv
time
day
limit
number
case
preclud
statist
analysi
determin
best
treatment
option
author
opinion
balloon
dilat
remain
good
firstlin
therapeut
modal
esophag
stent
appear
safe
effect
refractori
case
ductal
strictur
need
compar
balloon
dilat
prospect
studi
substanti
number
case
disclosur
disclosur
report
total
clientown
dog
includ
medic
record
dog
underw
gastroscopi
januari
decemb
retrospect
review
two
univari
analys
perform
order
identifi
associ
signal
clinic
sign
endoscop
histopatholog
variabl
glfh
fb
respect
signific
variabl
analys
includ
multivari
analysi
backward
elimin
use
select
final
model
variabl
associ
glfh
univari
analysi
includ
fb
p
intact
male
p
age
p
vomit
p
discolor
p
hemorrhag
p
ulcer
p
gastric
endoscopi
epitheli
lamina
propria
lymphocyt
invas
p
hlo
presenc
p
histopatholog
variabl
associ
fb
univari
analysi
includ
intact
male
p
age
p
vomit
p
discolor
p
hemorrhag
p
gastric
endoscopi
hlo
presenc
p
histopatholog
final
model
includ
fb
age
vomit
gastric
hemorrhag
hlo
presenc
fb
p
age
p
longer
associ
glfh
multivari
analysi
hlo
colon
associ
young
age
p
fb
p
although
associ
hlo
colon
young
age
identifi
studi
show
glfh
frequent
fb
would
expect
disclosur
disclosur
report
aim
prospect
studi
describ
cohort
cat
acquir
pst
confirm
perendoscop
measur
procedur
perform
oper
vf
use
gif
olympu
mm
diamet
videogastroscop
group
includ
cat
acquir
pst
cat
includ
group
pd
less
mm
control
group
group
b
includ
cat
present
period
normal
pd
gastrointestin
biopsi
submit
histolog
analysi
cat
includ
stomach
pyloru
duodenum
n
signal
clinic
sign
endoscop
histopatholog
find
compar
group
age
sex
weight
similar
group
chronic
vomit
frequent
clinic
complaint
group
group
group
b
food
vomit
occur
frequent
group
group
b
statist
differ
endoscop
find
consist
mild
gastriti
group
edema
hyperemia
frequent
note
around
pyloru
group
less
group
b
median
valu
pd
group
mm
statist
differ
group
b
mm
p
wilcoxonmannwhitney
test
histolog
chang
nonspecif
lymphocyticplasmacyt
infiltr
gastric
mucosa
cat
group
cat
group
b
pylor
fibrosi
found
cat
group
cat
group
b
result
confirm
acquir
pylor
stenosi
occur
cat
suffer
ibd
pathogen
mechan
clearli
understood
could
impli
mucos
scar
pylor
fibrosi
studi
pursu
inclus
addit
case
group
order
increas
statist
power
disclosur
disclosur
report
aim
studi
evalu
applic
toler
outcom
continu
posit
airway
pressur
cpap
compar
anoth
noninvas
oxygen
therapi
flowbi
dog
diagnos
cardiogen
pulmonari
edema
secondari
sever
mitral
valv
diseas
mvd
record
dog
diagnos
cardiogen
pulmonari
edema
base
clinic
find
thorac
radiograph
echocardiographi
retrospect
evalu
newli
diagnos
dog
mvd
dog
alreadi
treatment
mvd
includ
studi
thirti
dog
includ
studi
februari
dog
receiv
medic
treatment
base
clinic
statu
echocardiographi
result
divid
group
group
dog
receiv
oxygen
administr
cpaphelmet
posit
expiratori
pressur
pep
cm
h
group
dog
receiv
oxygen
flowbi
lmin
oxygen
administr
discontinu
base
clinic
improv
decreas
respiratori
labor
rr
respiratori
rate
emogasanalysi
paramet
paco
pao
pao
fio
improv
radiograph
sign
pulmonari
edema
group
mean
age
year
mean
bodi
weight
kg
eleven
dog
show
improv
rr
respiratori
labor
blood
ga
paramet
within
min
cpap
treatment
initi
radiograph
sign
pulmonari
edema
improv
within
h
treatment
cpap
intermitt
mean
wear
time
cpaphelmet
hday
h
h
butorphanol
administ
time
applic
cpaphelmet
mortal
rate
group
mean
age
year
mean
bodi
weight
kg
seven
dog
rr
respiratori
labor
blood
ga
paramet
improv
within
min
oxygen
flowbi
administr
radiograph
sign
pulmonari
edema
improv
median
h
h
oxygen
deliveri
continu
butorphanol
administr
necessari
three
time
per
day
mortal
rate
respiratori
failur
due
cardiogen
pulmonari
edema
secondari
mvd
common
diseas
dog
studi
cpaphelmet
interfac
valid
altern
oxygen
flowbi
therapi
though
clinic
improv
similar
first
min
cpaphelmet
reduc
need
butorphanol
administr
quicken
clinic
radiograph
sign
pulmonari
edema
improv
show
decreas
mortal
rate
compar
oxygen
flowbi
cpaphelmet
well
toler
dog
disclosur
disclosur
report
clinician
firstopinion
practic
commonli
diagnos
congest
heart
failur
chf
small
breed
dog
myxomat
mitral
valv
diseas
mmvd
chf
improv
accuraci
chf
diagnosi
develop
initi
algorithm
base
histor
physic
radiograph
find
might
help
clinician
first
opinion
practic
accur
diagnos
chf
dog
sought
refin
valid
algorithm
determin
histor
physic
radiograph
find
help
discrimin
dog
mmvd
chf
chf
group
collect
follow
histor
physic
examin
inform
smallbre
dog
present
evalu
cough
murmur
suspicion
chf
referr
clinician
presenc
absenc
cough
durat
cough
recent
worsen
cough
presenc
loud
crackl
murmur
intens
presenc
sinu
arrhythmia
heart
rate
inclin
respiratori
rate
presenc
absenc
dyspnea
sleep
respiratori
rate
respons
diuret
trial
consid
necessari
referr
clinician
radiograph
evalu
left
atrial
size
addit
dog
underw
echocardiograph
evalu
diagnosi
chf
chf
made
investig
case
use
requir
diagnost
test
treatment
valid
investig
histor
physic
variabl
exclud
diagnosi
chf
includ
presenc
sinu
arrhythmia
never
identifi
chf
dog
murmur
less
loud
heart
rate
bpm
inclin
rr
breathsmin
lessthanmoder
left
atrial
enlarg
radiograph
posit
diuret
trial
allevi
dyspnea
confirm
diagnosi
chf
cough
dog
chf
show
recent
worsen
cough
base
find
refin
algorithm
detect
either
sinu
arrhythmia
soft
murmur
sinu
rate
bpm
inclin
rr
breathsmin
exclud
diagnosi
chf
presenc
cough
crackl
help
recent
worsen
cough
warrant
increas
suspicion
chf
case
chf
suspect
resolut
dyspnea
appropri
diuresi
strongli
support
diagnosi
chf
well
refin
algorithm
perform
first
opinion
clinician
remain
determin
disclosur
disclosur
report
dr
rishniw
current
fund
studi
evalu
laryng
paralysi
acvim
foundat
grant
provid
continu
educ
talk
gener
practition
last
year
receiv
honoraria
dr
rishniw
paid
employe
veterinari
inform
network
thromboxan
txa
import
multifactori
mediat
pathogenesi
pulmonari
hypertens
although
endotheliumderiv
txa
caus
excess
pulmonari
vascular
resist
act
potent
vasoconstrictor
mitogen
vascular
smooth
muscl
cell
promot
platelet
aggreg
current
therapeut
strategi
pulmonari
hypertens
target
txa
format
aim
studi
assess
possibl
benefici
effect
inhibit
txa
synthesi
patient
pulmonari
hypertens
sixteen
clientown
dog
proven
moderatetosever
pulmonari
hypertens
randomli
assign
treatment
n
ozagrel
hydrochlorid
mgkg
bid
po
control
group
n
sildenafil
citrat
mgkg
bid
po
patient
alreadi
treat
standard
protocol
includ
sildenafil
ae
mgkg
bid
pulmonari
hypertens
associ
leftsid
heart
failur
laao
lviddn
exclud
popul
sever
clinic
indic
relat
hypoxia
lactat
spo
base
excess
thrombosi
ddimer
azotemia
bun
creatinin
congest
ntprobnp
echocardiograph
indic
peak
veloc
tricuspid
regurgit
ao
mpa
track
four
week
treatment
led
signific
gradual
decreas
lactat
ddimer
p
ae
mmoll
ae
ae
ae
lgml
respect
significantli
increas
spo
base
excess
p
ae
ae
ae
ae
mmoll
respect
patient
compar
control
treatment
group
exhibit
statist
signific
chang
lactat
level
p
spo
p
howev
treatment
txa
synthas
inhibitor
show
tendenc
improv
variabl
ntprobnp
tricuspid
regurgit
flow
implic
potenti
role
txa
synthas
inhibitor
pulmonari
vascular
imped
abnorm
behavior
lick
footpad
joint
report
put
side
effect
treatment
one
case
result
suggest
txa
synthas
inhibitor
may
contribut
improv
pulmonari
hemodynam
pulmonari
hypertens
allevi
pulmonari
vasoconstrict
prevent
thrombosi
disclosur
disclosur
report
pulmonari
hypertens
ph
may
lead
right
ventricular
rv
remodel
dysfunct
rightsid
congest
heart
failur
rchf
rv
enlarg
dysfunct
strongli
associ
prognosi
human
ph
refer
interv
rv
size
systol
function
describ
healthi
dog
aim
studi
assess
rv
size
systol
function
dog
ph
verifi
associ
sever
ph
prospect
multicent
observ
studi
includ
clientown
dog
ph
healthi
ph
classifi
accord
tricuspid
regurgit
pressur
gradient
trpg
mild
trpg
mmhg
n
dog
moder
trpg
mmhg
n
dog
sever
trpg
mmhg
n
dog
fourteen
dog
ph
rchf
echocardiograph
evalu
rv
obtain
left
apic
view
optim
right
heart
rv
dimens
evalu
rv
enddiastol
area
rveda
index
calcul
rveda
divid
bodi
surfac
area
echocardiograph
indic
rv
systol
function
tricuspid
annular
plane
systol
excurs
taps
rv
fraction
area
chang
fac
normal
bodi
weight
tapsen
facn
respect
rveda
index
significantli
higher
dog
mild
moder
sever
ph
healthi
dog
p
contrast
differ
rveda
index
found
dog
moder
sever
ph
rveda
index
significantli
higher
dog
rchf
comparison
dog
without
rchf
p
tapsen
refer
interv
found
dog
moder
ph
sever
ph
significantli
differ
among
dog
mild
moder
sever
ph
comparison
healthi
facn
refer
interv
found
dog
moder
ph
sever
ph
significantli
differ
dog
without
ph
irrespect
sever
differ
tapsen
facn
found
dog
without
rchf
conclus
rveda
index
increas
dog
ph
rchf
suggest
may
repres
use
paramet
assess
ph
sever
tapsen
facn
abnorm
dog
moderatetosever
ph
paramet
rv
dysfunct
seem
link
rchf
speci
studi
therefor
need
identifi
addit
factor
associ
rchf
dog
ph
disclosur
disclosur
report
rightsid
congest
heart
failur
rchf
secondari
rightsid
heart
pericardi
diseas
character
increas
right
atrial
system
venou
capillari
pressur
direct
right
atrial
pressur
measur
consid
gold
standard
identifi
rchf
invas
human
medicin
sonograph
identifi
distend
noncompli
caudal
vena
cava
cvc
noninvas
mean
detect
rchf
andor
estim
intravascular
volum
sonograph
cvc
dimens
healthi
dog
report
howev
effect
rchf
cvc
dimens
well
describ
object
studi
determin
cvc
measur
obtain
via
three
differ
sonograph
view
dog
rchf
outsid
refer
interv
ri
dog
present
rightsid
heart
diseas
ascit
prospect
evalu
via
longitudin
subxiphoid
view
sv
maxim
minim
cvc
diamet
svcvcmax
expir
svcvcmin
inspir
collaps
index
ci
measur
transvers
th
right
hepat
intercost
view
hv
use
measur
maxim
minim
cvc
hvcvcmax
hvcvcmin
aortic
diamet
singl
cvc
aortic
diamet
pvcvc
pvao
measur
via
longitudin
right
paralumbar
view
pv
cvc
dimens
adjust
three
view
use
allometr
scale
well
index
aortic
diamet
hv
pv
data
compar
ri
previous
establish
author
use
healthi
dog
variou
breed
data
express
median
rang
six
dog
weigh
kg
includ
diagnosi
includ
pulmonari
hypertens
n
congenit
heart
diseas
n
pericardi
effus
n
dog
svcvcmax
svcvcmin
ri
respect
dog
ci
within
ri
hvcvcmax
hvcvcmin
ri
dog
respect
hvcvcmaxao
hvcvcminao
ratio
ri
pvcvcao
ratio
ri
dog
pvcvc
diamet
use
allometr
scale
ri
one
dog
pilot
studi
suggest
enlarg
cvc
observ
dog
evid
rchf
cvc
distens
may
easiest
identifi
sv
could
due
proxim
cvc
relat
right
atrium
andor
influenc
respiratori
cycl
cvc
diamet
healthi
dog
dog
rchf
measur
sv
contrast
human
medicin
differ
ci
dog
rchf
healthi
dog
larger
studi
need
confirm
find
disclosur
disclosur
report
human
alter
heart
rate
variabl
hrv
associ
variou
form
intracrani
diseas
due
disturb
autonom
nervou
system
hrv
shown
hold
prognost
valu
patient
aim
studi
evalu
alter
hrv
dog
clinic
sign
intracrani
diseas
relationship
hrv
result
brain
imag
outcom
ambulatori
electrocardiograph
record
prospect
obtain
clientown
dog
histori
andor
neurolog
examin
consist
intracrani
diseas
data
collect
minimum
h
night
brain
imag
mri
ct
dog
hospit
control
data
gather
healthi
dog
use
parallel
studi
hrv
data
analyz
use
novacor
holtersoft
ultima
version
time
frequencydomain
measur
hrv
poincar
e
plot
descriptor
gener
data
two
dog
diseas
group
exclud
one
due
presenc
persist
arrhythmia
anoth
due
record
time
less
h
mean
heart
rate
diseas
group
higher
control
group
hrv
paramet
calcul
h
rest
data
group
measur
paramet
hrv
sdnn
sdnnidx
rmssd
apart
sdann
lower
diseas
group
control
group
p
distinct
poincar
e
plot
pattern
evid
diseas
group
compar
healthi
control
signific
differ
hrv
measur
h
record
dog
intracrani
lesion
present
imag
n
imag
abnorm
n
neither
signific
differ
aliv
month
follow
data
collect
n
n
pilot
studi
suggest
presenc
intracrani
diseas
may
associ
reduct
hrv
dog
regardless
underli
etiolog
hrv
appear
predict
brain
imag
find
small
cohort
dog
clinic
sign
intracrani
diseas
appear
relationship
hrv
surviv
disclosur
disclosur
report
diseas
sever
labrador
includ
famili
three
consecut
gener
aim
studi
describ
inherit
pattern
identifi
potenti
caus
gene
mutat
popul
studi
popul
consist
labrador
eight
dog
diagnos
differ
sever
diseas
one
year
old
healthi
litterm
affect
famili
three
dog
year
old
differ
breed
line
serv
control
clinic
diagnosi
made
electrocardiographi
echocardiographi
inherit
pattern
studi
pedigre
analysi
genom
dna
isol
edtaanticoagul
blood
sampl
use
commerci
kit
whole
exom
sequenc
we
healthi
diseas
litterm
use
identifi
candid
mutat
illumina
next
gener
sequenc
system
agil
sure
select
canin
exon
mb
librarykit
annot
select
target
mutat
gene
relat
calcium
transport
base
clinic
experi
calcium
channel
blocker
diltiazem
could
effect
control
diseas
sangersequenc
use
valid
we
result
studi
popul
control
capillarysequenc
system
chemistri
diseas
present
gener
affect
gender
affect
labrador
famili
although
symptom
vari
among
individu
sudden
death
young
age
occur
offspr
parent
clinic
affect
develop
congest
heart
failur
year
age
due
tachycardiomyopathi
anoth
observ
phenotyp
also
clinic
asymptomat
dog
without
arrhythmia
earli
stage
arvc
diagnosi
difficult
due
absenc
echocardiograph
chang
daytoday
arrhythmia
variabl
definit
diagnosi
requir
histopatholog
identif
transmur
fibrofatti
replac
right
ventricl
reduct
immunofluoresc
signal
desmosom
protein
plakoglobin
report
arvcaffect
human
boxer
reduct
plakoglobin
signal
within
endomyocardi
biopsi
sampl
emb
may
help
diagnos
arvc
emb
obtain
owner
consent
dog
advanc
cardiac
diseas
six
asymptomat
boxer
year
mild
moder
ventricular
arrhythmia
va
burden
investig
blind
breed
clinic
sign
dog
arvc
diagnos
emb
histopatholog
mt
dog
clinic
sign
consist
arvc
boxer
english
bulldog
two
asymptomat
boxer
moder
va
burden
confoc
microscopi
perform
emo
detect
immunoreact
signal
plakoglobin
emb
sampl
prepar
antibodi
recogn
cadherin
intercal
disc
marker
plakoglobin
fortytwo
sampl
posit
cadherin
signal
nondiagnost
plakoglobin
signal
reduc
sampl
boxer
english
bulldog
clinic
sign
histopatholog
diagnos
arvc
fourth
sampl
mongrel
diagnos
myocard
plakoglobin
signal
present
asymptomat
boxer
includ
histopatholog
diagnosi
arvc
result
suggest
reduc
plakoglobin
signal
emb
may
help
differenti
arvc
myocardi
diseas
dog
specif
clinic
sign
diseas
present
disclosur
disclosur
report
esvc
right
ventricular
volum
quantif
measur
realtim
echocardiographi
ecggat
slice
mdct
healthi
dog
nl
leblanc
kf
scollan
oregon
state
univers
corval
usa
accur
assess
right
ventricular
rv
structur
function
integr
compon
complet
cardiolog
evalu
veterinari
patient
assess
rv
perform
particularli
import
patient
pulmonari
hypertens
congenit
heart
diseas
acquir
myocardi
diseas
affect
rv
evid
human
medicin
suggest
rv
function
strongli
associ
outcom
mani
condit
aim
studi
evalu
accuraci
right
ventricular
volum
rvv
function
quantif
use
threedimension
echocardiographi
compar
electrocardiogramg
multidetector
comput
tomographi
ecggat
mdct
six
intact
hound
cross
dog
weigh
kg
anesthet
use
standard
protocol
spontan
ventil
dog
underw
ecggat
mdct
complet
examin
right
ventricular
enddiastol
volum
edv
endsystol
volum
esv
stroke
volum
sv
eject
fraction
ef
measur
use
softwar
specif
rvv
quantif
mdct
data
set
correl
level
agreement
method
determin
intraand
interobserv
variabl
assess
statist
signific
differ
sv
p
ef
p
obtain
mdct
signific
differ
edv
p
esv
p
rvv
obtain
mdct
statist
signific
differ
hr
note
method
p
correl
mdct
good
edv
esv
r
moder
ef
r
poor
sv
r
blandaltman
analysi
show
systemat
underestim
rvv
deriv
compar
mdct
averag
bia
ml
edv
esv
respect
intra
edv
esv
interobserv
edv
esv
variabl
accept
result
studi
suggest
use
measur
rvv
healthi
dog
feasibl
accept
reproduc
measur
rvv
underestim
made
mdct
therefor
absolut
volum
imag
techniqu
interchang
howev
signific
differ
ef
method
suggest
may
use
evalu
global
rv
function
monitor
trend
diseas
state
larger
prospect
studi
dog
without
cardiac
diseas
need
delin
benefit
constraint
method
disclosur
disclosur
report
type
ii
morpholog
pda
lefttoright
shunt
visual
case
base
transthorac
echocardiographi
tte
use
twodimension
threedimension
mode
well
colorflow
doppler
record
dog
previou
unsuccess
surgic
closur
pda
thoracotomi
report
refer
veterinarian
placement
sever
hemostat
clip
case
mild
hemorrhag
pda
correct
resorb
hemostat
compress
case
ice
ultrasound
system
viewmat
viewflex
plu
st
jude
medic
manipul
case
train
highli
experienc
observ
ice
imag
modal
second
observ
imag
set
need
viewflex
plu
cathet
introduc
left
right
femor
arteri
use
french
introduc
depend
dog
size
case
except
smallest
dog
kg
place
descend
aorta
dorsal
ductu
two
dog
underw
previou
unsuccess
surgic
closur
pda
thoracotomi
ice
provid
better
evalu
pda
morpholog
case
associ
lesion
case
tee
case
unlik
ice
tee
allow
optim
acoust
window
accur
visual
pda
area
hemostat
clip
case
ice
allow
confirm
complet
pda
occlus
use
combin
colorflow
doppler
mode
furthermor
two
dog
ice
use
sole
guidanc
deploy
acdo
devic
conclus
report
illustr
safe
effect
use
ice
dog
transcathet
procedur
disclosur
disclosur
report
new
echocardiograph
techniqu
allow
object
quantit
evalu
global
region
myocardi
function
analysi
motion
speckl
creat
interact
ultrason
beam
myocardium
examin
test
hypothesi
may
detect
left
ventricular
systol
dysfunct
diagnos
convent
echocardiographi
dog
sir
seventeen
dog
evid
sir
healthi
dog
control
group
includ
prospect
studi
procedur
perform
diagnost
purpos
control
group
compos
healthi
dog
undergo
surgic
castrat
ovariohysterectomi
exclud
studi
breed
predispos
dilat
cardiomyopathi
pregnant
femal
dog
treat
opioid
sed
anesthet
drug
h
echocardiographi
also
exclud
dog
previou
diagnosi
echocardiograph
evid
congenit
acquir
cardiac
diseas
dog
arrhythmia
time
hospit
admiss
dog
submit
standard
mmode
doppler
simultan
ecg
blood
pressur
measur
furthermor
blood
sampl
obtain
cbc
biochem
profil
measur
ctni
crp
serum
level
result
show
standard
echocardiograph
indic
systol
function
ef
fs
significantli
differ
two
group
contrari
left
ventricular
global
longitudin
peak
strain
endomyocardi
layer
stederiv
eject
fraction
steef
significantli
lower
sir
group
control
group
find
signific
correl
crp
serum
level
variabl
ctni
ste
variabl
furthermor
find
signific
differ
ctni
serum
level
two
group
studi
demonstr
sensit
standard
echocardiographi
detect
earli
mild
moder
myocardi
dysfunct
detect
convent
echocardiographi
popul
dog
sir
disclosur
disclosur
report
chronic
valvular
heart
diseas
common
cavali
king
charl
spaniel
ckc
howev
genet
factor
contribut
develop
progress
diseas
unknown
although
classic
consid
noninflammatori
diseas
upregul
express
gene
involv
inflamm
immun
function
identifi
affect
valvular
tissu
therefor
genet
determin
immun
respons
could
influenc
diseas
progress
individu
dog
aim
studi
document
major
histocompat
haplotyp
mhc
dog
leukocyt
antigen
dla
class
ii
haplotyp
ckc
examin
potenti
associ
individu
haplotyp
progress
diseas
dla
threelocu
haplotyp
determin
ckc
uk
n
australia
n
use
sequencebas
type
method
six
haplotyp
identifi
echocardiographi
perform
dog
evid
remodel
three
dog
test
remodel
defin
increas
leftatrialtoaort
ratio
increas
left
ventricular
intern
diamet
diastol
systol
normal
bodyweight
lviddi
lvidsi
associ
individu
haplotyp
presenc
remodel
investig
use
fisher
exact
test
odd
ratio
confid
interv
ci
also
calcul
age
dog
rang
year
data
dog
consid
two
haplotyp
significantli
associ
presenc
remodel
p
p
ci
respect
echocardiograph
evid
remodel
present
dog
year
old
absent
dog
year
old
significantli
p
associ
presenc
remodel
younger
age
odd
ratio
result
suggest
associ
mhc
dla
haplotyp
progress
chronic
valvular
heart
diseas
ckc
studi
recommend
explor
potenti
role
immun
system
pathogenesi
diseas
disclosur
disclosur
report
micro
ribonucl
acid
mirna
short
rna
molecul
regul
gene
express
show
vari
express
mani
diseas
includ
heart
diseas
mirna
stabl
detect
blood
therefor
potenti
biomark
myxomat
mitral
valv
diseas
mmvd
common
heart
diseas
dog
long
preclin
phase
progress
degener
mitral
valv
lead
eccentr
leftventricular
atrial
hypertrophi
eventu
succeed
congest
heart
failur
death
aim
investig
express
mirna
blood
plasma
dog
consecut
stage
mmvd
mirna
quantifi
blood
plasma
use
rtqpcr
dog
pass
stage
mmvd
modifi
chief
stage
oneway
repeat
measur
anova
pairwis
comparison
use
benjaminihochbergcorrect
show
signific
differ
p
express
within
mirna
downregul
mmvd
stage
compar
stage
factor
respect
downregul
mmvd
stage
compar
stage
factor
respect
signific
differ
stage
result
show
mirna
canin
blood
plasma
differ
express
progress
mmvd
howev
total
number
mirna
vari
differ
stage
small
evalu
role
mirna
potenti
biomark
studi
neededwith
bigger
popul
eventu
includ
stage
diseas
healthi
control
subject
disclosur
author
follow
disclosur
relat
studi
describ
abstract
american
kennel
club
canin
health
foundat
inc
raleigh
nc
us
provid
research
grant
cover
laboratori
consum
use
studi
financi
form
support
author
commerci
interest
made
invest
relat
studi
author
institut
benefit
result
studi
gift
hospit
travel
support
white
coat
effect
elev
blood
pressur
due
stress
anxieti
clinic
set
differenti
white
coat
effect
true
system
hypertens
challeng
object
studi
character
white
coat
effect
clientown
dog
determin
pharmacolog
manipul
butorphanol
decreas
effect
thirti
clientown
dog
enrol
client
train
collect
high
definit
oscillometr
hdo
blood
pressur
measur
home
hdo
measur
obtain
hospit
administr
butorphanol
client
questionnair
complet
assess
level
anxieti
measur
home
hospit
diastol
blood
pressur
dy
mean
arteri
pressur
map
arteri
puls
rate
hr
significantli
higher
hospit
butorphanol
compar
home
administr
butorphanol
abrog
differ
hr
significantli
lower
sedat
compar
sedat
hospit
remain
significantli
higher
compar
obtain
home
subject
anxieti
score
home
hospit
significantli
posit
correl
systol
sy
dy
map
anxieti
score
home
hospit
significantli
posit
correl
conclus
higher
dy
map
hr
seen
hospit
like
relat
whitecoat
effect
administr
butorphanol
decreas
effect
disclosur
disclosur
report
inform
preval
caus
heart
murmur
young
cat
scarc
prospect
studi
perform
investig
preval
heart
murmur
heart
diseas
explor
associ
auscultatori
echocardiograph
find
clinic
healthi
young
cat
may
march
healthi
cat
age
month
screen
auscult
shelter
veterinarian
singl
anim
shelter
rspca
yagoona
nsw
australia
heart
murmur
detect
cat
subsequ
within
month
investig
veterinari
cardiologist
nb
cardiolog
resid
gn
murmur
confirm
cat
murmur
characterist
time
grade
point
maxim
intens
record
one
murmur
systol
point
maximum
intens
murmur
often
difficult
local
subsequ
transthorac
echocardiographi
perform
cat
murmur
assess
patholog
nonpatholog
cat
multipl
congenit
heart
anomali
classifi
accord
sever
condit
effort
made
differenti
physiolog
innoc
murmur
consid
nonpatholog
heart
diseas
detect
cat
preval
total
popul
diagnos
includ
obstruct
n
nonobstruct
n
mitral
valv
dysplasia
ventricular
septal
defect
n
tricuspid
valv
dysplasia
n
pulmon
stenosi
n
doubl
chamber
right
ventricl
n
subvalvular
aortic
stenosi
n
hypertroph
cardiomyopathi
n
murmur
nonpatholog
cat
cat
dynam
right
ventricular
outflow
tract
obstruct
grade
murmur
n
patholog
posit
predict
valu
grade
murmur
associ
patholog
heart
diseas
ci
whilst
neg
predict
valu
grade
grade
murmur
associ
nonpatholog
heart
diseas
ci
ci
respect
conclus
studi
preval
heart
murmur
heart
diseas
respect
mitral
valv
dysplasia
ventricular
septal
defect
commonli
diagnos
murmur
grade
help
differenti
nonpatholog
patholog
heart
murmur
disclosur
disclosur
report
tachypnea
import
clinic
find
dog
cardiac
respiratori
disord
mani
healthi
cat
howev
high
respiratori
rate
veterinarian
consult
room
make
interpret
find
difficult
purpos
present
studi
establish
refer
rang
respiratori
rate
clinic
healthi
cat
veterinarian
consult
room
clinic
healthi
clientown
cat
privat
veterinari
practic
observ
singl
investig
may
august
cat
brought
consult
variou
reason
medic
histori
clinic
examin
reveal
abnorm
respiratori
rate
record
circumst
investig
veterinarian
consult
room
prior
manipul
owner
home
cat
rest
sleep
investig
watch
video
record
owner
home
cat
rest
sleep
owner
ask
perform
videorecord
immedi
count
respiratori
rate
total
adult
cat
median
age
year
rang
year
fulfil
inclus
criteria
calcul
refer
interv
respiratori
rate
veterinarian
consult
room
breathsmin
physic
examin
veterinarian
led
either
increas
n
decreas
n
unchang
n
respiratori
rate
cat
second
measur
could
perform
videorecord
provid
owner
rest
sleep
respiratori
rate
breathsmin
n
breathsmin
n
respect
count
singl
investig
videorecord
signific
declin
sleep
respiratori
rate
older
age
note
breathsmin
year
owner
abl
count
respiratori
rate
herhi
cat
case
report
valu
differ
respiratori
rate
observ
videorecord
owner
result
either
higher
lower
respiratori
rate
count
investig
video
conclud
refer
interv
veterinari
textbook
usual
report
healthi
cat
rest
respiratori
rate
valu
applic
veterinarian
consult
room
mani
cat
would
erron
categor
tachypnea
sinc
rest
sleep
respiratori
rate
show
less
variat
owner
educ
encourag
count
record
pet
respiratori
rate
visit
veterinarian
disclosur
disclosur
report
innoc
cardiac
murmur
often
found
asymptomat
puppi
age
week
extent
soft
murmur
recogn
first
opinion
veterinari
practition
unknown
octob
june
clientown
clinic
healthi
puppi
differ
breed
age
day
auscult
veterinari
cardiolog
specialist
final
year
veterinari
student
dog
auscult
variou
veterinari
practition
day
old
sever
practition
differ
practic
perform
auscult
averag
day
earlier
cardiologist
student
student
undergon
practic
train
cardiac
auscult
start
studi
find
cardiologist
student
practition
compar
agreement
practition
judgment
presenc
absenc
murmur
look
puppi
passport
puppi
auscult
cardiologist
practition
cardiologist
detect
murmur
puppi
murmur
systol
maxim
intens
agreement
find
cardiologist
veterinari
practition
poor
significantli
differ
p
cardiac
murmur
heard
practition
puppi
murmur
total
puppi
auscult
cardiologist
student
fair
agreement
signific
differ
p
found
weak
studi
practition
perform
auscult
differ
day
variou
circumst
howev
physiolog
anemia
known
contribut
genesi
innoc
murmur
preval
innoc
murmur
first
veterinari
health
check
higher
second
time
point
conclud
soft
innoc
cardiac
murmur
puppi
age
week
seldom
recogn
first
opinion
veterinarian
soft
murmur
detect
practition
probabl
louder
therefor
possibl
innoc
caus
congenit
cardiac
anomali
base
better
agreement
find
cardiologist
student
compar
find
cardiologist
practition
conclud
train
much
higher
effect
recognit
soft
cardiac
murmur
experi
even
train
short
disclosur
disclosur
report
use
stem
cell
treat
cardiac
diseas
gain
increas
interest
recent
year
cardiospherederiv
cell
cdc
adult
cardiac
progenitor
cell
popul
promis
candid
cellular
therapi
applic
rodent
model
phase
human
trial
ischem
myocardi
diseas
show
promis
measur
increas
left
ventricular
function
howev
much
remain
unknown
basic
biolog
especi
dog
expand
treatment
treat
canin
dilat
cardiomyopathi
requir
creation
cryopreserv
allogen
cell
bank
sinc
allow
time
access
larg
cell
number
avoid
obtain
diseas
autolog
myocardi
tissu
potenti
unstabl
dog
howev
cdc
cultur
condit
subject
plastic
similar
adult
stem
cell
popul
therefor
investig
passag
number
cryopreserv
may
affect
cellular
potenc
cdc
obtain
canin
atrial
explant
cdc
isol
character
five
cadav
consent
mesenchym
stem
cell
msc
isol
comparison
cdc
demonstr
popul
doubl
time
slower
msc
p
importantli
unchang
cryopreserv
p
cryopreserv
cdc
also
demonstr
multilineag
potenti
fresh
cell
show
commit
myocardi
endotheli
smooth
muscl
lineag
maintain
abil
form
clonal
coloni
flow
cytometri
analysi
reveal
fresh
cdc
high
proport
cell
express
ae
ae
vari
proport
ae
ae
ckit
ae
cell
ae
ae
popul
neglig
increas
passag
number
correl
increas
proport
cell
decreas
cell
p
respect
cryopreserv
popul
display
increas
posit
popul
p
fewer
cell
p
data
reveal
impact
differ
canin
donor
cell
phenotyp
signific
interdonor
variabl
cellular
morpholog
marker
express
overal
studi
show
despit
differ
cd
marker
popul
cryopreserv
canin
cdc
feasibl
without
alter
differenti
potenti
importantli
cdc
obtain
atrial
tissu
conform
gener
accept
profil
cdc
obtain
speci
canin
ventricular
tissu
studi
requir
investig
fundament
biolog
character
phenotyp
heterogen
stem
cell
popul
prior
clinic
applic
disclosur
disclosur
report
petplan
charit
trust
fund
research
aim
character
immuneregulatori
statu
canin
cdc
cardiospherederiv
cell
cdc
msc
lymph
node
cell
lnc
obtain
five
dog
immedi
postmortem
owner
consent
univers
ethic
approv
cell
isol
previous
publish
abil
cdc
form
clone
selfrenew
commit
multipl
lineag
assess
dog
genotyp
cell
assess
mhc
antigen
flow
cytometri
mix
lymphocyt
reaction
mlr
incorpor
respond
lnc
allogen
stimul
cdc
msc
perform
lnc
also
cultur
alon
combin
concanavalin
prolifer
assess
hthymidin
uptak
canin
cdc
demonstr
abil
self
renew
form
clonal
coloni
commit
multipl
lineag
myocardi
endotheli
smooth
muscl
dog
studi
heterozyg
vari
haplotyp
mlr
assay
lymphocyt
prolifer
abil
confirm
respons
concanavalin
stimul
cdc
produc
signific
prolifer
respond
lnc
compar
nonstimul
lnc
p
lack
respons
confirm
across
multipl
donor
respond
cell
mismatch
mhc
ii
haplotyp
interestingli
allogen
msc
stimul
respons
lnc
compar
nonstimul
cell
lnc
p
result
show
cdc
produc
immunolog
respons
vitro
model
transplant
immunereact
demonstr
cdc
possess
immuneprivileg
statu
studi
provid
evid
safe
use
allogen
cdc
treat
canin
dcm
disclosur
disclosur
report
petplan
charit
trust
fund
research
golden
retriev
dog
overrepres
higher
occurr
idiopath
ct
mix
breed
dog
underrepres
pc
cardiolog
servic
ascit
upon
present
idiopath
ct
pericardiectomi
associ
higher
pallor
inabl
ambul
upon
present
associ
lower
surviv
rate
surviv
rate
differ
dog
undergo
pc
right
left
hemithorax
surviv
rate
differ
dog
undergo
singl
undergo
sever
pc
howev
median
timeinterv
firsttosecond
secondtothird
pc
significantli
longer
survivor
compar
nonsurvivor
vs
p
vs
day
p
respect
two
dog
die
prior
pc
complet
seven
dog
underli
myxomat
mitral
valv
diseas
four
dachshund
three
left
atrialwal
ruptur
lead
acut
hemorrhag
ct
remain
three
pericardi
effus
modifi
transud
dog
drain
effus
volum
first
pc
significantli
posit
correl
r
p
prepc
sonograph
apextopericardi
distanc
associ
apextopericardi
distanc
p
volum
fluid
drain
pc
p
surviv
gener
dog
present
ct
poor
longterm
prognosi
howev
golden
retriev
dog
select
surgic
pericardiectomi
present
ascit
without
pallor
ambulatori
longer
interpericardiocentesi
interv
higher
surviv
rate
surviv
rate
affect
side
hemithorax
pericardiocentesi
perform
total
atrial
conduct
time
independ
predictor
atrial
fibril
af
human
estim
pulsedwav
tissu
doppler
imag
tdi
measur
time
onset
p
wave
peak
veloc
later
left
atrial
wall
ppa
prolong
ppa
identifi
peopl
high
risk
develop
af
studi
investig
echocardiograph
variabl
includ
ppa
measur
color
tdi
may
identifi
dog
develop
af
within
month
dog
af
retrospect
review
develop
newonset
af
within
month
previou
echo
includ
af
group
dog
underli
cardiac
diseas
develop
af
within
month
echo
also
review
includ
nonaf
group
nonaf
group
select
similar
bodi
weight
bw
left
atrial
dilat
la
ao
af
group
ppa
durat
measur
offlin
archiv
color
tdi
imag
place
region
interest
interatri
septum
color
ppa
ia
later
left
atrial
wall
color
ppa
later
ppa
durat
echo
variabl
mmode
pulsedwav
tdi
e
veloc
compar
group
receiv
oper
characterist
curv
use
identifi
best
af
predictor
dog
includ
af
nonaf
degen
mitral
valv
diseas
dilat
cardiomyopathi
frequent
cardiac
diseas
group
risk
newonset
af
associ
specif
breed
gender
neuter
statu
cardiac
diseas
bw
la
ao
color
ppa
ia
significantli
differ
group
af
group
significantli
greater
leftventricular
lv
enddiastol
ed
endsystol
es
volum
mmode
lv
ed
es
diamet
lv
es
diamet
index
bodi
weight
lv
es
volum
index
bodi
surfac
area
esvi
la
maxim
diamet
la
max
color
ppa
later
variabl
highest
area
curv
auc
ppa
later
la
max
esvi
color
ppa
later
cutoff
ms
specif
sensit
color
ppa
later
durat
superior
echo
variabl
predict
af
develop
within
month
la
max
second
highest
auc
despit
similar
la
ao
group
absolut
la
size
appear
play
import
role
af
rel
atrial
dilat
clinic
use
cutoff
intrainterobserv
variabl
need
confirm
prospect
studi
disclosur
disclosur
report
patent
ductu
arteriosu
pda
one
common
congenit
cardiac
diseas
dog
ecggat
comput
tomographi
angiographi
cta
complementari
minimallyinvas
way
earli
plan
intervent
occlus
aim
prospect
observ
studi
report
cta
find
associ
pda
total
dog
diagnos
pda
age
month
weigh
kg
enrol
dog
plan
undergo
possibl
intervent
occlus
anesthet
directli
cta
contrast
medium
inject
protocol
individu
tailor
total
inject
time
equal
sum
diagnost
scan
delay
scan
durat
first
mlkg
undilut
contrast
medium
mgiml
administ
two
third
total
inject
time
directli
follow
mlkg
dilut
contrast
medium
one
third
total
inject
time
ct
scan
trigger
manual
singl
breath
hold
contrast
bolu
reach
descend
aorta
scan
commenc
regardless
heart
rate
imag
reconstruct
perform
middiastol
rr
interv
dog
heart
rate
high
bpm
allow
imag
reconstruct
dog
sagitt
plane
imag
optim
visual
pda
minim
ductal
diamet
pulmonari
ostium
median
mm
rang
mm
ampulla
diamet
median
mm
rang
mm
ampulla
length
median
mm
rang
mm
angl
pda
aorta
median
rang
miller
type
pda
morpholog
type
n
type
n
type
iii
n
determin
total
dog
except
dog
type
iii
pda
morpholog
subsequ
underw
success
intervent
occlus
dog
avail
cta
imag
suspect
pda
morpholog
could
confirm
fluoroscopi
conclus
despit
fluoroscopi
remain
gold
standard
accur
size
pda
prior
intervent
occlus
cta
complementari
diagnost
method
may
provid
addit
relev
inform
plan
catheterbas
intervent
potenti
shorten
surgeri
time
reduc
amount
radiat
clinician
subject
disclosur
transcathet
embol
patent
ductu
arteriosu
pda
commonli
perform
minim
invas
cardiovascular
intervent
dog
prophylact
antibiot
routin
administ
periop
period
prevent
implantrel
bacteri
endocard
worldwid
increas
issu
antibiot
resist
question
aris
whether
routin
administr
prophylact
antibiot
evidencebas
present
retrospect
case
seri
includ
clientown
dog
underw
transcathet
embol
pda
author
clinic
inclus
criteria
author
either
primari
supervis
surgeon
least
month
followup
inform
avail
least
one
metal
implant
deliv
pda
local
system
antibiot
given
day
intervent
week
thereaft
followup
inform
gain
either
via
telephon
interview
owner
refer
veterinarian
via
recheck
examin
author
clinic
total
dog
fulfil
inclus
criteria
occlus
devic
detach
coil
dog
amplatz
canin
ductal
occlud
acdo
dog
human
amplatz
duct
occlud
dog
coil
acdo
implant
via
femor
arteri
dog
gener
anesthesia
fluoroscop
guidanc
median
age
dog
surgeri
month
rang
month
median
weight
kg
rang
kg
immedi
closur
pda
reach
dog
median
length
procedur
min
rang
min
median
length
followup
month
rang
month
none
dog
develop
clinic
sign
could
compat
bacteri
endocard
within
month
pdaocclus
import
weak
present
studi
retrospect
natur
anoth
weak
major
case
followup
inform
gain
via
telephon
interview
howev
bacteri
endocard
lifethreaten
condit
would
caus
mild
symptom
though
month
followup
might
look
arbitrarili
chosen
sever
veterinari
human
studi
use
cutoff
moreov
longer
incub
period
unlik
bacteria
assum
enter
circul
surgeri
find
present
studi
line
recent
human
recommend
recommend
routin
use
prophylact
antibiot
transcathet
pdaembol
disclosur
disclosur
report
shortterm
biolog
variabl
breed
differ
ntermin
probtyp
natriuret
peptid
ntprobnp
might
influenc
interpret
test
result
report
studi
aim
assess
variabl
plasma
ntprobnp
measur
month
healthi
labrador
retriev
also
investig
correl
urin
ntprobnp
creatinin
ratio
ubnpc
plasma
ntprobnp
concentr
fiftythre
labrador
retriev
median
age
year
rang
year
maintain
waltham
hous
studi
procedur
compli
anim
scientif
procedur
act
uk
residu
sampl
use
studi
dog
healthi
echocardiograph
normal
serial
sampl
fast
plasma
urin
perform
week
includ
assess
ntprobnp
measur
residu
plasma
urin
latter
index
creatinin
log
plasma
ntprobnp
analyz
linear
mix
model
reml
allow
repeat
measur
dog
time
random
effect
dog
categor
fix
effect
diet
week
interact
chang
baselin
week
chang
week
analyz
percentag
variabl
baselin
plasma
ntprobnp
calcul
averag
plasma
ntprobnp
dog
studi
point
calcul
avbnp
ntprobnp
standard
deviat
sdbnp
also
assess
spearman
correl
analysi
perform
investig
correl
ubnpc
plasma
ntprobnp
clinic
import
valu
plasma
ntprobnp
detect
wide
intraindividu
variabl
associ
percentag
variabl
plasma
ntprobnp
sdbnp
avbnp
measur
variabl
mild
posit
correl
age
avbnp
r
p
weak
posit
correl
ubnpc
plasma
ntprobnp
rho
p
plasma
ntprobnp
measur
clinic
healthi
labrador
frequent
outsid
laboratori
refer
interv
creat
fals
posit
test
compound
signific
measur
variabl
ubnpc
question
clinic
util
studi
necessari
valid
measur
disclosur
although
util
patientsid
ntprobnp
elisa
bnppoc
describ
cat
screen
cardiomyopathi
use
popul
potenti
lower
diseas
preval
unknown
retrospect
studi
aim
describ
gener
practic
bnppoc
use
estim
posit
predict
valu
ppv
echocardiograph
evid
cardiomyopathi
appar
healthi
cat
clinic
record
cat
undergo
bnppoc
march
review
signal
histori
examin
find
clinic
data
record
along
veterinarian
state
reason
test
perform
test
result
normal
abnorm
echocardiograph
find
avail
left
ventricular
wall
thick
mm
classifi
cat
hcm
left
atrial
enlarg
lae
present
la
ao
la
diamet
longaxi
mm
bnppoc
record
cat
male
median
age
year
murmur
detect
gallop
arrhythmia
frequent
reason
test
auscult
abnorm
preanesthet
assess
possibl
cardiacrel
sign
result
abnorm
cat
exclud
clinic
sign
n
unknown
reason
test
n
appar
healthi
cat
test
abnorm
underw
echocardiographi
hcm
lae
cat
diagnos
class
heart
diseas
gener
practic
popul
appar
healthi
cat
bnppoc
estim
ppv
hcm
lae
prospect
studi
need
valid
test
larger
popul
disclosur
disclosur
report
fiftyf
privat
own
cat
clinic
healthi
lvh
retrospect
select
complet
physic
examin
indirect
measur
arteri
blood
pressur
echocardiographi
peripher
ecg
standard
blood
work
includ
serum
thyroxin
concentr
avail
ecg
measur
includ
detect
type
arrhythmia
heart
rate
amplitud
durat
p
wave
qr
complex
st
segment
elev
depress
mean
electr
axi
p
wave
qr
complex
pq
qr
qt
qt
correct
heart
rate
qtc
durat
cat
lvh
outcom
data
caus
death
annot
avail
sinu
rhythm
diagnos
healthi
cat
lvh
remain
cat
lvh
show
differ
type
rhythm
disturb
includ
third
degre
atrioventricular
block
avb
sinu
rhythm
isol
atrial
ventricular
ectop
complex
sinu
bradycardia
sinu
rhythm
associ
first
degre
second
degre
avb
sinu
rhythm
associ
second
degre
avb
acceler
idioventricular
rhythm
ventricular
tachycardia
presenc
type
arrhythmia
sensit
specif
neg
predict
valu
posit
predict
valu
identifi
lvh
ecg
measur
perform
healthi
cat
cat
lvh
qt
qtc
statist
differ
healthi
cat
cat
lvh
p
variabl
among
healthi
cat
highest
valu
qt
qtc
ms
ms
respect
surviv
data
avail
cat
lvh
ecg
measur
perform
die
cardiac
relat
caus
median
surviv
time
day
measur
cat
qt
ms
ms
respect
day
measur
cat
qtc
ms
ms
respect
qt
ms
qtc
ms
predictor
death
cardiac
relat
caus
p
p
respect
surfac
ecg
seem
provid
use
diagnost
prognost
inform
cat
lvh
disclosur
disclosur
report
preval
dog
obes
increas
better
understand
metabol
overweight
dog
need
improv
obes
prevent
treatment
studi
aim
detect
quantifi
plasma
metabolit
feed
challengetest
dog
identifi
alter
metabol
relat
overweight
twentyeight
healthi
intact
male
labrador
retriev
dog
includ
classifi
lean
bodi
condit
score
bc
scale
overweight
bc
overnight
fast
plasma
sampl
collect
dog
fed
highfat
meal
postprandi
plasma
sampl
collect
hourli
h
nuclear
magnet
reson
nmr
conduct
plasma
metabolit
statist
evalu
result
show
postprandi
time
point
differ
fast
time
point
multivari
discrimin
analysi
crossvalid
anova
p
eleven
specif
metabolit
peak
concentr
mainli
h
postprandi
contribut
separ
carnitin
identifi
metabolit
relat
overweight
time
point
stepwis
logist
regress
analysi
p
overweight
dog
lower
carnitin
respons
mix
model
repeat
measur
analysi
p
notabl
fast
carnitin
concentr
overweight
dog
mean
ae
sd
ae
mm
close
propos
refer
limit
carnitin
defici
find
demonstr
nmr
suitabl
metabol
evalu
feedchalleng
dog
lower
carnitin
concentr
overweight
dog
warrant
investig
could
indic
carnitin
defici
alter
lipid
metabol
overweight
dog
disclosur
disclosur
report
kieferheck
b
dobeneck
unchen
oberschleissheim
germani
silicacontain
urolith
dog
occur
infrequ
analyz
urolith
europ
although
schenk
et
al
observ
peak
switzerland
affect
dog
predomin
male
year
old
year
old
neuter
male
terrier
mongrel
bc
histori
pancreat
examin
abdomin
pain
abdomin
ultrason
examin
reveal
abnorm
pancrea
hyperecho
structur
bladder
dog
urin
urin
sediment
posit
bacteria
erythrocyt
leucocyt
crystal
antimicrobi
treatment
start
pancreat
lipas
within
refer
rang
two
week
later
urin
sampl
collect
owner
contain
numer
struvit
crystal
anoth
sampl
obtain
one
week
later
cystocentesi
reveal
crystal
sign
inflamm
urin
ph
ultrasonograph
examin
bladder
day
afterward
show
multipl
urolith
stone
remov
surgic
analysi
reveal
silica
hypothes
silica
urolith
may
relat
silica
intak
plant
plant
byproduct
diet
consumpt
soil
silica
secondari
dietassoci
pica
case
dog
fed
commerci
gastro
intestin
low
fat
dri
diet
year
addit
dog
regularli
consum
fece
feral
rabbit
daili
walk
sinc
year
analysi
sampl
fece
show
contain
high
amount
insolubl
ash
fresh
matter
vs
dri
matter
pet
rabbit
intak
fece
togeth
soil
stick
might
caus
silica
urolith
case
sinc
sign
dysuria
abnorm
ultrasonograph
examin
bladder
urinalysi
recur
dog
kept
consum
rabbit
fece
three
month
restrict
phosphat
p
intak
crucial
patient
chronic
renal
insuffici
cri
especi
case
hyperphosphatemia
major
sourc
p
protein
bone
cartilag
well
inorgan
supplement
nutrit
technic
purpos
date
total
amount
p
diet
use
assess
daili
load
p
patient
besid
p
excess
suspect
play
role
also
pathogenesi
cri
aim
studi
test
effect
differ
p
sourc
bodi
base
differ
avail
miner
adult
beagl
ad
p
calcium
ca
determin
feed
control
diet
pdm
adapt
balanc
repeat
aim
pdm
ad
differ
phosphat
cahpo
nah
po
poultri
meal
na
p
ca
h
po
bone
meal
kh
po
k
p
adjust
cap
ratio
use
caco
except
diet
poultri
meal
cap
diet
na
p
pdm
due
low
accept
washout
period
serum
p
ca
pth
determin
preand
h
postprandi
preand
postprandi
urin
analyz
creatinin
p
statist
anova
bonferroni
kruskal
walli
tukey
accord
data
distribut
compar
control
ad
p
reduc
diet
pentaphosph
poultri
bone
meal
postprandi
urin
pcreatinin
increas
significantli
diet
control
poultri
bone
meal
true
postprandi
serum
p
concentr
level
even
refer
rang
nah
po
na
p
ca
h
po
kh
po
k
p
postprandi
pth
level
increas
threefold
na
k
compound
nah
po
na
p
kh
po
k
p
ca
h
po
caus
mean
concentr
near
refer
rang
first
time
studi
demonstr
dog
systemat
differ
p
digest
metabol
differ
p
sourc
often
use
petfood
relev
p
renal
diet
also
potenti
harm
effect
elev
serum
p
pth
level
skeleton
cardiovascular
system
kidney
healthi
anim
intak
highli
solubl
p
compound
na
k
phosphat
assess
differ
knowledg
total
amount
p
diet
suffic
decid
adequaci
potenti
harm
disclosur
disclosur
report
ideal
method
monitor
trilostan
therapi
dog
hypercortisol
hc
still
controversi
late
determin
pretrilostan
prepil
serum
cortisol
concentr
shown
repeat
either
posttrilostan
postacth
stimul
cortisol
therefor
prepil
cortisol
concentr
may
superior
cortisol
measur
monitor
purpos
well
known
cortisol
concentr
fluctuat
influenc
certain
circumst
eg
stress
aim
studi
investig
agreement
two
prepil
cortisol
measur
dog
hc
trilostan
therapi
client
own
dog
hc
treat
trilostan
twice
daili
prospect
enrol
cortisol
concentr
measur
two
time
h
apart
next
trilostan
dose
prepil
valu
assign
one
three
group
accord
control
cortisol
releas
excess
nmoll
adequ
nmoll
inadequ
nmoll
wilcoxon
sign
rank
test
use
examin
signific
differ
pair
measur
spearman
rank
correl
calcul
degre
agreement
group
assign
quantifi
kappa
total
cortisol
pair
dog
hc
includ
prepil
differ
significantli
p
signific
correl
two
valu
p
r
compar
prepil
prepil
higher
equal
lower
pair
group
agreement
prepil
moder
agreement
weight
kappa
pair
group
assign
disagre
would
led
differ
therapeut
decis
dog
certain
circumst
eg
excess
bark
hospit
difficulti
blood
collect
identifi
potenti
factor
explain
discrep
prepil
conclus
substanti
number
dog
larg
differ
two
prepil
valu
ascrib
certain
event
hospit
dog
record
incid
handl
might
affect
cortisol
releas
seem
import
whether
measur
two
prepil
valu
true
benefit
compar
determin
one
evalu
studi
disclosur
disclosur
report
nsr
member
vetoryl
novel
monitor
meet
organ
dechra
veterinari
product
ltd
cr
consult
boehring
ingelheim
novarti
anim
health
current
consult
dechra
limit
receiv
financi
support
endocrin
research
variou
compani
nestl
e
purina
hill
provet
antlia
sa
glycemicon
clinic
studi
fund
ecvimca
societi
compar
endocrinolog
current
medic
treatment
option
dog
cortisolsecret
adrenocort
tumor
at
trilostan
mitotan
howev
trilostan
palli
treatment
effect
tumor
mitotan
adrenocorticolyt
activ
caus
seriou
advers
effect
new
oral
avail
drug
known
select
adrenocorticolyt
activ
guinea
pig
dog
monkey
human
current
test
phase
ii
clinic
trial
at
human
select
potent
steroloacyltransferas
inhibitor
lead
accumul
free
cholesterol
adrenocort
cell
result
endoplasm
reticulum
stress
ultim
lead
apoptosi
inhibit
could
interest
therapi
option
dog
at
use
canin
at
express
aim
studi
determin
whether
use
select
inhibitor
could
potenti
treatment
canin
at
end
evalu
mrna
express
rtqpcr
at
carcinoma
adenoma
normal
adren
na
protein
express
immunohistochemistri
ihc
at
carcinoma
adenoma
na
slide
stain
polyclon
rabbitantihuman
antibodi
antibodi
specif
confirm
western
blot
semiquantit
hscore
protein
express
calcul
multipli
area
posit
stain
stain
intens
grade
score
mrna
detect
rtqpcr
sampl
test
signific
differ
found
na
mean
fold
chang
ae
adenoma
ae
carcinoma
ae
express
variabl
at
particular
carcinoma
signific
differ
found
protein
express
na
hscore
ae
adenoma
ae
carcinoma
ae
carcinoma
show
variabl
express
three
carcinoma
low
absent
protein
express
hscore
lower
one
conclus
mrna
present
protein
sampl
provid
solid
base
select
inhibitor
could
great
potenti
futur
treatment
canin
at
determin
effect
canin
at
studi
warrant
disclosur
disclosur
report
common
endocrin
disord
dog
present
medic
manag
canin
pdh
consist
either
trilostan
mitotan
therapi
treatment
disadvantag
associ
induct
hypoadrenocortic
therefor
specif
inhibit
glucocorticoid
synthesi
desir
recent
studi
indic
steroidogen
enzym
cytochrom
could
interest
target
select
inhibit
cortisol
product
without
imped
synthesi
aldosteron
abirateron
acet
aa
highli
select
irrevers
alreadi
avail
market
success
use
treatment
castrationresist
prostat
cancer
human
addit
registr
human
applic
probabl
enabl
rel
straightforward
implement
veterinari
clinic
practic
side
effect
aa
mostli
relat
hypocortisol
approach
seem
interest
novel
medic
treatment
option
canin
hypercortisol
aim
studi
determin
effect
aa
cortisol
synthesi
mrna
express
steroidogen
gene
encod
dehydrogenas
cellular
marker
prolifer
adrenocort
cell
viabil
canin
primari
adrenocort
cell
cultur
adren
gland
seven
healthi
dog
incub
variou
concentr
aa
pdh
mimick
coincub
synthet
acth
h
incub
rna
isol
evalu
gene
express
use
realtim
quantit
pcr
rtqpcr
cultur
medium
remov
measur
cortisol
h
incub
addit
cell
viabil
assess
use
assay
aa
dosedepend
decreas
cortisol
concentr
acthstimul
adrenocort
cell
ic
valu
nm
p
highest
aa
concentr
averag
suppress
cortisol
synthesi
sem
ae
mrna
express
significantli
alter
incub
aa
final
aa
significantli
affect
adrenocort
cell
viabil
conclud
aa
effect
reduc
cortisol
synthesi
vitro
without
affect
adrenocort
cell
viabil
prolifer
therefor
aa
seem
promis
futur
treatment
option
medic
manag
canin
cush
diseas
ascertain
vivo
studi
warrant
disclosur
disclosur
report
assess
malign
canin
cortisolsecret
adrenocort
tumor
at
remain
challeng
previou
studi
link
molecular
marker
surviv
time
dog
adrenalectomi
make
difficult
give
reliabl
prognosi
aim
studi
identifi
molecular
prognost
marker
larg
cohort
canin
at
could
enhanc
insight
individu
prognosi
could
also
provid
potenti
futur
treatment
target
fiftynin
dog
hypercortisol
due
underw
adrenalectomi
author
institut
followup
inform
avail
includ
studi
three
class
potenti
prognost
factor
review
firstli
clinic
data
includ
bodi
weight
age
time
surgeri
gender
neuter
statu
tumor
size
secondli
immunohistochem
label
index
thirdli
mrna
express
factor
associ
prolifer
at
includ
univari
analysi
perform
cox
proport
hazard
model
continu
variabl
log
rank
test
bivari
variabl
multivari
analysi
perform
use
multipl
linear
regress
forward
select
median
surviv
time
ae
month
univari
analysi
signific
prognost
factor
tumor
volum
cm
p
hazard
ratio
hr
maxim
diamet
tumor
cm
p
hr
label
index
p
hr
mrna
express
p
hr
p
hr
p
hr
p
hr
forward
stepwis
multivari
analysi
identifi
label
index
p
hr
mrna
express
p
hr
independ
predictor
poor
surviv
conclus
import
predictor
poor
surviv
label
index
express
result
show
import
includ
stain
histopatholog
assess
canin
at
moreov
sinc
pharmacolog
manipul
possibl
consider
impact
express
prognosi
indic
great
potenti
treatment
target
canin
at
near
futur
disclosur
disclosur
report
pheochromocytoma
may
difficult
differenti
adrenocort
tumor
dog
diagnosi
histopatholog
obtain
fineneedl
aspir
biopsi
adren
mass
invas
techniqu
risk
complic
measur
urin
catecholamin
metabolit
necessit
acidif
urin
hydrochlor
acid
associ
handl
risk
ideal
blood
marker
reliabl
differenti
catecholamineproduc
tumor
adrenocort
tumor
would
prefer
howev
direct
measur
plasma
catecholamin
metabolit
less
reliabl
measur
urin
catecholamin
metabolit
dog
measur
serum
inhibin
concentr
use
gonadoectom
dog
human
medicin
chromogranin
cga
establish
marker
neuroendocrin
tumor
net
chromogranin
store
secretori
granul
neuroendocrin
tissu
cosecret
epinephrin
norepinephrin
sympathet
stimuli
metabolit
cga
stabl
plasma
catecholamin
aim
present
studi
measur
compar
serum
concentr
cga
epitop
vasostatin
catestatin
serum
collect
surgeri
dog
histolog
confirm
catecholamineproduc
tumor
dog
adrenocort
tumor
serum
sampl
collect
surgeri
dog
adren
tumor
one
dog
extraadren
neuroendocrin
tumor
tumor
tissu
origin
confirm
histopatholog
catecholamineproduc
tumor
pheochromocytoma
extraadren
tumor
adrenocort
tumor
serum
concentr
vasostatin
catestatin
analyz
radioimmunoassay
ria
previous
valid
use
dog
statist
analysi
perform
nonparametr
test
use
softwar
r
version
dog
catecholamineproduc
tumor
median
serum
vasostatin
concentr
nmoll
iq
rang
nmoll
dog
adrenocort
tumor
median
serum
vasostatin
concentr
nmoll
iq
rang
nmoll
serum
vasostatin
concentr
significantli
higher
dog
catecholamineproduc
tumor
dog
adrenocort
tumor
wilcoxon
sign
rank
test
independ
group
p
statist
signific
differ
serum
catestatin
concentr
two
group
base
result
studi
conclud
serum
cga
epitop
vasostatin
may
valuabl
serum
biomark
differenti
catecholamineproduc
tumor
adrenocort
tumor
disclosur
disclosur
report
cabergolin
dopamin
receptor
agonist
second
line
medic
therapi
human
acromegal
patient
pasireotid
somatostatin
analogu
effect
medic
manag
option
felin
acromegali
cost
limit
factor
mani
owner
work
demonstr
dopamin
receptor
within
felin
acromegal
pituitari
hypothes
cabergolin
would
improv
diabet
control
concentr
diabet
acromegal
cat
prospect
cohort
studi
clientown
diabet
acromegal
cat
ethic
approv
urn
enrol
criteria
diagnosi
diabet
mellitu
concentr
ngml
owner
declin
altern
treatment
option
acromegali
patient
admit
hospit
day
underw
pituitari
imag
start
cabergolin
therapi
kelactin
kela
nv
day
cat
monitor
hospit
day
discharg
continu
treatment
home
serum
fructosamin
measur
day
day
month
possibl
medic
side
effect
record
descript
statist
nonparametr
test
use
analyz
data
six
cat
enrol
first
three
cat
receiv
h
po
second
three
cat
receiv
ugkg
h
po
cabergolin
median
concentr
day
ngml
rang
statist
differ
day
month
ngml
ngml
respect
median
fructosamin
concentr
day
lmoll
rang
statist
differ
day
month
respect
cat
receiv
pzi
insulin
prozinc
boehring
median
dose
day
unitskg
h
differ
day
month
respect
three
patient
experienc
singl
gastrointestin
upset
event
inappet
diarrhea
resolv
within
three
day
one
six
cat
experienc
improv
diabet
control
fructosamin
day
lmoll
month
lmoll
insulin
dose
day
unitkg
h
month
unitskg
h
although
decreas
concentr
day
ngml
month
ngml
cabergolin
therapi
use
investig
dose
durat
associ
reduct
concentr
test
diabet
acromegal
cat
glycem
control
improv
one
addit
case
altern
dose
regimen
longerterm
followup
assess
disclosur
disclosur
report
diabet
remiss
clinic
support
nestl
purina
boehring
ingelheim
underli
caus
diabet
mellitu
substanti
number
diabet
cat
serum
insulinlik
growth
measur
current
test
choic
concentr
greater
ngml
posit
predict
valu
therefor
commerci
laboratori
current
use
valu
cutoff
indic
like
hs
presenc
howev
endogen
insulin
avail
affect
synthesi
therebi
possibl
reduc
test
sensit
especi
newli
insulintr
diabet
acromegal
studi
two
main
question
mani
newli
diagnos
treat
diabet
cat
demonstr
serum
initi
suggest
subsequ
becom
suggest
hs
use
cutoff
ngml
strong
correl
endogen
insulin
concentr
untreat
diabet
cat
serial
blood
sampl
diabet
cat
prospect
recruit
first
opinion
uk
veterinari
practic
within
day
initi
insulin
treatment
serum
basal
serum
endogen
insulin
evalu
use
valid
commerci
offer
ria
elisa
respect
latter
untreat
diabet
cat
mann
whitney
test
use
compar
group
spearman
rank
correl
coeffici
assess
correl
endogen
insulin
p
consid
signific
serial
blood
sampl
cat
recruit
two
sampl
cat
three
four
five
sixtytwo
cat
least
one
measur
ngml
median
ngml
rang
median
unitskginject
insulin
rang
administ
cat
ngml
initi
show
ngml
therefor
attend
clinician
could
discard
possibl
hs
patient
median
subsequ
increas
ngml
rang
initi
receiv
median
day
insulin
treatment
rang
basal
endogen
insulin
untreat
diabet
cat
ngml
n
median
ngl
rang
significantli
lower
ngml
n
median
ngl
rang
p
moder
posit
correl
r
p
detect
endogen
insulin
untreat
cat
studi
approxim
newli
diagnos
diabet
cat
suggest
underli
hs
base
current
advoc
cutoff
initi
show
neg
valu
use
cutoff
lower
endogen
insulin
moder
correl
andor
suboptim
current
cutoff
valu
advic
could
contribut
factor
disclosur
disclosur
report
dysfunct
pancreat
betacel
crucial
pathophysiolog
diabet
base
light
microscopi
diabet
cat
reduc
number
betacel
whether
secretori
granul
mitochondria
central
cellular
function
viabil
abnorm
morpholog
unknown
furthermor
recent
investig
question
role
islet
amyloid
pathogenesi
diabet
cat
sinc
amount
differ
diabet
agematch
control
cat
howev
intracellular
aggreg
amylin
oligom
rather
extracellular
amyloid
may
principl
betacel
toxic
type
diabet
therefor
aim
studi
character
ultrastructur
lesion
betacel
diabet
cat
emphasi
granul
mitochondria
intracellular
amylin
aggreg
pancreas
diabet
control
cat
euthan
diseas
prospect
collect
sampl
harvest
within
h
death
glutaraldehydefix
control
cat
select
match
age
sex
bodi
weight
section
prepar
electron
microscopi
immunogold
label
use
antiinsulin
antiamylin
antibodi
betacel
morpholog
assess
includ
betacel
granul
area
eccentr
minimumtomaximum
diamet
ratio
granul
number
well
betacel
mitochondri
area
number
intercrista
distanc
intracellular
accumul
amylinposit
materi
outsid
granul
explor
nonparametr
test
use
statist
analysi
five
diabet
cat
control
includ
diabet
cat
betacel
clearer
cytoplasm
control
cat
median
area
betacel
granul
higher
diabet
control
vs
rang
p
median
number
lower
vs
rang
p
eccentr
differ
median
intercrista
distanc
mitochondria
higher
diabet
control
vs
rang
p
area
number
differ
mitochondria
diabet
cat
appear
swollen
amylinposit
materi
outsid
granul
observ
cytoplasm
diabet
cat
none
control
conclus
reduc
number
granul
might
suggest
remain
pool
betacel
diabet
cat
less
function
exhaust
excess
workload
reason
behind
larger
granul
size
uncertain
increas
intercrista
distanc
mitochondria
diabet
cat
well
swollen
appear
might
suggest
increas
permeabl
loss
function
appear
amylinposit
materi
outsid
granul
suggest
intracellular
aggreg
amylin
monom
oligom
may
possibl
contribut
betacel
death
disclosur
disclosur
report
claudia
reusch
consult
boehring
ingelheim
novarti
anim
health
current
consult
dechra
limit
receiv
financi
support
endocrin
research
variou
compani
nestl
e
purina
hill
provet
antlia
sa
glycemicon
clinic
studi
fund
ecvimca
societi
compar
endocrinolog
glycem
paramet
fructosamin
glycosyl
hemoglobin
serial
glucos
measur
sgm
alway
interpret
light
clinic
sign
exhibit
diabet
pet
sampl
artifact
assayissu
interday
variat
stress
yield
deceiv
laboratori
result
likewis
clinic
histori
suffer
interperson
variat
due
vari
way
ask
answer
question
interpret
nonstandard
languag
forget
question
lack
quantif
aim
studi
evalu
newli
design
simpl
diabet
clinic
score
dc
diabet
dog
dc
previous
valid
use
diabet
cat
diabet
dog
owner
ask
choos
specif
sever
rang
none
normal
mild
moder
sever
specif
diabet
clinic
sign
polyuria
polydipsia
polyphagia
attitud
activ
extent
possibl
weight
loss
establish
weigh
none
mild
moder
sever
sever
subsequ
convert
score
rang
none
normal
sever
yield
summar
total
score
dc
sign
combin
rang
clinic
sign
maximum
clinic
sign
dc
correl
one
follow
object
paramet
obtain
visit
fructosamin
averag
blood
glucos
sgm
avbg
water
intak
diari
appropri
descript
correl
statist
use
sixtyseven
diabet
dog
assign
dc
median
rang
signific
correl
present
avbg
n
spearman
rho
p
daili
water
intak
n
spearman
rho
p
dc
signific
correl
dc
fructosamin
n
spearman
rho
p
also
present
though
dog
concurr
hyperadrenocortic
hyperlipidemia
hypothyroid
diabet
ketoacidosi
remov
analysi
seventynin
percent
owner
report
question
clear
complet
clear
dc
prove
easi
comprehend
dog
owner
signific
correl
dc
object
clinic
paramet
suggest
could
repres
simpl
object
tool
describ
commun
quantifi
clinic
sign
encount
diabet
dog
clinic
practic
research
set
differ
dc
object
paramet
investig
disclosur
disclosur
report
iatrogen
hypothyroid
develop
postradioiodin
treatment
felin
hyperthyroid
incid
may
dosedepend
cat
develop
iatrogen
hypothyroid
greater
incid
develop
azotemia
cat
remain
euthyroid
dog
experimentallyinduc
hypothyroid
decreas
glomerular
filtrat
rate
gfr
endogen
creatinin
product
suggest
use
creatinin
marker
kidney
function
hypothyroid
cat
could
underestim
incid
develop
kidney
diseas
longitudin
studi
evalu
thyroid
renal
function
cat
post
lowdos
mbq
radioiodin
therapi
hyperthyroid
cat
present
lowdos
radioiodin
therapi
felin
centr
langford
vet
prospect
enrol
studi
baselin
one
six
postradioiodin
treatment
thyroid
renal
function
evalu
via
total
thyroxin
thyroid
stimul
hormon
tsh
via
serum
creatinin
concentr
scr
gfr
correct
slopeintercept
iohexol
clearanc
respect
cat
categor
overt
hypothyroid
nmoll
tsh
ngml
subclin
hypothyroid
nmoll
tsh
ngml
euthyroid
nmoll
ngml
hyperthyroid
nmoll
timepoint
decreas
gfr
defin
mlminkg
azotemia
scr
twentyseven
cat
recruit
studi
complet
followup
two
lost
onemonth
four
two
cat
remain
persist
hyperthyroid
one
underw
repeat
radioiodin
treatment
five
cat
remain
hyperthyroid
onemonth
euthyroid
seven
cat
develop
overt
hypothyroid
onemonth
two
preced
subclin
hypothyroid
none
cat
regain
normal
thyroid
function
one
cat
subclin
hypothyroid
followup
avail
cat
develop
transient
overt
subclin
hypothyroid
cat
develop
overt
hypothyroid
develop
decreas
renal
function
decreas
gfr
preced
azotemia
develop
cat
twentyeight
percent
cat
develop
overt
hypothyroid
could
document
posttreat
highlight
import
continu
monitor
thyroid
function
posttreat
even
cat
receiv
lowdos
radioiodin
therapi
reduc
renal
function
document
overtli
hypothyroid
cat
gfr
detect
declin
renal
function
earlier
scr
suggest
gfr
may
use
monitor
renal
function
cat
postradioiodin
therapi
howev
studi
limit
small
number
cat
develop
overt
hypothyroid
studi
evalu
optim
method
detect
earli
declin
renal
function
requir
disclosur
disclosur
report
studi
fund
petsav
grant
langford
vet
clinic
research
fund
nc
finch
current
receiv
direct
research
support
boehring
anim
health
petsav
langford
vet
clinic
research
fund
wellcom
trust
current
receiv
indirect
research
support
zoeti
idexx
previous
receiv
direct
support
agria
pet
insur
previous
receiv
indirect
support
msd
anim
health
salari
current
fund
wellcom
trust
current
member
govern
council
cat
fanci
veterinari
advisori
committe
previous
receiv
honorarium
speak
notforprofit
organ
occasion
pharmaceut
industri
articl
publish
peer
nonpeer
review
public
tasker
past
st
receiv
financi
support
hemoplasma
research
zoeti
anim
health
vectorborn
diseas
research
bayer
anim
health
st
receiv
financi
support
current
infecti
diseas
research
bsava
petsav
langford
trust
petplan
chari
unit
langford
vet
univers
bristol
carri
pcr
describ
studi
st
paid
provid
continu
profession
develop
notforprofit
organ
occasion
commerci
compani
around
world
hibbert
ah
receiv
financi
support
felin
hyperthyroid
diseas
research
bsava
petsav
tosoh
bioscienc
langford
vet
langford
trust
ah
paid
provid
continu
profession
develop
notforprofit
organ
occasion
commerci
compani
around
world
major
dog
primari
hypoadrenocortic
ph
diseas
character
absolut
defici
glucocorticoid
mineralocorticoid
consequ
patient
requir
lifelong
replac
hormon
sinc
applic
respect
drug
restor
physiolog
hormon
level
biorhythm
overdos
may
possibl
longterm
manag
unlik
glucocorticoid
excess
overdos
mineralocorticoid
may
go
clinic
unnot
due
role
key
mediat
renal
damag
progress
kidney
diseas
mineralocorticoid
overdos
repres
matter
concern
aim
studi
investig
kidney
function
mean
sdma
creatinin
cr
dog
ph
longterm
mineralocorticoid
therapi
twentyseven
clientown
dog
ph
receiv
either
desoxycorticosteron
pival
docp
fludrocortison
acet
fc
minimum
month
includ
studi
concentr
cr
measur
regular
reevalu
retriev
medic
record
retrospect
sdma
measur
use
valid
immunoassay
refer
laboratori
idexx
diavet
treatment
time
rang
month
median
nine
dog
treat
fc
dog
docp
dog
fc
chang
docp
poor
respons
advers
effect
time
diagnosi
dog
elev
sdma
wherea
cr
elev
dog
paramet
normal
start
therapi
two
dog
develop
persist
elev
sdma
month
start
therapi
fc
docp
respect
follow
elev
cr
month
later
clinic
sign
work
consist
chronic
kidney
diseas
ckd
dog
although
sdma
within
refer
interv
dog
dog
show
elev
cr
perman
one
signific
correl
sdma
cr
demonstr
r
p
statist
evid
differ
cr
sdma
fc
docp
group
conclus
select
dog
may
develop
ckd
longterm
mineralocorticoid
therapi
preval
ckd
ph
might
higher
gener
dog
popul
howev
verifi
larger
number
dog
signific
elev
cr
normal
sdma
unclear
possibl
reflect
preren
azotemia
earli
kidney
dysfunct
disclosur
disclosur
report
cr
consult
boehring
ingelheim
novarti
anim
health
current
consult
dechra
limit
receiv
financi
support
endocrin
research
variou
compani
nestl
e
purina
hill
provet
antlia
sa
glycemicon
clinic
studi
fund
ecvimca
societi
compar
endocrinolog
nsr
member
vetoryl
novel
monitor
meet
organ
dechra
veterinari
product
ltd
desoxycorton
pival
docp
dechra
pure
mineralocorticoid
concurr
dose
glucocorticoid
need
individu
titrat
current
done
basi
clinic
sign
contrast
dog
treat
fludrocortison
mixtur
mineralocorticoid
glucocorticoid
receiv
addit
glucocorticoid
supplement
follow
stabil
object
studi
compar
acth
concentr
dog
treat
fludrocortison
dog
treat
docp
prednisolon
prospect
crossov
trial
perform
use
dog
hypoadrenocortic
previous
stabil
fludrocortison
dog
randomli
alloc
one
two
group
treat
month
fludrocortison
month
docp
prednisolon
vice
versa
prednisolon
dose
adjust
accord
clinic
sign
two
dog
fail
complet
trial
three
patient
receiv
prednisolon
concurr
least
part
fludrocortison
phase
data
dog
phase
remov
analysi
acth
level
measur
start
end
treatment
phase
use
immunoradiometr
assay
nationwid
laboratori
test
normal
perform
mannwhitney
u
test
use
compar
variou
acth
concentr
prednisolon
dose
start
end
docp
phase
pearson
correl
use
compar
final
prednisolon
dose
acth
concentr
end
docp
phase
signific
differ
acth
concentr
docp
median
pgml
compar
fludrocortison
median
pgml
start
docp
median
pgml
also
signific
reduct
prednisolon
dose
docp
phase
median
start
dose
mgkg
mgkg
month
treatment
docp
prednisolon
dog
acth
concentr
less
pgml
suggest
suppress
acth
secret
signific
correl
found
final
prednisolon
dose
acth
concentr
end
docp
phase
contrast
dog
acth
concentr
pgml
possibl
suggest
inadequ
glucocorticoid
supplement
follow
month
treatment
fludrocortison
conclud
mani
dog
hypoadrenocortic
treat
docp
dose
prednisolon
potenti
reduc
base
acth
concentr
disclosur
disclosur
report
lead
author
posit
previous
fund
dechra
ltd
manufactur
zycort
studi
fund
dechra
primari
hyperaldosteron
pha
suggest
common
cat
previous
thought
profibrot
proinflammatori
effect
aldosteron
may
contribut
progress
hypertens
kidney
damag
aim
present
studi
perform
pilot
studi
plasma
aldosteron
concentr
pac
plasma
renin
activ
pra
hypertens
cat
chronic
azotemia
sweden
twentyon
cat
chronic
azotemia
includ
studi
blood
sampl
collect
prechil
edta
tube
centrifug
separ
plasma
store
transport
commerci
laboratori
analysi
pac
measur
elisa
pra
radioimmunoassay
blood
pressur
bp
highdefinit
oscillometri
statist
analysi
perform
nonparametr
test
free
softwar
r
version
cat
median
pac
pmoll
rang
pmoll
refer
rang
pmoll
seventeen
cat
pac
refer
rang
pac
detect
limit
pmoll
median
pra
ngmlhr
rang
ngmlhr
refer
rang
ngml
hr
five
cat
pra
refer
rang
median
aldosteronetorenin
activ
ratio
arr
rang
eleven
cat
hypertens
bp
mmhg
median
pac
hypertens
cat
pmoll
rang
median
pac
normotens
cat
pmoll
rang
statist
differ
pac
pra
hypertens
normotens
cat
mannwhitneywilcoxon
test
p
p
respect
five
cat
pac
pmoll
hypertens
four
hypertens
cat
pra
lower
refer
rang
arr
cat
one
cat
arr
euthan
histopatholog
examin
reveal
mix
diffus
nodular
hyperplasia
z
glomerulosa
right
adren
gland
bilater
chronic
activ
interstiti
nephriti
remain
two
cat
arr
result
present
studi
indic
presenc
reninindepend
aldosteron
secret
cat
chronic
azotemia
surprisingli
high
proport
cat
subnorm
pac
observ
need
investig
conclus
drawn
disclosur
disclosur
report
scholarship
foundat
elsa
paulsson
memori
fund
grant
financ
part
cost
studi
dr
hanson
receiv
european
societi
endocrinologydechra
veterinari
product
travel
grant
research
veterinari
endocrinolog
financi
support
foundat
research
agria
insur
compani
swedish
research
council
thure
f
karin
forsberg
stiftels
hypothyroid
one
common
endocrinopathi
dog
diagnosi
hypothyroid
reli
upon
measur
basal
plasma
concentr
total
thyroxin
thyroid
stimul
hormon
tsh
low
plasma
combin
high
plasma
tsh
point
primari
hypothyroid
howev
hypothyroid
dog
tsh
valu
within
refer
rang
consequ
low
plasma
total
concentr
combin
plasma
tsh
concentr
within
refer
rang
distinguish
dog
hypothyroid
dog
nonthyroid
ill
nti
potenti
interest
observ
previou
studi
lee
et
al
et
al
hypothyroid
dog
associ
increas
releas
growth
hormon
gh
aim
studi
evalu
whether
trh
stimul
test
differenti
dog
nti
dog
hypothyroid
plasma
tsh
concentr
within
refer
rang
measur
plasma
concentr
gh
tsh
dog
clinic
sign
consist
hypothyroid
plasma
concentr
refer
interv
nmoll
plasma
tsh
concentr
within
refer
interv
includ
studi
thyroid
scintigraphi
perform
classifi
dog
hypothyroid
nti
dog
underw
trh
stimul
test
plasma
concentr
tsh
gh
measur
twice
intraven
administr
trh
min
trh
administr
dog
classifi
hypothyroid
dog
nti
thyroid
scintigraphi
differ
baselin
characterist
group
except
gender
plasma
tsh
concentr
chang
significantli
hypothyroid
dog
administr
trh
wherea
significantli
increas
nti
dog
p
contrast
plasma
gh
concentr
increas
significantli
hypothyroid
dog
trh
administr
p
wherea
chang
nti
dog
trh
stimul
test
measur
circul
concentr
tsh
gh
could
use
differenti
hypothyroid
dog
nti
dog
clinic
sign
hypothyroid
low
basal
concentr
basal
tsh
concentr
within
refer
interv
promis
test
might
valuabl
use
primari
veterinari
practic
disclosur
disclosur
report
studi
partial
fund
grant
american
kennel
club
veterinari
literatur
data
interact
thyroid
gland
femal
reproduct
statu
lack
furthermor
previou
studi
often
refer
male
dog
data
avail
thyroid
influenc
differ
phase
bitch
estrou
cycl
aim
studi
determin
influenc
differ
phase
estrou
cycl
thyroid
hormon
german
shepherd
bitch
seventeen
clinic
healthi
german
shepherd
bitch
month
year
old
monitor
complet
estrou
cycl
proestru
estru
diestru
anestru
differ
phase
determin
vagin
cytolog
two
blood
sampl
collect
cephal
vein
phase
pm
h
fast
thyroid
hormon
tsh
progesteron
serum
triglycerid
cholesterol
assess
blood
sampl
begin
end
studi
complet
hematolog
biochem
evalu
also
perform
seven
bitch
bred
studi
hormon
concentr
also
evalu
pregnanc
data
statist
analyz
correl
test
perform
thyroid
pituitari
hormon
age
differ
hormon
assess
thyroid
pituitari
sexual
hormon
estradiol
cholesterol
oneway
anova
use
compar
averag
paramet
thyroidpituitari
differ
phase
cycl
diestru
gravidarum
gravidarum
effect
size
cohen
root
mean
squar
standard
effect
calcul
measur
magnitud
strength
statist
signific
research
find
signific
neg
correl
age
r
p
r
p
r
p
found
one
way
anova
show
concentr
estrou
diestrou
phase
significantli
higher
proestrou
anestr
phase
p
tsh
concentr
diestru
pregnanc
significantli
differ
two
tail
ttest
p
even
though
higher
tsh
concentr
pregnanc
evid
r
p
r
p
posit
significantli
associ
progesteron
tsh
posit
significantli
correl
r
p
neg
significantli
correl
r
p
cholesterol
neg
significantli
correl
r
p
significantli
higher
diestru
r
p
signific
correl
total
triglycerid
result
show
influenc
reproduct
statu
thyroid
function
especi
progesteronepreval
phase
diestru
especi
relat
concentr
disclosur
disclosur
report
recent
valid
pharmacodynam
assay
pd
use
monitor
dog
treat
cyclosporin
assess
interferongamma
infc
studi
date
look
cytokin
secret
detect
dog
receiv
immunosuppress
drug
aim
studi
evalu
multipl
immunosuppress
drug
determin
individu
whether
affect
secret
infc
tumor
necrosi
factor
alpha
tnfa
healthi
dog
use
multiplex
assay
blood
obtain
healthi
adult
walker
hound
immunosuppress
treatment
standard
dose
use
random
crossov
studi
design
treatment
includ
azathioprin
cyclosporin
mycophenol
mofetil
leflunomid
prednison
blood
sampl
prior
follow
day
treatment
four
dog
test
drug
minimum
wash
period
three
week
whole
blood
activ
either
phorbol
acet
ionomycin
pmai
lipopolysaccharid
lp
cytokin
supernat
analyz
use
multiplex
assay
kruskalw
test
use
test
carryov
effect
drug
wilcoxon
signedrank
test
use
assess
activ
effect
cytokin
product
pretreat
stimul
blood
pmai
significantli
increas
infc
tnfa
wherea
stimul
lp
significantli
increas
tnfa
product
p
cytokin
signific
increas
either
activ
signific
carri
effect
detect
drug
use
azathioprin
leflunomid
mycophenol
treatment
reliabl
chang
cytokin
product
cytokin
test
dog
treat
cyclosporin
detect
tnfa
infc
treatment
blood
stimul
pmai
dog
treat
prednison
mark
reduct
tnfa
product
pretreat
concentr
pmai
stimul
dog
dog
reduct
least
tnfa
concentr
respect
lp
stimul
specif
pattern
cytokin
suppress
may
use
monitor
efficaci
immunosuppress
dog
treat
cyclosporin
prednison
clear
trend
seen
immunosuppress
drug
test
disclosur
disclosur
report
fund
coauthor
includ
fund
australian
research
council
canin
health
foundat
canin
research
foundat
hill
pet
nutrit
nexvet
biolog
plasvacc
none
fund
directli
relat
project
none
author
share
receiv
consult
fee
financi
interest
compani
neither
famili
member
indirect
immunofluoresc
iif
ana
test
standard
method
detect
ana
test
ana
specif
differ
techniqu
elisa
immunoblot
immunodiffus
routin
perform
human
dog
aid
diagnosi
diseas
sever
specif
ana
identifi
human
identifi
also
suspect
canin
sle
slerel
disord
mani
case
main
antigen
target
antibodi
identifi
iifana
posit
dog
usual
divid
two
subgroup
depend
fluoresc
pattern
speckl
pattern
chromosom
reactiv
homogen
pattern
chromosom
reactiv
previou
studi
shown
dog
speckl
iifana
pattern
posit
immunodiffus
aim
investig
immunodiffus
id
techniqu
use
sera
iifana
posit
dog
may
identifi
specif
ana
relev
human
patient
also
identifi
differ
subgroup
unknown
antigen
sera
iifana
posit
dog
speckl
fluoresc
pattern
part
studi
german
shepherd
dog
three
nsdtr
eight
dog
seven
differ
breed
ten
healthi
dog
differ
breed
use
control
thirtyon
iifana
posit
dog
posit
immunodiffus
twentynin
posit
dog
could
divid
three
separ
group
base
reaction
immunodiffus
group
n
group
n
reactiv
unknown
antigen
differ
group
group
n
antibodi
direct
rnp
breed
associ
ana
specif
observ
nsdtr
german
shepherd
dog
nsdtr
belong
group
group
consist
german
shepherd
dog
id
techniqu
thu
show
iifana
canin
sera
may
divid
subgroup
reflect
specif
ana
reactiv
dog
specif
ana
reactiv
could
identifi
might
indic
dogspecif
autoantigen
investig
canin
sera
need
order
identifi
specif
antigen
reactiv
ana
disclosur
disclosur
report
recov
initi
gener
interest
regard
poor
prognosi
veterinari
patient
suffer
cardiopulmonari
arrest
cpa
produc
evidencebas
guidelin
care
howev
scant
document
postdischarg
outcom
anim
surviv
studi
aim
describ
mortal
associ
inhospit
cpa
determin
median
surviv
time
dog
cat
surviv
cpa
examin
incid
persist
acquir
neurolog
deficit
medic
record
anim
underw
cardiopulmonari
resuscit
cpr
referr
centr
review
factor
examin
includ
speci
age
manag
depart
locat
hospit
arrest
primari
diseas
process
close
versu
open
cpr
return
spontan
circul
rosc
time
death
caus
death
survivor
discharg
identifi
anim
primari
care
veterinarian
contact
provis
medic
record
follow
discharg
total
anim
underw
cpr
dog
cat
anim
achiev
rosc
surviv
discharg
complet
medic
record
obtain
survivor
five
neurolog
deficit
includ
depress
mentat
ataxia
circl
blind
leav
hospit
either
complet
resolut
signific
improv
neurolog
deficit
within
one
month
eight
anim
die
follow
discharg
prior
complet
studi
period
howev
two
exclud
analysi
discharg
explicitli
palli
visit
remain
six
anim
median
surviv
time
day
day
fifteen
anim
aliv
complet
studi
median
day
follow
discharg
proport
anim
surviv
discharg
similar
report
veterinari
literatur
whilst
immedi
prognosi
anim
undergo
cpa
poor
anim
surviv
discharg
life
expect
reason
prognosi
good
improv
acquir
neurolog
deficit
felin
primari
erythrocytosi
pe
rare
myeloprolif
disord
caus
excess
increas
pack
cell
volum
pcv
veterinari
literatur
spars
isol
report
minim
inform
regard
prognosi
evalu
retrospect
multicentr
case
seri
felin
pe
aim
increas
understand
diseas
progress
guid
manag
prognost
theori
possibl
underli
genet
caus
evalu
compar
natur
histori
felin
pe
human
polycythemia
vera
pv
case
requir
document
increas
pcv
suffici
investig
exclud
rel
secondari
erythrocytosi
followup
data
least
twelv
month
death
eighteen
cat
five
uk
veterinari
hospit
includ
signific
trend
signal
note
seizur
mentat
chang
common
present
sign
n
median
pcv
total
protein
gl
respect
consist
blood
cell
chang
sixteen
cat
surviv
discharg
phlebotomi
perform
initi
cat
discharg
six
case
eventu
requir
phlebotomi
hydroxyurea
common
adjunct
therapi
n
fourteen
patient
aliv
time
write
surviv
time
month
case
seri
demonstr
manag
felin
pe
gener
welltoler
evid
prolong
surviv
time
diseas
characterist
similar
subset
human
pv
caus
mutat
exon
janu
kinas
gene
repres
possibl
futur
therapeut
target
disclosur
disclosur
report
canin
idiopath
pulmonari
fibrosi
cipf
progress
parenchym
lung
diseas
unknown
origin
poorli
understood
pathophysiolog
mainli
occur
old
west
highland
white
terrier
whwt
comput
tomograph
histopatholog
find
cipf
share
characterist
human
usual
intestin
pneumonia
uip
typic
pattern
ipf
human
nonspecif
interstiti
pneumonia
nsip
pattern
human
nsip
pattern
commonli
observ
hypersensit
pneumon
inflammatori
pulmonari
syndrom
result
sensit
inhal
antigen
fungal
particl
caus
irrevers
lung
fibrosi
chronic
stage
given
etiolog
identifi
cipf
object
studi
investig
potenti
fungal
caus
convent
panfung
pcr
assay
target
conserv
rdna
gene
intern
transcrib
spacer
region
fungi
use
two
primer
pair
perform
use
dna
extract
lung
tissu
sampl
whwt
affect
cipf
n
agematch
unaffect
control
n
dna
soil
aspergillu
fumigatu
isol
includ
posit
control
water
sampl
test
neg
control
addit
serum
sampl
whwt
affect
cipf
agematch
unaffect
whwt
test
precipitin
speci
environment
fungu
use
electrosyneresi
cellulos
acet
fungal
sequenc
amplifi
lung
sampl
suggest
invas
fungal
infect
heavi
colon
unlik
cipf
hand
result
serolog
assay
reveal
presenc
arc
precipitin
indic
posit
result
reaction
test
posit
result
cipf
popul
vs
control
p
support
increas
preval
environment
fungal
exposur
cipf
dog
compar
control
lichtheimia
corymbifera
commonli
involv
antigen
human
farmer
lung
hypersensit
pneumon
number
precipitin
arc
significantli
higher
cipf
dog
comparison
control
p
whether
find
reflect
lung
sensit
fungal
allergen
involv
pathogenesi
cipf
warrant
investig
disclosur
disclosur
report
record
case
diagnos
eosinophil
bronchiti
eb
idiopath
eosinophil
bronchopneumopathi
ebp
four
univers
hospit
uk
review
case
exclud
full
record
avail
pulmonari
diseas
neoplasia
parasit
pneumon
identifi
follow
inform
retriev
breed
age
sex
weight
clinic
sign
presenc
eosinophilia
thorac
imag
find
bronchoscopi
result
classifi
mild
moder
sever
balf
cytolog
result
eosinophil
pleocytosi
classifi
mild
moder
sever
infecti
diseas
screen
concurr
diseas
process
follow
subgroup
creat
acut
month
clinic
sign
versu
chronic
month
clinic
sign
radiograph
chang
bronchialperibronchi
pattern
vs
interstiti
alveolar
pattern
radiograph
chang
vs
pulmonari
pattern
group
comparison
chisquar
fisher
exact
test
carri
regard
age
weight
bronchoscopi
score
presenc
eosinophilia
bronchiectasi
degre
eosinophilia
balf
inclus
criteria
met
case
median
age
year
iqr
femal
crossbre
dog
commonli
affect
commonest
clinic
sign
cough
classifi
chronic
acut
group
versu
group
group
versu
group
circul
eosinophilia
occur
bronchiectasi
case
bronchoscopi
score
mild
moder
sever
balf
result
mild
patient
moder
sever
eb
case
p
p
less
like
eosinophilia
case
higher
degre
eosinophil
pleocytosi
balf
p
case
suffer
bronchiectasi
differ
p
clinic
variabl
eb
versu
ebp
group
acut
chronic
case
conclus
studi
includ
dog
eosinophil
lung
diseas
eld
gener
ebd
particular
commonli
young
adult
femal
crossbre
dog
commonli
affect
eb
dog
without
radiograph
chang
repres
differ
eld
popul
less
sever
eosinophil
pleocytosi
balf
absenc
bronchiectasi
eosinophilia
unlik
situat
human
medicin
obviou
clinic
diagnost
differ
acut
chronic
eld
dog
disclosur
disclosur
report
diagnos
idiopath
eosinophil
bronchiti
eb
idiopath
eosinophil
bronchopneumopathi
ebp
review
total
respons
tr
partial
respons
pr
resolut
improv
clinic
sign
respect
remiss
longterm
remiss
absenc
respiratori
sign
follow
discontinu
therapi
one
six
month
respect
relaps
reoccurr
clinic
sign
remiss
follow
subgroup
establish
acut
month
clinic
sign
versu
chronic
month
clinic
sign
radiograph
chang
bronchialperibronchi
pattern
versu
interstitialalveolar
pattern
radiograph
chang
versu
pulmonari
pattern
prednisolon
dose
mgkgday
antiinflammatoryav
mgkgday
immunomediatedi
group
compar
achiev
remiss
longterm
remiss
chisquar
fisher
exact
test
probabl
achiev
remiss
longterm
remiss
evalu
kaplan
meier
curv
long
rank
test
oral
prednisolon
administ
case
receiv
singleinh
therapi
also
receiv
combin
inhal
fluticason
differ
subgroup
p
immunosuppress
antiinflammatori
prednisolon
start
case
respect
differ
subgroup
p
latter
increas
immunosuppress
dose
control
clinic
sign
requir
surviv
deatheuthanasia
due
respiratori
diseas
respect
tr
pr
occur
case
respect
remiss
longterm
remiss
achiev
case
respect
relaps
occur
case
remiss
longterm
remiss
achiev
tr
pr
remiss
longterm
remiss
probabl
achiev
remiss
longterm
remiss
differ
p
subgroup
although
possibl
trend
toward
increas
likelihood
achiev
longterm
remiss
versu
group
observ
conclus
studi
includ
idiopath
eosinophil
lung
diseas
rare
lead
euthanasia
death
clinic
respons
achiev
dog
unlik
situat
human
found
evid
dog
eb
versu
ebp
dog
acut
versu
chronic
diseas
differ
outcom
mani
dog
achiev
total
respons
remiss
antiinflammatori
dose
prednisolon
plusminu
inhal
therapi
howev
whether
dog
immunosuppress
dose
use
less
like
achiev
longterm
remiss
warrant
studi
disclosur
disclosur
report
human
deviat
core
airway
microbiota
thought
predispos
develop
exacerb
progress
respiratori
diseas
object
describ
chang
airway
fecal
microbiota
cat
transit
healthi
day
asthmat
earli
week
chronic
week
stage
gut
microbiota
influenc
microbi
commun
distant
site
howev
asthma
local
diseas
hypothes
would
result
decreas
rich
divers
lower
airway
microbiota
contribut
state
dysbiosi
fecal
microbiota
would
remain
unaffect
fecal
oropharyng
op
bronchoalveolar
lavag
bal
sampl
collect
eight
healthi
research
cat
day
week
experiment
asthma
induct
use
bermuda
grass
allergen
extract
dna
underw
pcr
rrna
gene
sequenc
rich
divers
rel
abund
repres
oper
taxonom
unit
otu
determin
via
rm
anova
rank
p
princip
compon
analysi
pca
use
visual
related
sampl
differ
commun
composit
timepoint
test
use
permanova
braycurti
similar
indic
fece
decreas
rich
day
week
p
op
sampl
rich
increas
week
versu
day
p
respect
signific
chang
rel
abund
predomin
taxa
found
fecal
op
sampl
time
bal
rich
significantli
decreas
day
week
mean
otu
respect
p
rel
abund
pseudomonadacea
decreas
day
week
p
increas
sphingobacteriacea
bradyrhizobiacea
p
within
bal
permanova
detect
signific
differ
p
divers
sampl
collect
day
week
compar
timepoint
upper
lower
airway
commun
differ
fecal
microbiota
upper
airway
increas
rich
without
chang
rel
abund
predomin
taxa
note
asthma
induct
contrast
lower
airway
microbiota
undergo
signific
chang
earli
chronic
stage
asthma
decreas
rel
abund
organ
associ
healthi
airway
support
concept
airway
dysbiosi
knowledg
chang
asthmat
airway
microbi
popul
open
door
investig
modul
airway
microbiota
attenu
diseas
disclosur
disclosur
report
aspirationrel
respiratori
syndrom
well
recogn
human
half
healthi
adult
aspir
without
appar
clinic
consequ
understand
frequenc
sever
reflux
microaspir
healthi
individu
critic
determin
role
respiratori
diseas
pathogenesi
dog
analog
inform
lack
object
pilot
studi
use
scintigraph
reflux
studi
investig
frequenc
locat
durat
reflux
aspir
event
healthi
dog
healthi
dog
without
aerodigest
symptom
within
preced
month
fed
meal
contain
mci
colloid
mtechnetium
phytat
time
activ
curv
tac
quantifi
pharynx
three
esophag
zone
min
postingest
static
imag
lung
obtain
h
evalu
aspir
reflux
character
count
exceed
background
activ
data
report
descript
median
rang
five
healthi
adult
dog
median
year
rang
year
enrol
dog
reflux
event
median
rang
total
min
dynam
collect
period
reflux
limit
distal
esophag
reflux
rise
n
reflux
failur
clearanc
fall
n
reflux
appropri
clearanc
tac
pharyng
contamin
identifi
one
dog
aspir
observ
dog
dog
scintigraph
reflux
studi
document
reflux
may
complement
videofluoroscop
swallow
studi
esophag
ph
monitor
reflux
aspir
common
healthi
dog
must
consid
interpret
result
clinic
affect
dog
disclosur
disclosur
report
canin
angiostrongylosi
consid
emerg
condit
belgium
gold
standard
diagnosi
base
detect
firststag
larva
baermann
fecal
analysi
howev
imperfect
sensit
main
disadvantag
test
altern
method
includ
serolog
molecular
assay
develop
improv
diagnosi
detect
circul
antigen
seem
enabl
diagnosi
patenc
howev
sensit
naturallyinfect
dog
neg
baermann
analysi
document
pcr
bronchoalveolar
lavag
fluid
balf
recent
report
valuabl
tool
help
dog
neg
baermann
analysi
compar
use
fecal
serolog
test
balf
analysi
investig
naturallyinfect
dog
aim
studi
report
compar
result
rapid
test
detect
circul
antigen
baermann
analysi
pcr
balf
small
seri
dog
angiostrongylosi
dog
suspect
angiostrongylosi
base
clinic
find
result
three
differ
diagnost
method
avail
retrospect
includ
three
method
pcr
perform
balf
rapid
blood
test
angiodetect
tm
idexx
laboratori
baermann
analysi
perform
three
fecal
sampl
seven
dog
select
owner
report
cough
dyspnea
variabl
sever
week
month
durat
pcr
balf
posit
dog
rapid
test
neg
dog
uninterpret
anoth
one
among
dog
neg
rapid
test
baermann
analysi
also
neg
dog
bronchoscopi
pcr
balf
thu
essenti
diagnosi
dog
present
moderatetosever
clinic
sign
week
pcr
balf
consid
gold
standard
rel
sensit
rapid
test
baermann
analysi
would
respect
conclus
even
though
baermann
analysi
rapid
test
use
firstlin
tool
avail
costeffect
noninvas
might
lower
sensit
balf
pcr
analysi
earli
case
base
small
descript
seri
bronchoscopi
pcr
balf
may
consid
clinicallysuspect
dog
rapid
test
baermann
analysi
neg
studi
includ
elisa
assay
antigen
antibodi
warrant
help
select
appropri
diagnost
test
canin
angiostrongylosi
disclosur
disclosur
report
cough
protect
mechan
promot
clearanc
respiratori
tract
also
contribut
patholog
clinic
diseas
marker
target
therapeut
intervent
cough
assess
dog
subject
gener
base
owner
percept
object
method
evalu
need
human
acoust
cough
monitor
provid
object
data
cough
number
intens
examin
acoust
waveform
hypothes
healthi
dog
would
demonstr
cough
waveform
could
distinguish
acoust
behavior
ab
whine
bark
growl
lick
drink
chew
throatclear
data
obtain
healthi
employeeown
dog
inform
consent
acoust
behavior
record
use
ctalaryngealmicrophon
analyz
use
ravenpro
bioacoust
analysi
softwar
ab
durat
peak
amplitud
frequenc
time
peak
amplitud
frequenc
power
energi
interand
intragroup
statist
analysi
perform
use
oneway
anova
rank
p
signific
except
throatclear
cough
distinguish
everi
evalu
ab
one
analyz
waveform
paramet
p
betweensubject
differ
identifi
cough
throatclear
group
waveform
paramet
behavior
show
statist
signific
withingroup
variat
p
cough
throatclear
clinic
similar
mechan
protect
airway
repeat
acoust
featur
distinguish
common
ab
consist
dog
acoust
monitor
may
provid
object
mean
evalu
cough
dog
respiratori
diseas
assess
respons
therapeut
intervent
disclosur
disclosur
report
tracheal
stent
indic
dog
refractori
tracheal
collaps
inform
regard
clinic
improv
owner
satisfact
follow
stent
scarc
object
studi
screen
clinic
radiograph
endoscop
predictor
improv
surviv
tracheal
stent
ii
assess
longterm
owner
satisfact
dog
treat
tracheal
stent
retrospect
identifi
dog
surviv
day
stent
includ
data
extract
medic
record
thorac
radiograph
review
assess
potenti
clinic
improv
surviv
predictor
via
univari
multivari
analys
clinic
improv
studi
via
paramet
cough
respiratori
distress
noisi
breath
fatig
rank
owner
base
sever
stent
use
subject
scale
owner
satisfact
measur
via
scale
twentyseven
dog
includ
median
surviv
time
stent
day
rang
predictor
clinic
improv
stent
identifi
age
stent
p
fatig
score
improv
p
noisi
breath
score
improv
p
total
clinic
score
improv
p
owner
satisfact
p
significantli
associ
surviv
stent
univari
analysi
age
stent
p
noisi
breath
score
improv
p
owner
satisfact
p
remain
signific
surviv
predictor
multivari
analysi
median
satisfact
score
rang
owner
would
redo
procedur
base
result
age
stent
owner
satisfact
noisi
breath
improv
prognost
factor
tracheal
stent
owner
satisfact
overal
good
disclosur
disclosur
report
dog
nasal
discharg
prospect
enrol
ct
endoscop
find
indic
sna
fungal
cultur
pcr
posit
afumigatu
trephin
frontal
sinu
perform
involv
seen
ct
could
reach
endoscop
fungal
plaqu
loosen
curett
remov
affect
frontal
sinu
suction
flush
use
copiou
amount
balanc
electrolyt
solut
l
trephin
perform
fungal
plaqu
necrot
materi
sinu
loosen
forcep
endoscop
guidanc
flush
evid
fungal
materi
left
frontal
sinu
flush
suction
continu
nasal
caviti
procedur
flush
suction
last
h
perform
visibl
fungal
materi
necrot
tissu
remov
antifung
drug
use
recheck
endoscopi
sinonas
flush
repeat
week
later
resolut
sna
defin
absenc
visibl
fungal
plaqu
neglig
amount
necrot
materi
present
second
flush
clinic
sign
month
later
base
telephon
commun
far
dog
enrol
mean
year
old
month
reevalu
dog
die
unrel
sna
month
enrol
trephin
perform
dog
fungal
materi
seen
dog
recheck
endoscopi
median
day
owner
confirm
nasal
discharg
telephon
commun
median
day
preliminari
studi
suggest
antifung
drug
need
treatment
canin
sna
debrid
perform
meticul
absolut
fungal
materi
remov
disclosur
disclosur
report
diagnosi
chronic
kidney
diseas
ckd
cat
current
made
use
creatinin
indirect
marker
glomerular
filtrat
rate
gfr
togeth
histor
clinic
inform
evalu
urin
concentr
abil
howev
creatinin
recogn
insensit
earli
declin
gfr
symmetr
dimethylarginin
sdma
novel
biomark
gfr
studi
suggest
may
sensit
creatinin
detect
earli
declin
fibroblast
growth
factor
phosphatur
hormon
known
increas
declin
gfr
shown
predict
onset
azotemia
cat
year
indic
disturb
phosphat
homeostasi
introduct
sdma
led
identif
cat
sdma
increas
plasma
creatinin
remain
within
refer
interv
ri
current
littl
understand
metabol
chang
present
cat
aim
studi
examin
relationship
plasma
sdma
concentr
nonazotem
geriatr
cat
clinicopatholog
inform
cat
year
sourc
record
two
first
opinion
practic
cat
current
histor
diagnosi
azotem
ckd
creatinin
serum
thyroxin
nmoll
chronic
diseas
exclud
cat
categor
two
group
elev
sdma
sdma
within
ri
store
sampl
use
quantifi
cat
data
present
median
th
th
percentil
comparison
made
group
use
mannwhitney
u
test
relationship
numer
variabl
evalu
use
spearman
correl
p
concentr
phosphat
concentr
differ
group
p
weak
posit
relationship
demonstr
sdma
r
p
creatinin
r
p
cat
elev
sdma
higher
concentr
sdma
within
ri
suggest
presenc
alter
phosphat
homeostasi
despit
signific
differ
plasma
phosphat
concentr
studi
requir
identifi
factor
influenc
relationship
util
concentr
inform
manag
cat
earli
stage
ckd
disclosur
renal
aklotho
function
coreceptor
fibroblast
growth
factor
therefor
play
import
role
phosphat
homeostasi
transmembran
protein
primarili
found
renal
tubul
express
reduc
patient
chronic
kidney
diseas
ckd
human
studi
anim
model
aklotho
defici
associ
hyperphosphatemia
renal
fibrosi
increas
mortal
chronic
kidney
diseas
common
disord
age
cat
hyperphosphatemia
excess
import
prognost
indic
role
aklotho
assess
cat
date
therefor
aim
local
renal
aklotho
protein
felin
kidney
tissu
formalinfix
paraffinembed
section
postmortem
kidney
tissu
cat
vari
kidney
function
immunohistochem
stain
use
rabbit
polyclon
antiaklotho
antibodi
dilut
antiklotho
antibodi
abcam
cambridg
uk
visual
immunoenzymat
antigen
detect
system
rabbit
specif
hrpdab
detect
kit
abcam
cambridg
uk
mous
kidney
section
use
posit
control
felin
kidney
section
incub
isotypespecif
immunoglobulin
substitut
primari
antibodi
serv
neg
control
stain
specif
section
counterstain
hematoxylin
western
blot
analysi
perform
felin
renal
tubular
cell
lysat
assess
molecular
size
antibodybound
protein
western
blot
analysi
show
primari
antibodi
bound
singl
antigen
kda
size
appropri
molecular
size
aklotho
posit
stain
detect
neg
isotyp
control
section
confirm
specif
stain
aklotho
alphaklotho
protein
express
identifi
immunohistochem
proxim
distal
tubul
murin
felin
kidney
tissu
intens
stain
distal
tubul
compar
proxim
tubul
renal
aklotho
protein
express
cat
show
similar
express
report
speci
work
necessari
investig
loss
aklotho
express
occur
felin
ckd
relat
renal
fibrosi
miner
bone
disord
cat
ckd
disclosur
earli
detect
decreas
glomerular
filtrat
rate
gfr
dog
difficult
current
method
insensit
refer
rang
wide
sensit
biomark
warrant
aim
studi
investig
use
new
marker
symmetr
dimethylarginin
sdma
comparison
creatinin
detect
decreas
gfr
dog
without
stabl
diagnosi
chronic
kidney
diseas
ckd
ninetyseven
clientown
dog
prospect
includ
studi
dog
diagnosi
strong
suspicion
ckd
healthi
dog
dog
underw
physic
examin
blood
pressur
measur
urinalysi
hematolog
blood
biochemistri
cardiac
urinari
ultrasound
examin
scintigraphi
calcul
glomerular
filtrat
rate
mgfr
decreas
mgfr
predefin
mlminl
normal
estim
extracellular
plasma
volum
ecfv
instead
bodi
weight
less
depend
hydrat
statu
dog
estim
ecfv
perform
accord
routin
use
rutlandpatlak
plot
mathemat
model
describ
transfer
technetiumdtpa
blood
compart
renal
compart
creatinin
sdma
posit
correl
r
reciproc
creatinin
sdma
linearli
correl
gfr
r
respect
sensit
creatinin
sdma
prespecifi
cutoff
l
respect
detect
abnorm
gfr
exactli
dog
studi
specif
creatinin
sdma
conclus
diagnost
perform
creatinin
sdma
use
prespecifi
cutoff
detect
decreas
gfr
dog
studi
similar
disclosur
disclosur
report
increas
glomerular
filtrat
rate
gfr
decreas
muscl
mass
make
identif
chronic
kidney
diseas
ckd
hyperthyroid
cat
challeng
symmetr
dimethylarginin
sdma
promis
indirect
renal
biomark
correl
close
gfr
healthi
geriatr
ckd
cat
aim
studi
evalu
sdma
reliabl
renal
biomark
hyperthyroid
cat
fortyseven
clientown
hyperthyroid
nonazotem
creatinin
lmoll
cat
prospect
enrol
treat
radioiodin
antithyroid
medic
discontinu
day
prior
treatment
cat
free
medic
least
day
prior
treatment
free
clinic
relev
system
diseas
creatinin
sdma
idexx
sdma
tm
test
determin
month
treatment
gfr
plasma
exogen
creatinin
clearanc
test
measur
cat
expect
creatinin
significantli
increas
p
gfr
significantli
decreas
p
treatment
sdma
significantli
chang
time
p
cat
becam
azotem
creatinin
lmoll
normal
sdma
time
point
sdma
elev
lgdl
cat
normal
treatment
cat
gfr
avail
cat
within
normal
limit
sdma
normal
sdma
increas
lgdl
cat
borderlin
low
gfr
defin
gfr
mlminkg
pearson
correl
n
gfr
sdma
moder
low
r
p
r
p
correl
gfr
creatinin
moder
r
p
r
p
forti
fortyon
cat
pretreat
sdma
within
refer
interv
remain
nonazotem
posttreat
howev
enough
patient
becam
azotem
posttreat
evalu
sdma
predict
posttreat
renal
azotemia
previou
studi
show
sdma
promis
renal
biomark
studi
necessari
fulli
assess
util
felin
hyperthyroid
disclosur
disclosur
report
studi
support
idexx
laboratori
avail
marker
acut
kidney
injuri
aki
lack
sensit
specif
consequ
diagnosi
aki
delay
gradei
aki
commonli
unrecogn
hypothes
urinari
interleukin
il
sensit
specif
marker
aki
urin
sampl
healthi
dog
dog
lower
urinari
tract
diseas
lutd
chronic
kidney
diseas
ckd
acut
kidney
injuri
aki
risk
aki
collect
urin
concentr
measur
use
elisa
correct
urinari
creatinin
sixtysix
dog
includ
posit
correl
p
r
median
healthi
lutd
ckd
aki
dog
risk
pgmg
pgmg
pgmg
pgmg
pgmg
respect
median
pg
mg
pgmg
pgmg
pgmg
pgmg
respect
signific
differ
among
studi
group
higher
aki
group
compar
group
except
differ
aki
ckd
group
median
dog
risk
aki
higher
compar
healthi
dog
p
p
respect
roc
analysi
ucr
aki
predictor
area
curv
respect
cutoff
point
associ
sensit
specif
respect
respect
conclus
sensit
specif
marker
aki
aki
associ
high
mortal
partial
due
late
recognit
use
avail
marker
current
research
aim
identifi
new
aki
biomark
howev
specif
hamper
also
express
extraren
tissu
recent
assay
develop
kidneyspecif
urinari
clusterin
uclu
serum
urin
cystatin
b
scysb
ucysb
respect
assess
util
dog
recruit
categor
healthi
control
chronic
kidney
diseas
ckd
aki
uti
median
uclusucr
ngmg
rang
control
uti
ckd
aki
group
respect
differenti
control
aki
receiv
oper
roc
area
curv
auc
ci
roc
analysi
appli
dog
auc
ci
cutoff
ngmg
result
sensit
specif
median
scysb
ng
ml
rang
ngml
ngml
control
ckd
aki
group
respect
differenti
control
aki
auc
ci
roc
analysi
appli
dog
show
auc
ci
ngml
cutoff
gave
sensit
specif
roc
analysi
ucysb
compar
aki
group
gave
auc
ci
ngml
cutoff
associ
sensit
specif
respect
conclus
novel
kidneyspecif
biomark
differenti
aki
healthi
control
urinari
tract
condit
specif
major
advantag
compar
previous
report
biomark
disclosur
studi
shown
increas
preval
urinari
tract
infect
uti
cat
chronic
kidney
diseas
ckd
inform
avail
dog
aim
studi
determin
preval
uti
cohort
dog
ckd
investig
impact
age
sex
includ
neuter
statu
iri
stage
dog
retrospect
recruit
two
veterinari
teach
hospit
januari
june
diagnos
ckd
cultur
perform
urin
collect
cystocentesi
ckd
diagnos
dog
increas
blood
creatinin
concentr
consist
clinic
andor
ultrasonograph
sign
azotem
dog
dog
creatinin
concentr
renal
proteinuria
minim
concentr
urin
ultrasonograph
sign
ckd
abnorm
renal
histolog
iri
stage
azotem
dog
categor
iri
stage
creatinin
valu
measur
least
two
week
apart
other
left
unstag
dog
diseas
could
predispos
uti
receiv
treatment
could
impact
urinari
specif
graviti
exclud
differ
group
assess
use
chisquar
mannwhitney
test
statist
signific
defin
p
two
hundr
one
dog
includ
uti
escherichia
coli
identifi
lower
urinari
tract
sign
report
dog
uti
sixtyon
azotem
dog
could
stage
uti
twenti
eight
percent
dog
stage
dog
stage
dog
stage
dog
stage
ckd
uti
dog
stage
significantli
less
uti
dog
stage
p
respect
signific
differ
group
signific
differ
found
preval
uti
age
neuter
preval
uti
higher
femal
male
p
preval
uti
popul
dog
ckd
asymptomat
alreadi
describ
femal
overrepres
high
preval
urin
cultur
could
recommend
dog
ckd
regardless
age
sex
iri
stage
even
though
true
clinic
impact
find
current
unknown
disclosur
disclosur
report
phylogeni
antibiot
resist
profil
resistom
urinari
e
coli
isol
individu
dog
differ
time
point
investig
gain
better
understand
recurr
persist
e
coli
uti
microbiolog
databas
uvet
werribe
anim
hospit
screen
urinari
e
coli
isol
dog
least
two
posit
urin
cultur
comorbid
date
respect
urin
cultur
retriev
dog
medic
record
e
coli
strain
recov
frozen
storag
bank
subject
whole
genom
sequenc
core
genom
studi
strain
compar
refer
strain
multilocu
sequenc
type
mlst
identifi
strain
resistom
determin
search
genom
known
antibiot
resist
gene
seventysix
e
coli
strain
dog
analyz
dog
condit
predispos
uti
treat
antibiot
posit
urin
cultur
number
examin
e
coli
strain
per
individu
dog
rang
median
origin
recov
median
time
span
day
rang
day
overal
e
coli
phylogenet
divers
differ
mlst
record
core
genom
similar
refer
none
e
coli
isol
ident
core
genom
howev
dog
median
e
coli
highli
similar
core
genom
singl
nucleotid
differ
rang
identifi
highli
similar
e
coli
origin
cultur
urin
affect
dog
median
time
span
day
rang
day
case
highli
similar
strain
ident
resistom
time
dog
least
one
strain
phylogenet
differ
also
present
dog
strain
cultur
episod
highli
similar
strain
thirtyf
strain
phenotyp
multidrugresist
mdr
differ
antibiot
resist
gene
median
identifi
appar
correl
time
point
strain
isol
ie
late
earli
diseas
mdr
statu
result
studi
suggest
major
e
coli
isol
urin
dog
comorbid
either
belong
one
evolv
lineag
sever
highli
similar
lineag
coexist
given
dog
chang
resistom
uncommon
disclosur
disclosur
report
dr
bulach
affili
doherti
appli
microbi
genom
doherti
institut
melbourn
australia
laboratori
work
abstract
perform
doherti
institut
affili
univers
melbourn
fluoroquinoloneresist
fq
r
subclon
e
coli
sequenc
type
nest
esbl
associ
subset
global
dissemin
virul
group
e
coli
multidrugresist
lineag
caus
infect
human
within
phylogenet
group
sequenc
type
complex
anoth
human
increasingli
resistanceassoci
e
coli
lineag
studi
aim
detect
evalu
preval
human
pandem
clone
among
e
coli
strain
caus
urinari
tract
infect
companion
anim
character
virul
antimicrobi
resist
studi
e
coli
isol
companion
anim
urinari
tract
infect
studi
regard
clonal
background
virul
antimicrobi
resist
suscept
toward
sixteen
antimicrobi
agent
done
disk
diffus
pcrbase
assay
use
detect
phylogroup
pathogen
associatedisland
pai
n
urovirul
gene
n
antimicrobi
resist
gene
n
human
pandem
e
coli
lineag
furthermor
thirdgener
cephalosporin
resist
e
coli
type
mlst
order
detect
e
coli
sequenc
type
complex
regard
phylogenet
background
isol
predominantli
n
follow
groupa
n
n
groupd
n
lineag
repres
n
uropathogen
strain
common
n
mdr
fq
r
common
pathogen
virulenceassoci
gene
profil
pai
pai
iv
pai
ii
n
ecppapefiucd
n
strain
n
fq
r
produc
subclon
among
e
coli
phylogroup
repres
lineag
n
follow
n
isol
mdr
bla
produc
one
also
bla
pai
virul
gene
profil
belong
mostli
pai
pai
iv
n
pai
ii
iv
n
ecpapapef
n
respect
studi
report
first
time
detect
worldwidedissemin
virul
mdr
fq
r
human
clone
subclon
companion
anim
detect
human
highrisk
pandem
e
coli
lineag
caus
uti
companion
anim
besid
anim
health
problem
great
publichealth
concern
acknowledg
diagnosi
canin
urinari
tract
infect
uti
base
posit
urin
cultur
inflammatori
sediment
practic
cultur
andor
sediment
analysi
alway
perform
prior
use
antibiot
odd
ration
prescrib
inclin
measur
biomark
specif
test
uti
would
therefor
great
valu
human
concentr
number
urinari
biomark
increas
uti
yet
evalu
dog
determin
behav
similarli
aim
determin
whether
measur
inflammatori
biomark
canin
urin
could
correctli
identifi
bacteri
infect
hypothesi
crp
procalcitonin
lactoferrin
concentr
canin
urin
confirm
infect
significantli
increas
compar
control
specif
canin
elisa
develop
crp
procalcitonin
lactoferrin
select
given
associ
uti
human
medicin
assay
underw
comprehens
valid
prior
initi
studi
biomark
measur
residu
urin
sampl
follow
routin
urinalysi
cohort
dog
confirm
uti
n
control
cohort
without
uti
n
inclus
criteria
uti
group
posit
urin
cultur
inflammatori
urin
sediment
control
sampl
inact
sediment
steril
cultur
studi
approv
establish
ethic
review
committe
compar
nonparametr
dataset
mannwhitney
test
perform
multipl
comparison
nonparametr
dataset
kruskal
walli
test
use
signific
increas
crp
p
lactoferrin
p
concentr
uti
sampl
control
enterococci
significantli
increas
crp
concentr
compar
coliform
p
mix
bacteri
popul
p
enterococci
significantli
increas
concentr
compar
coliform
p
enterococci
significantli
increas
procalcitonin
concentr
compar
mix
bacteri
popul
p
roc
curv
use
determin
sensit
specif
crp
lactoferrin
detect
uti
crp
cutoff
ngml
gave
sensit
specif
lactoferrin
cutoff
ngml
gave
sensit
specif
combin
crp
lactoferrin
gave
sensit
specif
uti
correl
crp
lactoferrin
excel
r
pilot
studi
demonstr
novel
urin
biomark
either
alon
combin
identifi
uti
dog
bacteria
increas
concentr
biomark
urin
other
result
demonstr
potenti
valu
measur
urinari
biomark
inclin
screen
urin
sampl
infect
improv
antibiot
stewardship
disclosur
disclosur
report
dr
dun
consult
role
avacta
anim
health
dr
slater
chief
scientif
offic
avacta
anim
health
dr
moodi
barrasshemmen
assay
develop
scientist
employ
avacta
anim
health
calcium
oxal
caox
ureterolithiasi
emerg
caus
felin
ureter
obstruct
uo
last
year
sever
risk
factor
uo
identifi
includ
hypercalcemia
one
studi
show
hypocalcemia
frequent
cat
urethr
obstruct
hyperphosphatemia
hypothes
causal
factor
aim
retrospect
studi
assess
ioniz
calcium
concentr
ica
vari
cat
uo
uo
manag
cat
uo
group
ica
measur
least
three
time
minim
period
day
enrol
compar
control
group
includ
cat
ckd
stage
iri
group
uo
treat
medic
surgic
procedur
group
includ
cat
group
includ
cat
time
diagnosi
differ
median
creatinin
concentr
median
ica
distribut
hypercalcem
normocalcem
hypocalcem
cat
group
median
phosphoru
concentr
significantli
higher
group
mgl
vs
mgl
p
time
signific
increas
proport
hypercalcem
cat
observ
group
end
studi
versu
ci
versu
ci
p
averag
time
onset
hypercalcemia
cat
day
rang
among
hypercalcem
group
proport
cat
normoor
hypercalcem
vari
studi
period
result
suggest
ica
monitor
cat
uo
presenc
ioniz
hypercalcemia
could
misdiagnos
time
diagnosi
becom
evid
uo
treatment
result
suggest
concurr
hyperphosphatemia
could
explain
find
identif
ioniz
hypercalcemia
potenti
risk
factor
uo
import
appropri
manag
cat
disclosur
disclosur
report
aim
character
urinari
find
urinalysi
urin
chemistri
qualit
proteinuria
result
retrospect
evalu
cat
rtpcr
posit
urin
femv
femv
femv
compar
ckd
healthi
blood
donor
cat
anim
follow
inform
avail
signal
histori
physic
exam
clinicopatholog
evalu
includ
cbc
serum
chemistri
profil
urinalysi
includ
urin
specif
graviti
usg
dipstick
sediment
examin
urin
proteintocreatinin
ratio
upc
fraction
excret
electrolyt
urin
sdspage
stain
coomassi
blue
urin
cultur
kidney
histopatholog
immunohistochemistri
femv
evalu
necropsi
n
data
analyz
descript
statist
compar
use
nonparametr
test
kruskalw
test
p
valu
consid
signific
femv
outdoor
domest
shorthair
cat
neuter
male
femal
spay
median
age
month
rang
signific
increas
upc
observ
femv
median
rang
compar
healthi
subject
median
rang
p
statist
differ
detect
infect
cat
ckd
cat
median
rang
femv
sdspage
qualit
proteinuria
show
differ
compar
healthi
cat
particular
tubular
pattern
evidenc
decreas
uromodulin
increas
number
intens
low
molecular
weight
protein
indic
renal
involv
although
less
sever
ckd
cat
renal
patholog
show
tubulointerstiti
nephriti
posit
immunohistochem
stain
femvn
protein
tubular
cell
urin
find
femv
suggest
presenc
earli
tubulointerstiti
damag
character
tubular
proteinuria
mild
reduct
urin
concentr
abil
urin
electrolyt
handl
dysfunct
detect
prospect
studi
combin
longterm
patient
followup
renal
patholog
urin
evalu
warrant
obtain
better
character
potenti
femvassoci
renal
damag
disclosur
disclosur
report
commerci
avail
nonabsorb
litter
becom
increasingli
popular
urin
collect
cat
object
studi
assess
effect
devic
routin
felin
urinalysi
result
potenti
issu
address
date
thirtyon
cat
subject
cystocentesi
urinalysi
part
diagnost
workup
includ
fraction
urin
sampl
collect
cystocentesi
immedi
process
obtain
refer
urinalysi
usg
dipstick
upc
remain
urin
pour
nonabsorb
litter
tray
urin
specimen
retriev
tray
immedi
h
room
temperatur
urinalysi
repeat
term
effect
urin
time
contact
litter
urinari
analyt
assess
use
gener
linear
model
dunnett
test
rang
result
obtain
refer
specimen
wide
vast
major
sampl
neg
keton
glucos
bilirubin
test
urin
retriev
tray
keton
reagent
pad
found
unreli
result
analyt
test
statist
differ
refer
specimen
occas
observ
differ
clinic
relev
usg
h
protein
reagent
pad
result
dipstick
h
conclus
urin
collect
within
h
contact
nonabsorb
litter
test
suitabl
upc
measur
dipstick
reagentpad
usg
assess
disclosur
disclosur
report
urin
inpati
collect
h
prior
studi
kept
refriger
pool
sampl
divid
three
sampl
titrat
naoh
hcl
achiev
consist
visual
urin
dipstick
ph
read
sampl
sampl
sampl
respect
read
obtain
calibr
refer
bench
top
ph
meter
sampl
kept
chill
studi
period
studi
particip
given
one
aliquot
sampl
six
urin
dipstick
oper
ask
measur
record
urin
ph
aliquot
use
first
standard
visual
autom
analyz
read
method
nineteen
final
year
student
veterinarian
surgeon
veterinari
nurs
particip
studi
standard
visual
read
ph
valu
number
particip
record
result
bracket
sampl
sampl
sampl
use
autom
analyz
result
obtain
sampl
sampl
sampl
concord
result
studi
particip
author
occur
visual
read
autom
analyz
result
sampl
visual
report
alkalin
ph
particip
acid
ph
particip
conclus
standard
visual
read
urinari
dipstick
demonstr
poorer
interoper
reproduc
measur
canin
urinari
ph
comparison
autom
method
potenti
clinic
implic
sampl
classifi
acid
alkalin
instanc
potenti
affect
clinic
decis
make
disclosur
disclosur
report
dog
natur
occur
parvoviru
infect
may
risk
develop
acut
kidney
injuri
due
sever
risk
factor
includ
sever
dehydr
system
inflammatori
respons
syndrom
sepsi
earli
detect
kidney
injuri
import
yet
challeng
convent
renal
paramet
serum
creatinin
scr
blood
urea
nitrogen
bun
insensit
marker
earli
stage
kidney
injuri
dysfunct
therefor
aim
studi
investig
potenti
kidney
injuri
dog
natur
occur
parvovir
infect
compar
standard
novel
urinari
biomark
twentytwo
dog
parvovir
infect
prospect
enrol
compar
eight
clinic
healthi
control
dog
blood
urin
sampl
collect
present
group
h
later
patient
group
urinari
immunoglobulin
g
uigg
creactiv
protein
ucrp
measur
document
glomerular
injuri
wherea
urinari
retinolbind
protein
urbp
neutrophil
gelatinaseassoci
lipocalin
ungal
serv
biomark
tubular
injuri
biomark
compar
routin
renal
function
paramet
includ
scr
bun
urinari
protein
creatinin
ratio
upc
urin
specif
graviti
usg
commerci
elisa
valid
measur
canin
uigg
ucrp
urbp
ungal
use
statist
analysi
perform
use
nonparametr
mannwhitney
wilcoxon
sign
rank
test
dog
parvoviru
infect
significantli
higher
concentr
uigg
p
ucrp
p
urbp
p
ungal
p
compar
healthi
dog
ucrp
urbp
remain
significantli
higher
compar
control
p
p
respect
concentr
uigg
decreas
significantli
p
parvoviru
infect
dog
mark
contrast
scr
significantli
lower
dog
parvovir
infect
p
p
respect
compar
healthi
dog
bun
significantli
differ
p
although
usg
upc
significantli
higher
dog
parvoviru
p
p
respect
upc
remain
significantli
higher
p
compar
healthi
dog
conclus
studi
show
dog
parvovir
infect
acut
kidney
injuri
manifest
glomerular
tubular
level
remain
undetect
routin
renal
function
marker
scr
bun
result
emphas
ad
valu
novel
kidney
injuri
urinari
biomark
detect
monitor
patient
risk
disclosur
disclosur
report
introduct
canin
lymphoma
common
hematopoiet
neoplasia
dog
routin
treat
multidrug
chemotherapi
protocol
despit
high
initi
respons
rate
tumor
relaps
common
often
resist
chemotherapi
result
treatment
failur
altern
treatment
option
mandatori
sinc
masitinib
show
mild
antiprolif
effect
lymphoid
cell
protein
kinas
inhibitor
pki
might
provid
altern
materi
method
canin
bcell
lymphoid
cell
line
doxorubicinvincristin
resist
sublin
demonstr
pgp
overexpress
cell
line
cultur
previous
describ
cell
viabil
assess
use
colorimetr
assay
cell
seed
plate
densiti
cell
per
well
cell
cultur
medium
contain
concentr
rang
pki
test
incub
h
resazurin
ad
h
prior
analysi
reduc
fluoresc
molecul
resorufin
measur
light
absorb
fluoresc
spectrophotomet
nm
experi
perform
triplic
cell
surviv
calcul
divid
light
absorb
treat
cell
control
cell
correct
background
absorb
concentr
depend
effect
analyz
nonlinear
regress
log
transform
pki
concentr
median
inhibitori
concentr
calcul
measur
pki
antiprolif
effect
graph
fit
accord
doserespons
curv
result
variou
pki
cell
rang
sorafenib
quizartinib
sunitinib
toceranib
tozasertib
dasatinib
pazopanib
nilotinib
erlotinib
axitinib
gefitinib
imatinib
masitinib
lapatinib
vandetanib
relev
differ
found
pki
test
conclusiondiscuss
sever
pki
inhibit
lymphoid
cell
prolifer
good
direct
activ
shown
inhibitor
raf
alk
pimkinas
fak
aurora
kinas
requir
clinic
evalu
pki
target
ckit
pdgfr
vegfr
show
variabl
antiprolif
effect
pki
target
egfr
littl
inhibitori
effect
pki
test
show
similar
cell
suggest
pgp
overexpress
role
tumor
resist
pki
guarante
valu
case
tumor
resist
cystostat
drug
disclosur
disclosur
report
p
dubreuil
involv
research
masitinib
abscienc
masitinib
tyrosin
kinas
inhibitor
tki
licens
treatment
nonresect
canin
mast
cell
tumor
major
target
includ
ckit
pdgfr
fak
kinas
aberr
express
ckit
fak
found
human
patient
affect
cutan
mucos
melanoma
masitinib
tki
similar
target
use
human
patient
advanc
stage
melanoma
bear
ckit
mutat
encourag
result
role
ckit
fak
pdgfr
canin
melanoma
extens
investig
although
ckit
mutat
seem
uncommon
strong
ckit
express
found
around
canin
oral
melanoma
howev
correl
ckit
mutat
express
prognosi
still
uncertain
pdgfr
express
found
around
oral
canin
melanoma
shown
correl
wors
prognosi
one
studi
express
import
fak
canin
melanoma
report
yet
aim
small
studi
assess
respons
rate
lesser
extent
surviv
advanc
stage
iii
iv
canin
melanoma
treat
masitinib
proof
concept
masitinib
may
potenti
play
role
treatment
diseas
eleven
dog
prospect
enrol
two
digit
one
anal
eight
oral
melanoma
dog
progress
gross
diseas
despit
convent
treatment
includ
studi
dog
stage
thorac
radiographi
fine
needl
aspir
region
lymph
node
palpabl
one
dog
thorac
ct
abdomin
ultrasound
dog
previous
receiv
variou
combin
surgeri
radiotherapi
melanoma
vaccin
treatment
two
dog
achiev
partial
respons
five
dog
stabl
diseas
four
progress
diseas
dog
median
ttp
time
tumor
progress
mst
median
surviv
time
day
respect
masitinib
gener
well
toler
side
effect
observ
three
patient
one
experienc
grade
anemia
neutropenia
one
grade
anorexia
one
grade
diarrhea
mucos
melanoma
aggress
diseas
carri
poor
prognosi
effect
system
treatment
current
avail
control
progress
metastat
diseas
small
studi
show
efficaci
end
stage
diseas
indic
masitinib
offer
potenti
treatment
canin
melanoma
studi
earlier
stage
diseas
possibl
combin
modal
need
support
find
disclosur
disclosur
report
masitinib
tablet
donat
ab
scienc
varieti
therapi
employ
manag
anal
sac
apocrin
gland
adenocarcinoma
asaga
includ
surgeri
radiotherapi
chemotherapi
toceranib
phosphat
shown
anticanc
activ
dog
advanc
asaga
may
relat
receptor
tyrosin
kinas
express
kit
ret
pdgfr
whilst
patient
present
advanc
region
nodal
metastas
typic
iliosacr
lymphat
centr
stage
unfortun
present
distant
metastas
temper
owner
desir
choos
aggress
locoregion
therapi
includ
lymph
node
extirp
radiotherapi
inde
therapi
would
also
treat
distant
metastat
deposit
system
therapi
would
still
requir
success
manag
fifteen
dog
present
stage
asaga
presenc
distant
metastas
prior
therapi
two
patient
primari
tumor
anal
sac
surgic
excis
diagnost
procedur
present
clinic
sign
relat
abnorm
defec
eight
patient
dog
diagnos
due
incident
discoveri
anoth
problem
n
pupd
n
spinal
pain
n
varieti
breed
repres
though
english
cocker
spaniel
dog
lymph
node
metastasi
site
metastasi
includ
lung
n
liver
confirm
n
highli
suspici
n
lumbar
spine
n
kidney
skin
peritoneum
n
median
toceranib
dose
mgkg
rang
administ
mondaywednesdayfriday
basi
concurr
medic
firocoxib
n
carprofen
n
prednisolon
n
latter
manag
concurr
hypercalcemia
malign
seriou
toxic
seen
toceranib
therapi
three
episod
hematolog
toxic
grade
anemia
n
transient
mild
thrombocytosi
n
seen
one
dog
experienc
episod
grade
diarrhea
necessit
short
treatment
break
reinstitut
lower
dose
routin
repeat
stage
advis
perform
reduct
tumor
burden
classifi
stabl
diseas
seen
one
patient
progress
diseas
observ
median
surviv
time
toceranibtr
patient
day
rang
day
substanti
higher
day
median
ci
day
day
ci
day
previous
report
varieti
nontki
therapi
toceranib
phosphat
success
welltoler
monotherapi
dog
stage
asaga
disclosur
disclosur
report
ucd
significantli
neuter
male
femal
p
p
significantli
higher
percentag
malign
tumor
ucd
p
compar
dvcr
epitheli
neoplasm
common
tissu
data
set
skin
adnexa
commonli
affect
site
group
follow
gastrointestin
system
intact
femal
similar
rel
risk
mammari
neoplasia
compar
neuter
femal
data
set
dvcr
signific
higher
proport
mammari
gland
tumor
danish
data
p
comparison
danish
american
cat
show
epitheli
tissu
integu
commonli
affect
site
higher
proport
mammari
gland
tumor
dvcr
data
like
relat
higher
percentag
intact
femal
disclosur
disclosur
report
gold
standard
determin
causal
ebvassoci
lymphoma
detect
viral
transcript
express
latenc
promot
uncontrol
growth
aim
studi
investig
gene
express
fivassoci
lymphoma
target
open
read
frame
orf
two
identifi
compar
sequenc
analys
homologu
express
ebvassoci
malign
homologu
kshv
vflip
encod
antiapoptot
protein
third
identifi
rnaseq
analys
felin
lymphoma
transcriptom
homologu
kshv
lytic
cycl
activ
frozen
biopsi
case
highgrad
b
cell
lymphoma
aris
cat
seroposit
fiv
seroneg
felv
identifi
tissu
bank
case
includ
tumor
dna
posit
pcr
nine
sampl
met
inclus
criteria
total
rna
purifi
frozen
tissu
treat
dnase
onestep
rtpcr
assay
amplifi
mrna
splice
product
design
optim
ident
rtpcr
product
migrat
expect
size
confirm
sequenc
case
express
gene
detect
four
cat
test
neg
three
transcript
studi
demonstr
first
time
express
felin
lymphoma
tissu
investig
local
gene
express
cell
type
determin
tissu
specif
warrant
studi
fund
morri
anim
foundat
grant
number
disclosur
disclosur
report
human
pretreat
plasma
ddimer
level
report
predict
surviv
sever
type
malign
object
studi
evalu
prognost
valu
pretreat
ddimer
level
dog
highgrad
lymphoma
fortyeight
owneddog
multicentr
highgrad
lymphoma
enrol
prospect
observ
clinic
studi
signal
clinic
find
histolog
cytolog
report
immunophenotyp
complet
clinic
stage
respons
treatment
record
dog
accord
classif
pretreat
ddimer
level
measur
quantit
ddimer
turbidometr
immunoassay
nyco
card
reader
ii
nycom
dog
randomli
assign
two
differ
treatment
group
blind
fashion
receiv
antineoplast
drug
etoposid
phosphat
dog
involv
studi
follow
protocol
period
week
protocol
consist
four
cycl
mgkg
etoposid
phosphat
mgm
iv
inject
everi
week
inject
daili
consecut
day
shortterm
respons
assess
repeat
complet
stage
day
accord
recist
criteria
publish
peripher
nodal
lymphoma
dog
dog
follow
everi
month
relaps
case
relaps
complementari
chopbas
chemotherapi
protocol
propos
dog
owner
median
valu
pretreat
plasma
ddimer
lg
ml
rang
lgml
optim
cutoff
valu
ddimer
base
progress
free
interv
pfi
lgml
hr
p
ddimer
level
lgml
significantli
associ
inferior
pfi
vs
day
p
dog
ddimer
level
lgml
significantli
wors
surviv
ddimer
level
lgml
os
vs
day
p
high
ddimer
level
correl
versu
relaps
lymphoma
b
versu
lymphoma
clinic
stage
substag
morphotyp
high
ddimer
level
remain
independ
predictor
treatment
receiv
etoposid
phosphat
vs
p
differ
respons
rate
pfi
dog
treat
versu
etoposid
phosphat
orr
vs
p
pfi
vs
day
p
respect
conclus
pretreat
plasma
ddimer
level
may
serv
simpl
effect
predictor
prognosi
dog
highgrad
lymphoma
high
pretreat
ddimer
level
associ
short
pfi
poor
overal
surviv
dog
enrol
prospect
doubleblind
random
clinic
trial
disclosur
disclosur
report
studi
conduct
oncovet
clinic
research
ocr
part
collabor
research
project
ocr
pierr
fabr
medica
pulmonari
carcinoma
infrequ
document
cat
intraextrathorac
metastat
diseas
appear
common
surgeri
gold
standard
oper
tumor
studi
assess
efficaci
medic
treatment
case
metastasi
aim
studi
determin
clinic
respons
chemotherapi
primari
felin
pulmonari
carcinoma
evid
metastat
diseas
medic
record
multipl
institut
search
cat
cytolog
histopatholog
confirm
primari
pulmonari
carcinoma
concurr
comput
tomographysuspect
metastas
subsequ
underw
treatment
cytotox
chemotherapeut
tyrosin
kinas
inhibitor
drug
cat
underw
surgic
resect
primari
tumor
associ
metastas
includ
thirteen
cat
select
inclus
median
age
year
rang
year
median
bodi
weight
kg
rang
present
clinic
sign
includ
cough
tachypnea
gastrointestin
sign
abdomin
pain
lethargi
diffus
nodular
pattern
consist
metastasi
lung
parenchyma
present
case
addit
locat
identifi
case
intrathorac
node
kidney
medic
treatment
includ
vinorelbin
carboplatin
toceranib
phosphat
metronom
cyclophosphamid
cat
variabl
improv
clinic
sign
initi
treatment
experienc
moder
mild
toxic
cat
requir
hospit
due
advers
event
overal
median
time
progress
ttp
first
line
medic
treatment
day
rang
day
four
cat
evid
diseas
progress
chemotherapi
receiv
rescu
treatment
ttp
rang
day
case
clinic
respons
could
assess
one
renal
metastas
diagnosi
develop
renal
metastas
receiv
treatment
two
patient
initi
demonstr
stabl
diseas
later
develop
intraocular
retrobulbar
metastas
respect
patient
repeat
imag
cat
partial
respons
stabl
diseas
progress
diseas
overal
median
surviv
time
day
rang
day
four
cat
still
aliv
time
data
analysi
median
followup
day
rang
day
studi
suggest
chemotherapi
may
achiev
stabl
diseas
cat
primari
metastat
lung
tumor
extend
surviv
time
possibl
cat
surviv
year
base
result
medic
treatment
appear
well
toler
consid
advanc
diseas
stage
disclosur
disclosur
report
ovarian
neoplasm
bitch
age
ae
year
submit
histopatholog
routin
diagnosi
includ
macroscop
immunohistochem
cytokeratin
actin
investig
case
preoper
serum
sampl
avail
retrospect
amh
valu
measur
autom
chemiluminescenceimmunoassay
ovarian
tumor
unilateralbilater
diagnos
gct
ovarian
carcinoma
adenoma
teratoma
dysgerminoma
leiomyoma
leiomyosarcoma
hemangiosarcoma
stromal
tumor
lymphoma
luteoma
multipl
differ
neoplasm
certain
sign
malign
obviou
gct
six
dysgerminoma
one
teratoma
carcinoma
lymphoma
sarcoma
case
multipl
tumor
bitch
teratoma
younger
median
year
dog
ovarian
neoplasm
median
year
median
diamet
cm
normal
ovari
cm
ovarian
adenoma
carcinoma
cm
gct
dysgerminoma
cm
teratoma
within
ovarian
tumor
popul
breed
group
sheepdog
cattledog
spitz
primit
type
repres
respect
howev
look
sampl
percentag
tumor
sampl
ts
submit
laboklin
year
breed
group
less
repres
sheepdog
cattledog
ts
spitz
primit
type
ts
amh
valu
ngml
significantli
higher
gct
median
n
dysgerminoma
median
n
ovarian
carcinoma
adenoma
median
n
conclus
sheepdog
cattledog
spitz
primit
type
seem
predisposit
ovarian
tumor
although
vari
median
size
age
bitch
ovarian
neoplasm
distinguish
clinic
macroscop
find
histolog
investig
need
final
diagnosi
prognosi
howev
measur
amh
serum
concentr
may
help
identifi
gct
presurg
studi
perform
investig
amh
valu
case
ovarian
cyst
disclosur
disclosur
report
sever
author
studi
belong
laboklin
gmbh
cokg
diagnost
laboratori
offer
amh
measur
client
gum
arab
coat
radioact
gold
nanoparticl
aunp
effect
retain
result
tumor
reduct
mous
model
human
prostat
carcinoma
object
determin
toxic
preliminari
efficaci
aunp
administ
intralesion
dog
spontan
occur
carcinoma
prostat
hypothesi
intralesion
aunp
would
caus
short
term
swell
caus
system
toxic
result
tumor
stabil
shrinkag
follow
institut
anim
care
use
committe
approv
dog
diagnosi
prostat
carcinoma
without
bladder
involv
elig
enrol
inform
owner
consent
stage
perform
inject
aunp
achiev
ct
guidanc
per
site
multipl
site
total
amount
vari
base
tumor
size
complet
blood
count
chemistri
panel
urinalysi
perform
weekli
week
follow
treatment
ct
scan
perform
week
treatment
nuclear
scintigraphi
perform
regularli
min
h
h
day
postinject
determin
degre
retent
aunp
prostat
follow
week
trial
period
chemotherapi
could
start
discret
pet
owner
twentytwo
dog
enrol
dog
metastasi
lymph
node
sublumbar
region
dog
evid
metastasi
two
dog
treat
biolog
equival
dose
gy
dog
treat
gy
one
dog
die
day
post
inject
due
urethr
obstruct
either
tumor
swell
diseas
progress
follow
event
dog
evid
urethr
obstruct
urethr
stent
place
n
prior
treatment
fifteen
dog
receiv
chemotherapi
median
surviv
time
dog
receiv
chemotherapi
day
rang
day
compar
day
rang
day
dog
averag
tumor
retent
aunp
day
postinject
loss
occur
urin
bladder
accumul
dose
found
heart
lung
liver
spleen
kidney
determin
whole
bodi
planar
imag
day
posttreat
median
reduct
tumor
volum
one
month
aunp
therapi
dog
conclus
intratumor
administr
aunp
caus
acut
system
toxic
dog
may
effect
decreas
tumor
size
howev
local
tumor
swell
possibl
dog
must
close
monitor
evid
urethr
obstruct
disclosur
disclosur
report
grant
financi
support
work
support
grant
univers
missouri
institut
clinic
translat
scienc
nihsbir
phase
ii
contract
shasun
nbi
llc
au
kvk
rk
cofound
nanoparticl
biochem
inc
felin
panleukopenia
highli
contagi
often
fatal
diseas
cat
caus
felin
panleukopenia
viru
fpv
canin
parvoviru
cpv
strain
carnivor
protoparvoviru
clinic
diseas
rare
seen
australia
sinc
outbreak
report
nation
onlin
diseas
surveil
report
tool
aim
studi
determin
strain
canin
protoparvoviru
epidemiolog
factor
involv
outbreak
felin
panleukopenia
report
sinc
veterinarian
shelter
owner
contact
arrang
sitevisit
collect
sampl
obtain
inform
anim
movement
biosecur
vaccin
protocol
qualit
analysi
dna
extract
fece
tissu
repres
cat
outbreak
clinic
sign
panleukopenia
andor
posit
fecal
antigen
cpv
test
pcr
sequenc
gene
phylogenet
analysi
outbreak
cpvlike
fpvlike
sequenc
avail
genbank
perform
use
maximum
likelihood
method
three
outbreak
caus
fatal
identifi
melbourn
b
melbourn
mildura
citi
km
melbourn
c
melbourn
sydney
outbreak
mildura
melbourn
caus
ident
close
relat
fpv
genotyp
sydney
outbreak
caus
differ
fpv
genotyp
case
municip
charit
privat
shelter
shelter
highest
number
fatal
perform
routin
vaccin
shelter
administ
vaccin
diseas
occur
incomplet
vaccin
cat
cat
vaccin
due
respiratori
diseas
movement
unvaccin
cat
municip
shelter
network
privat
foster
carer
identifi
outbreak
includ
melbourn
mildura
outbreak
b
median
age
cat
diagnosi
week
outbreak
occur
summer
autumn
coincid
peak
shelter
intak
kitten
felin
panleukopenia
caus
fpv
reemerg
major
caus
mortal
australian
felin
shelter
associ
inadequ
vaccin
biosecur
practic
disclosur
disclosur
report
studi
fund
grant
nsw
cat
protect
societi
australian
companion
anim
health
foundat
irma
project
id
canin
parvovirus
cpv
felin
panleukopenia
viru
fpv
strain
carnivor
protoparvoviru
infect
replic
canid
felid
use
convent
pcr
recent
studi
report
high
preval
fecal
shed
cpv
among
asymptomat
shelter
cat
uk
identifi
cat
potenti
reservoir
infect
aim
studi
determin
preval
fecal
shed
cpv
asymptomat
shelterh
cat
australia
one
hundr
stool
sampl
unvaccin
cat
hous
dual
caninefelin
shelter
collect
store
test
viral
dna
extract
fece
homogen
wv
solut
fece
phosphat
buffer
salin
pb
boil
supernat
centrifug
chill
ice
repeat
centrifug
identifi
pcr
inhibit
fecal
dna
extract
dilut
supernat
spike
felin
genom
dna
ng
test
use
pcr
amplifi
felin
gapdh
gene
felin
gapdh
amplifi
spike
fecal
sampl
dilut
sampl
dilut
pcr
inhibit
gapdh
one
sampl
dilut
abolish
dilut
fecal
dna
extract
dilut
n
dilut
n
shelter
cat
screen
presenc
cpv
fpv
use
pcr
assay
amplifi
bp
region
gene
use
primer
pb
process
parallel
sampl
extract
pcr
serv
neg
control
dna
previous
sequenc
canin
cpv
isol
posit
control
sampl
test
posit
complet
gene
sequenc
differenti
fpv
cpv
cpv
dna
detect
stool
cat
fpv
dna
detect
stool
cat
contrast
result
uk
shelter
fecal
shed
cpv
asymptomat
shelterh
cat
detect
studi
preval
fpv
shed
low
futur
studi
screen
carnivor
protoparvovirus
use
quantit
pcr
assay
warrant
rule
lowlevel
shed
undetect
convent
pcr
disclosur
disclosur
report
felin
panleukopenia
viru
fpv
infect
lead
sever
leukopenia
gastrointestin
sign
cat
mortal
rate
besid
support
therapi
inform
regard
specif
treatment
yet
limit
affect
cat
class
cpg
oligodeoxynucleotid
cpga
short
singlestrand
dna
molecul
contain
unmethyl
cytosinephosphateguanosin
motif
stimul
product
type
interferon
studi
cat
show
abil
cpga
induc
antivir
state
vivo
inhibit
replic
fpv
vitro
therefor
aim
studi
investig
effect
cpga
surviv
clinic
score
white
blood
cell
wbc
red
blood
cell
rbc
platelet
count
well
viremia
fecal
viral
shed
cat
natur
infect
fpv
cat
posit
fecal
parvoviru
antigen
test
prospect
enrol
present
clinic
laboratori
sing
fpv
bodi
weight
g
unvaccin
previous
treat
cat
randomli
alloc
receiv
cpga
placebo
subcutan
admiss
h
case
treat
support
therapi
clinic
score
deriv
attitud
appetit
vomit
diarrhea
temperatur
assign
daili
death
day
blood
fecal
sampl
collect
admiss
day
complet
blood
count
obtain
realtim
pcr
perform
quantifi
fpv
dna
blood
fecal
sampl
chisquar
test
mix
anova
use
compar
treatment
group
fortytwo
cat
includ
receiv
cpga
placebo
surviv
rate
differ
cat
treat
cpga
placebo
vs
respect
p
differ
group
observ
clinic
score
rbc
platelet
viremia
fecal
viral
shed
time
point
mean
wbc
count
higher
cat
treat
cpga
placebo
day
ae
vs
ae
respect
p
time
point
cat
show
discomfort
cpga
inject
conclus
treatment
cpga
improv
surviv
clinic
score
reduc
viral
shed
suggest
drug
treatment
regimen
use
studi
benefici
cat
affect
fpv
lack
favor
respons
cpga
might
due
delay
improv
wbc
count
note
administr
cpga
may
pain
cat
disclosur
disclosur
report
aim
studi
determin
whether
evid
infect
feral
carnivor
viral
traffic
companion
anim
ii
model
silico
suscept
tasmanian
devil
reticuloendotheli
tissu
sampl
sourc
deceas
feral
carnivor
pcr
amplif
sequenc
bp
region
gene
phylogenet
analysi
partial
gene
sequenc
perform
use
maximum
likelihood
method
tasmanian
devil
suscept
infect
investig
comparison
transferrin
receptor
type
tfr
sequenc
bind
site
suscept
carnivor
phylogenet
analysi
tfr
protein
tissu
sampl
feral
cat
fox
collect
analyz
dna
detect
feral
cat
fox
cat
sampl
anim
cull
compris
relat
fpv
genotyp
includ
one
genotyp
ident
detect
fpv
outbreak
cat
shelter
melbourn
anoth
close
relat
fpv
strain
identifi
burmes
kitten
melbourn
tfr
aminoacid
residu
critic
parvoviru
bind
glutam
arginin
respect
tasmanian
devil
tfr
contrast
leucin
lysin
asparagin
canid
felid
host
tasmanian
devil
tfr
protein
distantli
relat
host
studi
provid
evid
feral
cat
reservoir
ccpv
infect
viral
traffic
feral
carnivor
companion
anim
australia
tfr
gene
analysi
indic
tasmanian
devil
unlik
suscept
import
biosecur
implic
captiv
breed
program
disclosur
disclosur
report
studi
fund
australian
companion
anim
health
foundat
univers
sydney
charl
perkin
centr
fellowship
grant
boehring
ingelheim
novel
paramyxoviru
felin
morbilliviru
femv
recent
detect
stray
cat
itali
accord
previou
studi
conduct
countri
femv
suspect
associ
felin
chronic
kidney
diseas
ckd
aim
investig
femv
occurr
provinc
teramo
central
itali
ii
associ
femv
ckd
lesion
iii
analyz
genom
circul
femv
urin
sampl
collect
cat
present
veterinari
teach
hospit
vth
unit
local
veterinari
practition
screen
group
n
addit
urin
cat
group
c
n
belong
coloni
also
test
well
intern
organ
carcass
group
b
n
formalinfix
paraffin
embed
section
kidney
cat
either
stain
h
e
incub
ab
femvn
protein
qpcrposit
rna
employ
sispang
final
portion
polymeras
l
gene
amplifi
rtpcr
posit
sampl
carcass
divid
subgroup
includ
viru
lesion
viru
lesion
viru
lesion
group
urin
sampl
posit
qpcr
wherea
group
c
sampl
posit
carcass
result
posit
qpcr
kidney
urinari
bladder
constantli
posit
viral
rna
also
detect
brain
spleen
one
cat
bilater
subacutetochron
lymphoplasmacyt
interstiti
nephriti
observ
qpcr
posit
cat
also
show
scatter
immunolabel
viral
antigen
within
renal
parenchyma
mostli
involv
cortic
kidney
tubul
surround
inflammatori
cell
sequenc
l
gene
also
obtain
posit
sampl
genet
divers
observ
differ
group
two
put
differ
viral
variant
nt
id
observ
one
variant
present
highest
nt
differ
shown
obtain
sequenc
group
nt
id
occurr
femv
group
mirror
seen
cat
countri
femv
occurr
group
c
higher
previou
studi
genom
divers
also
demonstr
femv
circul
provinc
believ
scatter
viral
antigen
immunolabel
detect
renal
tubular
epithelia
well
surround
inflammatori
cell
get
along
well
intermitt
viral
excret
urin
statist
analys
current
underway
disclosur
disclosur
report
aim
studi
evalu
sensit
specif
realtim
revers
transcript
polymeras
chain
reaction
rtqpcr
abl
distinguish
two
felin
coronaviru
fcov
pathotyp
felin
infecti
periton
viru
fipv
felin
enter
coronaviru
fecv
cerebrospin
fluid
csf
cat
suspect
fip
studi
popul
consist
cat
confirm
fip
six
neurolog
sign
control
group
cat
ten
neurolog
sign
fip
consid
differenti
diagnosi
definit
diagnos
diseas
csf
cat
test
presenc
felin
coronaviru
fcov
rna
rtqpcr
posit
case
pathotyp
determin
accord
gene
sequenc
sensit
specif
includ
confid
interv
ci
calcul
fipv
detect
csf
three
cat
fip
six
cat
fip
fcov
rna
detect
viru
load
low
allow
pathotyp
fcov
detect
control
cat
specif
rtqpcr
ci
sensit
detect
fcov
sensit
detect
fipv
pathotyp
cat
ci
cat
neurolog
sign
specif
rtqpcr
excel
neg
test
result
rule
fip
disclosur
disclosur
report
dr
christian
leutenegg
head
molecular
diagnost
idexx
laboratori
inc
dr
org
balzer
dr
nikola
pantchev
employ
idexx
laboratori
ludwigsburg
laboratori
offer
fcov
fip
viru
realtim
rtpcr
commerci
basi
perform
test
studi
idexx
play
role
studi
design
collect
interpret
data
decis
submit
manuscript
public
commerci
conflict
interest
inform
gener
sole
scientif
dissemin
author
declar
compet
interest
aim
studi
determin
preval
select
tickborn
pathogen
tick
collect
cat
uk
pathogen
evalu
anaplasma
phagocytophilum
bartonella
spp
includ
bartonella
hensela
hepatozoon
spp
babesia
spp
borrelia
spp
includ
borrelia
burgdorferi
sensu
lato
hemoplasma
speci
includ
mycoplasma
haemof
mhf
candidatu
mycoplasma
haemominutum
cmhm
candidatu
mycoplasma
turicensi
cmt
tick
collect
cat
present
veterinarian
uk
practic
tick
speci
identifi
morpholog
underw
dna
extract
use
commerci
avail
kit
follow
pcr
assay
either
convent
quantit
realtim
qpcr
tickborn
pathogen
specifi
assay
previous
valid
detect
target
speci
felin
rdna
serv
endogen
intern
pcr
control
assess
within
hemoplasma
qpcr
addit
sampl
spike
intern
amplif
control
iac
monitor
inhibit
posit
sampl
gener
pcr
bartonella
spp
hepatozoon
spp
borrelia
spp
submit
dna
sequenc
speci
identif
total
tick
collect
ixod
ricinu
ixod
hexagonu
ixod
triangulicep
rdna
amplifi
tick
undetect
result
like
due
tick
unf
iac
pcr
result
reveal
evid
inhibit
tick
contain
pathogen
tick
contain
two
agent
detect
babesia
spp
result
data
provid
valuabl
inform
preval
tickborn
pathogen
tick
found
cat
uk
preval
found
similar
report
tick
collect
dog
uk
lower
report
tick
cat
european
countri
first
report
detect
h
silvestri
tick
collect
domest
cat
world
disclosur
disclosur
report
canin
babesiosi
caus
babesia
rossi
infect
virul
case
suffer
major
complic
includ
hemolyt
anemia
hepatopathi
acut
renal
failur
acut
respiratori
distress
syndrom
hypoglycemia
cerebr
hemorrhag
pancreat
diseas
mortal
rate
consequ
need
improv
understand
risk
factor
associ
poor
clinic
outcom
current
studi
examin
associ
b
rossi
infect
serum
concentr
hydroxyvitamin
oh
major
circul
vitamin
metabolit
hypovitaminosi
report
wide
rang
infecti
diseas
human
dog
low
vitamin
statu
associ
poor
clinic
outcom
first
studi
investig
vitamin
statu
canin
babesiosi
hypothesi
studi
dog
babesiosi
would
lower
vitamin
statu
healthi
dog
hypovitaminosi
would
associ
diseas
sever
serum
oh
metabolit
measur
highperform
liquid
chromatographi
dog
exclud
group
less
year
old
concurr
diseas
receiv
corticosteroid
blood
collect
upon
admiss
babesiosi
case
score
sever
previous
describ
babesiosi
complic
inter
alia
high
serum
lactat
hypoglycemia
hypercortisolemia
hypothyroxinemia
presenc
sir
receiv
score
final
total
individu
sever
score
calcul
dog
babesiosi
n
significantli
lower
oh
concentr
control
group
n
ae
vs
ae
p
ancova
analysi
demonstr
effect
babesiosi
oh
concentr
compar
control
dog
still
signific
consid
effect
age
weight
addit
hypovitaminosi
significantli
affect
serum
creatinin
alt
concentr
therebi
elimin
effect
renal
insuffici
liver
damag
respect
moreov
correl
analysi
reveal
hypovitaminosi
significantli
correl
time
last
meal
anorexia
yet
hypovitaminosi
significantli
influenc
hypoproteinemia
hypoalbuminemia
hypoglobulinemia
final
among
babesiosi
case
sever
score
signific
invers
correl
r
p
serum
oh
concentr
result
indic
hypovitaminosi
associ
canin
babesia
rossi
infect
invers
correl
oh
concentr
sever
score
associ
hypovitaminosi
hypoproteinemia
hypoalbuminemia
hypoglobulinemia
indic
hypovitaminosi
might
help
indic
sever
prognosi
disclosur
disclosur
report
bloodstream
infect
substanti
caus
morbid
mortal
critic
ill
veterinari
patient
blood
cultur
gold
standard
diagnosi
bacteremia
infrequ
obtain
due
technic
practic
difficulti
sampl
acquisit
ill
patient
urin
cultur
sometim
recommend
surrog
blood
cultur
part
better
noth
approach
studi
evalu
abil
urin
cultur
predict
bloodstream
infect
retrospect
evalu
blood
aerob
anaerob
cultur
submit
nc
state
veterinari
hospit
calcul
growth
rate
blood
urin
nonurin
blood
urin
nonurin
cultur
submit
blood
isol
commonli
coagulaseposit
staphylococcu
spp
escherichia
coli
escherichia
coli
common
urinari
isol
along
enterococcu
coagulaseposit
staphylococcu
urin
blood
sampl
submit
parallel
yield
simultan
growth
sampl
concord
yield
discord
urinari
bloodstream
infect
overal
urinari
isol
poorli
reflect
bloodstream
isol
sensit
specif
gener
concord
includ
true
posit
n
true
neg
n
urinari
bloodstream
isol
urin
cultur
isol
poor
posit
predict
valu
neg
predict
valu
bloodstream
infect
appar
except
patient
suspect
urogenit
infect
sourc
renal
prostat
etc
n
concord
urinari
bloodstream
infect
coagulaseposit
staphylococcu
infect
like
concord
nonurin
sampl
submit
parallel
blood
cultur
also
evalu
biliari
intraven
cathet
sampl
carri
ppv
short
recommend
bloodstream
infect
suspect
blood
cultur
acquir
coagulaseposit
staphylococci
isol
urinari
tract
ill
patient
rais
clinic
suspicion
potenti
concord
bloodstream
infect
due
high
discord
rate
particular
blood
cultur
perform
potenti
septic
anim
immunosuppress
bacteriuria
neither
substitut
screen
bacteremia
fact
base
calcul
fals
neg
rate
treatment
urinari
tract
pathogen
like
bacterem
anim
would
lead
treatment
incorrect
bloodstream
pathogen
time
though
urin
cultur
encourag
part
complet
diagnost
workup
substitut
blood
cultur
disclosur
disclosur
report
jacob
director
ncsu
clinic
microbiolog
laboratori
disclosur
report
klebsiella
pneumonia
import
nosocomi
pathogen
increasingli
report
multidrugresist
mdr
companion
anim
ca
urinari
tract
infect
uti
may
becom
infect
mdr
virul
k
pneumonia
thu
act
reservoir
human
studi
aim
character
compar
clonal
related
k
pneumonia
isol
companion
anim
human
uti
k
pneumonia
isol
ca
n
commun
hospitalacquir
human
uti
n
test
disk
diffus
suscept
ast
antimicrobi
accord
clsi
resist
isol
screen
sixteen
resist
gene
seven
virul
gene
pcr
ca
isol
thirdgener
cephalosporin
resist
human
isol
type
mlst
popul
structur
ca
human
isol
character
pfgexbai
macrorestrict
use
diceupgma
cluster
analysi
toler
highrisk
clonal
k
pneumonia
lineag
predomin
ca
isol
n
cluster
togeth
similar
index
si
ca
isol
belong
two
cluster
si
interestingli
ca
show
resist
fluoroquinolon
n
mainli
due
two
human
k
pneumonia
detect
one
belong
cluster
ca
human
k
pneumonia
share
fimhmrkdkfuycfm
virul
profil
n
also
harbor
yersiniabactin
addit
human
k
pneumonia
unknown
st
also
cluster
n
n
cahuman
strain
fluoroquinoloneresist
hospit
adapt
k
pneumonia
clonal
lineag
detect
ca
n
human
n
show
mdr
ast
profil
pfge
analysi
close
relat
si
share
sever
virul
fimhmrkdkpnycfmyersiniabactin
resist
dhaaphaiiaaac
ibtet
gene
ca
strain
also
harbor
qnrb
ca
n
human
n
show
cluster
si
although
similar
pfge
analysi
ast
vari
strain
ca
human
harbor
respect
studi
show
ca
human
becom
infect
clonal
relat
k
pneumonia
belong
highrisk
clonal
lineag
result
reveal
potenti
zoonot
natur
k
pneumonia
uti
ca
therefor
infect
control
measur
advis
owner
avoid
spread
resist
virul
k
pneumonia
acknowledg
dermatophytosi
ringworm
common
cutan
fungal
infect
cat
dog
mani
cat
dermatophytosi
infect
microsporum
cani
strain
highli
contagi
zoonot
potenti
lifethreaten
treatabl
curabl
due
highli
contagi
natur
diseas
accur
time
diagnosi
dermatophytosi
import
laboratori
diagnosi
dermatophyt
routin
includ
direct
microscop
evalu
clinic
specimen
follow
cultur
special
media
consid
gold
standard
consid
sensit
abl
speciat
requir
day
plate
observ
yield
neg
result
realtim
polymeras
chain
reaction
pcr
also
call
quantit
pcr
qpcr
advanc
molecular
technolog
ideal
suit
detect
infecti
pathogen
qpcr
test
develop
target
gene
sequenc
genu
specif
trichophyton
spp
microsporum
spp
betaactin
specif
microsporum
cani
assay
clinic
valid
includ
sampl
collect
cat
sampl
collect
expos
cat
without
lesion
sampl
collect
cat
confirm
dermatophytosi
lesion
cultur
posit
lesion
sampl
dermatophytosi
confirm
cat
pcr
posit
sampl
well
addit
posit
lesion
sampl
total
cat
cultur
sensit
specif
compar
pcr
lesion
sampl
cat
without
lesion
expos
diseas
cat
also
test
determin
pcr
sensit
detect
fomit
carrier
pcr
detect
posit
sampl
expos
cat
compar
cultur
posit
expos
cat
cat
lesion
monitor
regular
interv
system
topic
therapi
averag
time
resolut
day
shortest
durat
resolut
day
therefor
recommend
pcr
monitor
start
around
week
treatment
summari
qpcr
compar
convent
cultur
show
excel
sensit
clinic
case
lesion
pick
signific
fals
posit
signal
cat
expos
infect
dermatophyt
use
monitor
therapi
success
pair
speed
result
qpcr
panel
excel
util
diagnosi
dermatophytosi
disclosur
disclosur
report
author
coauthor
employe
idexx
laboratori
inc
ess
treat
first
opinion
referr
practic
histolog
diagnosi
idiopath
chronic
hepat
enrol
prospect
attend
veterinari
surgeon
ask
give
prednisolon
mgkgday
submit
regular
blood
result
progress
report
author
ten
femal
four
male
ess
enrol
median
age
diagnosi
year
month
rang
year
case
treat
corticosteroid
within
month
studi
mean
prednisolon
start
dose
mgkgday
rang
mgkgday
case
receiv
addit
therapi
includ
combin
sadenosylmethionin
silybin
ursodeoxychol
acid
hepat
diet
prednisolon
dose
taper
appropri
sever
month
accord
patient
clinic
biochem
respons
focus
alkalin
phosphatas
alkp
alanin
aminotransferas
alt
bilirubin
case
show
improv
clinic
includ
resolut
jaundic
vomit
polyuriapolydipsia
two
case
euthan
due
ch
receiv
prednisolon
surviv
time
day
diagnosi
remain
patient
aliv
clinic
well
patient
still
receiv
mean
dose
mgkg
prednisolon
everi
day
eod
rang
mg
kgday
median
time
sinc
diagnosi
day
rang
day
twosid
wilcoxon
test
demonstr
signific
p
reduct
serum
alkp
alt
bilirubin
follow
prednisolon
therapi
median
valu
immedi
start
immunosuppress
dose
prednisolon
iul
iul
lmoll
alkp
alt
bilirubin
respect
result
studi
demonstr
markedli
improv
surviv
histor
cohort
ess
ch
manag
immunosuppress
dose
prednisolon
serial
measur
alkp
alt
bilirubin
use
monitor
patient
progress
disclosur
disclosur
report
time
normal
histopatholog
featur
base
wsava
guidelin
character
moder
sever
chronic
inflamm
hepatocellular
apoptosi
necrosi
fibrosi
case
classifi
idiopath
therefor
optim
manag
ch
establish
corticosteroid
report
prolong
surviv
dog
suggest
immunemedi
mechan
diseas
howev
corticosteroid
caus
signific
side
effect
induc
steroid
hepatopathi
confound
interpret
liver
enzym
therapi
date
studi
investig
use
altern
immunosuppress
therapi
cyclosporin
cy
manag
canin
idiopath
ch
primari
aim
retrospect
studi
evalu
safeti
efficaci
cy
treatment
idiopath
ch
secondari
aim
identifi
factor
influenc
cy
treatment
respons
time
remiss
remiss
defin
normal
serum
alt
hypothes
cy
therapi
would
achiev
remiss
ii
lower
pretreat
clinic
score
higher
serum
alt
would
predict
prolong
time
remiss
fortysix
dog
diagnos
idiopath
ch
treat
cy
met
inclus
criteria
case
exclud
lack
biochem
data
concurr
immunosuppress
therapi
failur
complet
least
week
cy
therapi
evid
biochem
improv
penicillamin
antibiot
administr
twentyf
differ
breed
repres
age
rang
year
median
year
fiftytwo
percent
femal
spay
male
castrat
treatment
sideeffect
includ
gastrointestin
sign
rang
mild
inappet
vomit
diarrhea
gingiv
hyperplasia
thirtyf
dog
achiev
remiss
base
alt
normal
median
time
remiss
month
three
dog
reach
partial
remiss
alt
valu
declin
remain
upper
limit
normal
eight
case
achiev
remiss
initi
serum
alt
activ
hepat
copper
concentr
dri
weight
clinic
score
influenc
remiss
cy
prove
effect
achiev
remiss
base
normal
serum
alt
canin
idiopath
ch
limit
includ
retrospect
natur
studi
concurr
therapi
given
variabl
longterm
followup
lack
post
treatment
biopsi
disclosur
disclosur
report
canin
chronic
hepat
cch
character
histolog
hepatocellular
apoptosi
necrosi
variabl
mononuclear
mix
inflammatori
infiltr
regener
fibrosi
lifeexpect
follow
diagnosi
unpredict
rang
day
year
report
prognost
indic
hyperbilirubinemia
hypoalbuminemia
presenc
ascit
cirrhosi
unreli
particularli
endstag
diseas
hepatocyt
express
univers
cellcycl
inhibitor
marker
cellular
senesc
strongli
neg
correl
outcom
human
alcohol
nonalcohol
relat
liver
diseas
better
prognost
marker
histolog
clinic
score
system
express
investig
cch
studi
investig
whether
hepatocyt
express
increas
cch
express
associ
surviv
case
cch
retriev
patholog
databas
liver
biopsi
sampl
review
use
routin
stain
hematoxylin
eosin
rhodanin
siriu
red
immunohistochemistri
perform
use
monoclon
mous
antihuman
select
case
four
control
liver
sampl
normal
histolog
histori
liver
diseas
express
manual
quantifi
score
hepatocyt
eight
highpow
field
case
two
blind
observ
express
percentag
total
hepatocyt
number
kendal
tau
correl
coeffici
use
assess
relationship
express
surviv
time
age
signific
set
p
tail
twenti
two
dog
cch
select
signific
neg
correl
hepatocellular
express
median
rang
surviv
day
rang
correl
express
age
median
year
rang
inclus
exclus
case
copperassoci
diseas
gave
similar
result
three
four
control
sampl
young
dog
year
display
neglig
express
expect
fourth
control
sampl
dog
high
percentag
hepatocyt
studi
demonstr
express
normal
dog
increas
age
expect
upregul
cch
indic
state
cellular
senesc
irrespect
age
median
percentag
senesc
hepatocyt
cch
higher
human
hepat
cell
indistinguish
normal
hepatocyt
use
routin
stain
unabl
perform
normal
hepat
function
quantif
cch
may
therefor
provid
addit
inform
regard
hepat
function
furthermor
neg
correl
express
surviv
identifi
suggest
role
quantif
determin
prognosi
cch
disclosur
disclosur
report
portal
vein
thrombosi
pvt
caus
partial
total
obstruct
portal
blood
flow
lead
prehepat
portal
hypertens
canin
pvt
consid
rare
entiti
classifi
two
categori
acut
chronic
base
present
clinic
condit
diagnosi
canin
pvt
gener
perform
use
abdomin
ultrasound
howev
ultrasound
oper
depend
human
comput
tomographi
ct
angiographi
prefer
diagnosi
extens
evalu
pvt
retrospect
review
veterinari
clinic
data
includ
case
diagnos
pvt
use
ct
angiographi
chronic
pvt
classifi
pvt
absenc
abdomin
pain
shock
variabl
includ
signal
clinic
sign
clinicopatholog
data
diagnost
imag
find
treatment
outcom
collect
eleven
dog
includ
studi
seven
male
four
femal
median
age
bodi
weight
year
kg
respect
ten
dog
concurr
condit
pancreat
n
frequent
one
glucocorticoid
administ
prior
diagnosi
pvt
six
dog
ascit
confirm
four
dog
clinicopatholog
analysi
reveal
elev
liver
enzym
level
eight
dog
hypoalbuminemia
nine
thrombocytopenia
four
serum
ddimer
concentr
measur
ten
dog
elev
valu
observ
ten
abdomin
ultrasonographi
reveal
pvt
eight
dog
diagnosi
miss
three
ct
scan
reveal
pvt
main
portal
vein
ten
dog
dog
obtain
followup
data
two
reexamin
use
ct
angiographi
reduct
size
organ
thrombi
confirm
studi
popul
pancreat
administr
glucocorticoid
found
close
associ
chronic
pvt
although
succeed
diagnos
pvt
ultrasonographi
major
dog
techniqu
fail
provid
correct
diagnosi
three
thu
case
pvt
suspect
base
laboratori
test
result
undetect
abdomin
ultrasound
scan
ct
angiographi
would
provid
altern
option
detail
diagnosi
followup
disclosur
disclosur
report
gall
bladder
mucocoel
gbm
lead
caus
biliari
diseas
dog
predispos
breed
includ
shetland
sheepdog
cocker
spaniel
chihuahua
miniatur
schnauzer
border
terrier
bt
previous
describ
predispos
may
reflect
geograph
differ
popular
high
incid
gbm
note
bt
hospit
suggest
breed
predisposit
retrospect
evalu
medic
record
januari
april
perform
identifi
dog
ultrasonograph
diagnosi
gbm
dog
year
age
seen
studi
period
bt
thirtyseven
dog
bt
nonbt
includ
labrador
retriev
affenpinsch
shetland
sheepdog
miniatur
schnauzer
individu
breed
diagnos
gbm
base
ultrasound
alon
ultrasound
histopatholog
confirm
odd
ratio
calcul
perform
evalu
predisposit
bt
gbm
compar
nonbt
gbm
respect
signal
age
sex
neuter
statu
hematolog
biochem
measur
outcom
data
bt
present
gbm
confid
interv
signific
differ
gender
neuter
statu
bt
gbm
wider
hospit
popul
dog
gbm
bt
significantli
older
nonbt
median
rang
vs
rang
p
signific
differ
hematolog
biochem
paramet
bt
nonbt
nonbt
bt
manag
without
surgeri
bt
nonbt
one
two
nonbt
concomit
endocrinopathi
diabet
mellitu
hypothyroid
hyperadrenocortic
present
postcholecystectomi
bt
diagnos
one
endocrinopathi
bt
diabet
mellitu
hyperadrenocortic
median
surviv
time
could
calcul
either
group
mortal
signific
differ
surviv
rate
group
nonbt
bt
still
aliv
time
write
basi
singlecentr
studi
bt
may
breed
predisposit
gbm
would
interest
see
data
replic
european
hospit
studi
bt
warrant
identifi
factor
influenc
predisposit
possibl
prevent
measur
disclosur
disclosur
report
method
retrospect
studi
medic
record
juli
februari
cat
cehpss
review
diagnosi
cehpss
made
diagnost
imag
confirm
coeliotomi
cat
treat
cb
bast
perform
preand
postop
includ
result
twentythre
cat
includ
studi
popul
compris
differ
breed
median
age
month
median
bodi
weight
kg
eleven
cat
femal
entir
spay
cat
male
entir
neuter
common
clinic
find
includ
abnorm
behavior
ptyalism
ataxia
stunt
growth
copper
color
irid
inappet
depress
seizur
postmeal
bast
surgeri
abnorm
cat
two
cat
normal
fast
bile
acid
cat
receiv
medic
treatment
surgeri
treatment
includ
lactulos
clavulanateamoxicillin
ampicillin
metronidazol
levetiracetam
phenobarbiton
protein
restrict
diet
prescrib
cat
median
durat
medic
treatment
day
prior
surgeri
day
rang
surgeri
case
cehpss
detect
ultrasound
one
cat
computedtomographi
angiographi
portovenographi
perform
cat
bast
perform
follow
cb
median
day
day
bast
normal
cat
cat
persist
increas
result
two
develop
multipl
acquir
portosystem
shunt
one
remain
free
clinic
sign
year
later
euthan
due
seizur
complet
closur
patent
shunt
achiev
second
surgeri
remain
cat
abnorm
bast
nineteen
cat
aliv
free
sign
last
followup
least
month
surgeri
month
three
cat
develop
postop
seizur
treatment
anticonvuls
result
complet
partial
resolut
seizur
two
cat
one
cat
euthan
due
uncontrol
seizur
conclus
cehpss
occlus
cb
cat
carri
good
short
longterm
prognosi
disclosur
disclosur
report
indocyanin
green
icg
fluoresc
dye
sole
excret
liver
without
enterohepat
recircul
recent
shown
feasibl
noninvas
transcutan
icg
clearanc
assess
hepat
function
instantan
followup
studi
dog
congenit
extrahepat
singl
portosystem
shunt
pss
includ
month
surgic
closur
cellophan
band
silk
ligatur
icg
clearanc
studi
done
transcutan
fluorometr
take
serial
blood
sampl
min
iv
inject
mgkg
icg
transcutan
icg
clearanc
measur
use
two
miniatur
devic
detect
icg
fluoresc
excit
wave
length
nm
emiss
wave
length
nm
method
half
life
time
hlt
se
hlt
tc
plasma
disappear
rate
pdr
se
pdr
tc
min
retent
rate
se
tc
calcul
base
curv
within
minut
icg
inject
pss
closur
defin
base
doppler
sonographi
angiographi
dog
shunt
vessel
close
month
dog
pss
still
partial
open
one
dog
die
oper
transcutan
icg
clearanc
easili
perform
without
complic
well
toler
dog
signific
differ
open
close
pss
pdr
pdr
se
p
pdr
tc
p
se
p
tc
p
hlt
linear
correl
coeffici
pdr
se
pdr
tc
se
tk
hwz
se
hwz
tk
r
r
r
respect
contrast
invas
method
overlap
except
one
dog
pdr
tc
tc
open
close
pss
first
transcutan
icg
clearanc
studi
dog
liver
diseas
transcutan
assess
superior
invas
method
result
avail
immedi
limit
invas
method
dynam
charact
make
transcutan
liver
function
test
icg
clearanc
worthi
test
veterinari
medicin
disclosur
one
author
n
gretz
owner
patent
use
transcutan
measur
devic
glau
j
elliott
b
albrecht
univers
zurich
zurich
switzerland
depart
compar
biomed
scienc
royal
veterinari
colleg
univ
london
uk
boehring
ingelheim
vetmedica
gmbh
ingelheim
germani
hypertens
ht
associ
risk
target
organ
damag
tod
wellrecogn
cardiovascular
problem
elderli
cat
consequ
earli
recognit
treatment
ht
crucial
prospect
multicentr
placebo
control
blind
studi
evalu
telmisartan
hypertens
cat
diagnos
systol
blood
pressur
sbp
mmhg
two
day
ht
caus
classifi
chronic
kidney
diseas
ckd
control
hyperthyroid
combin
idiopath
cat
sbp
mmhg
evid
tod
pretreat
vasoact
substanc
exclud
cat
random
ratio
either
receiv
mg
kg
telmisartan
oral
solut
placebo
h
studi
consist
day
efficaci
phase
day
extend
use
phase
efficaci
telmisartan
defin
priori
signific
mean
sbpreduct
day
compar
placebo
mmhg
sbp
popul
mean
reduct
day
compar
baselin
predefin
post
inclus
remov
criteria
advers
event
withdraw
owner
consent
owner
noncompli
tod
sbp
mmhg
miss
sbp
data
imput
databas
use
last
observ
carri
forward
method
remov
reason
tod
sbp
mmhg
data
present
mean
ae
efficaci
popul
includ
telmisartan
placebo
cat
age
bodi
weight
breed
distribut
ht
caus
baselin
sbp
similar
group
baselin
sbp
telmisartangroup
ae
mmhg
placebogroup
ae
mmhg
telmisartan
treatment
gave
rise
significantli
larger
reduct
mean
sbp
rel
baselin
compar
placebo
day
ae
mmhg
n
vs
ae
mmhg
n
p
day
data
cat
exclud
two
two
cat
imput
give
reduct
sbp
rel
baselin
ae
mmhg
n
ae
mmhg
n
telmisartan
placebo
group
respect
proport
cat
sbp
reduct
mmhg
baselin
day
placebo
group
telmisartan
group
mean
sbp
decreas
telmisartan
group
day
ae
mmhg
rel
baselin
n
advers
event
evenli
distribut
group
efficaci
phase
would
expect
elderli
cat
suffer
ckd
diseas
age
extend
use
phase
conclus
telmisartan
oral
solut
safe
significantli
reduc
sbp
clinic
relev
magnitud
hypertens
cat
fourmonth
studi
period
disclosur
disclosur
report
studi
plan
organ
financ
boehring
ingelheim
gastroduoden
ulcer
recogn
complic
nsaid
corticosteroid
therapi
liver
diseas
sepsi
neoplasia
retrospect
studi
indic
male
middleag
larg
breed
dog
commonli
affect
rottweil
affect
younger
age
helicobact
associ
chronic
gastriti
effect
gastric
mucos
barrier
function
gmbf
unknown
previou
use
chamber
ex
vivo
injuri
model
examin
chang
gmbf
relat
ulcer
injuri
vivo
identif
factor
associ
gmbf
measur
transepitheli
electr
resist
ter
could
identifi
risk
factor
gastroduoden
ulcer
vivo
prospect
studi
ter
measur
control
acidinjur
canin
tissu
determin
factor
associ
chang
gmbf
includ
age
sex
neuter
statu
breed
largesmal
presenc
degre
helicobact
infect
canin
gastric
mucosa
collect
immedi
postmortem
randomsourc
dog
schedul
euthanasia
anim
control
facil
acid
ringer
solut
ph
appli
mucosa
tissu
dog
also
maintain
neutral
ph
ringer
solut
control
gmbf
assess
use
ter
age
gender
neuter
statu
breed
larg
vs
small
breed
presencedegre
helicobact
infect
correl
baselin
ter
chang
control
ter
time
chang
ter
acid
injuri
recoveri
ter
acid
injuri
ttest
mannwhitney
rank
sum
test
use
compar
gender
neuter
statu
breed
larg
vs
small
presenc
helicobact
ter
base
normal
helicobact
infect
correl
ter
use
spearman
rank
correl
age
compar
ter
use
linear
regress
multipl
linear
regress
identifi
predict
factor
signific
set
p
femal
dog
neuter
dog
higher
baselin
ter
p
higher
age
associ
decreas
recoveri
acid
injuri
p
helicobact
breed
size
associ
chang
ter
sex
neuter
statu
predict
baselin
ter
age
predict
recoveri
acid
injuri
studi
demonstr
factor
associ
decreas
gmbf
either
baselin
injuri
elev
baselin
ter
femal
dog
may
support
previous
report
male
sex
predilect
dog
current
studi
young
middleag
decreas
recoveri
injur
mucosa
may
support
previou
find
predilect
middleag
dog
develop
ulcer
work
need
determin
factor
relev
vivo
determin
overal
preval
diseas
disclosur
disclosur
report
fecal
occult
blood
fob
test
provid
quick
easi
way
screen
patient
gastrointestin
bleed
sensit
fob
test
kit
recent
evalu
use
cat
fed
canin
pack
red
blood
cell
howev
develop
time
test
interpret
limit
detect
fresh
whole
blood
given
stool
sampl
yet
report
goal
determin
limit
detect
whole
blood
felin
stool
sampl
well
determin
accur
time
assess
fob
sampl
util
test
kit
popul
cat
stool
recent
deworm
healthi
indoor
cat
enrol
studi
two
gram
stool
separ
cat
test
neg
fob
test
util
sampl
control
increment
quantiti
edta
whole
blood
ad
gram
pool
stool
control
stool
sampl
set
triplic
interpret
follow
time
point
fresh
h
lowest
repeat
reliabl
quantiti
blood
detect
stool
time
point
blood
howev
littl
blood
detect
control
sampl
fresh
h
minimum
gram
oz
stool
collect
detect
blood
stool
sampl
addit
result
repeat
fob
test
interpret
fresh
h
post
setup
fob
test
fast
noninvas
diagnost
tool
screen
low
level
blood
stool
cat
disclosur
disclosur
report
goal
perform
fob
test
use
human
point
care
test
healthi
cat
screen
potenti
subclin
diseas
fresh
stool
sampl
collect
litterbox
within
h
defec
sampl
test
three
separ
time
point
cat
presum
healthi
recent
deworm
individu
hous
rang
age
week
year
total
stool
sampl
cat
analyz
stool
cat
time
point
test
triplic
use
fob
test
kit
test
interpret
perform
fresh
h
fob
test
setup
nine
stool
sampl
posit
test
interpret
fresh
sampl
remain
posit
subsequ
test
interpret
h
fresh
posit
stool
differ
cat
subsequ
posit
stool
differ
cat
one
later
diagnos
ulcer
stomat
kitten
signific
parasit
use
screen
test
fob
test
detect
posit
result
studi
patient
popul
interpret
fresh
sampl
howev
test
interpret
h
post
set
posit
result
patient
popul
fob
test
use
screen
test
cat
repeat
test
recommend
differenti
transient
activ
bleed
disclosur
disclosur
report
clinic
diagnosi
pancreat
cat
challeng
clinic
sign
nonspecif
avail
serum
test
includ
serum
amylas
lipas
activ
felin
trypsinlik
immunoreact
ftli
lack
specif
andor
sensit
speci
serum
specif
felin
pancreat
lipas
spec
fpl
current
use
serum
test
pancreat
cat
base
test
rapid
inclin
semiquantit
test
estim
fpl
snap
fpl
tm
serum
develop
current
studi
evalu
sensit
specif
tool
pancreat
cat
aim
studi
evalu
specif
snap
fpl
two
group
cat
healthi
cat
b
sick
cat
without
clinic
suspicion
pancreat
total
cat
includ
studi
clinic
healthi
base
histori
physic
examin
cat
sick
group
sick
cat
consist
cat
wide
varieti
diseas
pancreat
consid
major
differenti
final
diagnosi
pancreat
would
explain
clinic
sign
avail
whole
blood
collect
cat
serum
separ
store
analysi
snap
fpl
test
perform
interpret
accord
manufactur
instruct
specif
calcul
group
cat
separ
group
combin
total
cat
found
abnorm
snap
fpl
result
cat
belong
group
sick
cat
specif
snap
fpl
among
healthi
sick
cat
respect
overal
specif
snap
fpl
test
high
specif
pancreat
healthi
cat
sick
cat
without
clinic
suspicion
pancreat
abnorm
snap
fpl
result
alway
indic
pancreat
follow
quantit
analysi
addit
due
lack
histopatholog
examin
pancrea
subclin
pancreat
inflamm
exclud
cat
abnorm
snap
fpl
result
studi
need
evalu
specif
diagnost
tool
cat
clinic
sign
compat
pancreat
histopatholog
evid
pancreat
disclosur
disclosur
report
dr
xenouli
present
lectur
sponsor
idexx
laboratori
past
ii
snap
fpl
test
provid
idexx
involv
design
studi
interpret
result
refeed
starvat
lead
rang
fluid
electrolyt
hematolog
shift
associ
metabol
abnorm
call
refeed
syndrom
human
refeed
syndrom
well
document
cat
prospect
studi
conduct
ill
cat
hospit
intern
medicin
servic
inadequ
food
intak
three
day
refe
enter
feed
object
follow
clinic
biolog
paramet
known
modifi
refeed
syndrom
first
five
day
enter
refeed
initi
nutrit
assess
done
cat
sodium
phosphoru
potassium
ioniz
calcium
magnesium
glucos
insulin
albumin
hematocrit
creatin
kinas
cardiac
troponin
serum
amyloid
evalu
time
feed
tube
placement
three
five
day
refeed
physiolog
paramet
record
twice
day
daili
weight
done
nutrit
plan
base
nutrit
assess
implement
cat
februari
decemb
cat
recruit
seven
cat
complet
studi
stress
preclud
adequ
blood
sampl
six
cat
one
cat
remov
feed
tube
day
two
cat
die
seven
cat
ae
year
old
six
cat
anorect
three
seven
day
one
cat
dysorex
three
month
two
cat
hepat
lipidosi
consid
risk
develop
refeed
syndrom
one
threemonth
histori
dysorexia
icteru
mark
emaci
admiss
develop
day
refeed
sever
electrolyt
shift
mark
hypokalemia
hypomagnesemia
moder
hypophosphatemia
aggrav
anemia
acut
elev
creatin
kinas
activ
bilirubinemia
concomitantli
respiratori
distress
vomit
muscl
weak
hypotens
strongli
suspect
refeed
syndrom
none
six
cat
develop
clinic
sign
remark
biolog
abnorm
potenti
link
refeed
glycemia
insulinemia
consist
higher
day
day
cat
mild
moder
hypophosphatemia
document
cat
mild
hypokalemia
cat
mild
hypomagnesemia
cat
pilot
studi
signific
combin
biolog
abnorm
suspect
link
refeed
observ
cat
care
nutrit
plan
adequ
electrolyt
supplement
critic
avoid
refeed
complic
strongli
debilit
cat
could
risk
develop
complic
despit
adequ
precaut
disclosur
disclosur
report
granulocyt
increas
concentr
canin
fece
serum
found
dog
ce
intestin
mucos
mpo
activ
report
increas
human
inflammatori
bowel
diseas
ibd
also
anim
model
human
ibd
howev
intestin
mucos
mpo
investig
dog
ce
evalu
level
mucos
mpo
dog
ce
comparison
healthi
dog
use
enzymelink
immunoassay
spectrophotometr
method
respect
addit
assess
associ
mucos
mpo
level
canin
clinic
ibd
activ
index
cibdai
histopatholog
find
clinic
outcom
serum
albumin
concentr
intestin
mucos
biopsi
collect
dog
ce
duodenum
n
ileum
n
colon
n
cecum
n
histor
intestin
tissu
sampl
healthi
beagl
dog
serv
control
duodenum
ileum
colon
n
cecum
n
data
present
median
interquartil
rang
comparison
healthi
control
mucos
concentr
cedog
higher
duodenum
vs
p
colon
vs
p
mucos
mpo
activ
cedog
higher
control
dog
duodenum
mucos
concentr
show
signific
associ
p
sever
macrophag
infiltr
duodenum
total
histopatholog
injuri
epitheli
injuri
colon
mucos
mpo
activ
show
signific
associ
p
sever
total
histopatholog
injuri
epitheli
injuri
eosinophil
infiltr
duodenum
duoden
concentr
show
strong
neg
correl
serum
albumin
concentr
r
p
signific
associ
mucos
mpo
level
cibdai
clinic
outcom
studi
show
mucos
concentr
mpo
activ
increas
duodenum
colon
dog
ce
mucos
mpo
also
increas
ileum
cecum
result
provid
support
evid
possibl
diagnost
valu
mpo
dog
ce
disclosur
disclosur
report
trypsinlik
immunoreact
tli
cobalamin
folat
frequent
measur
canin
gastrointestin
disord
howev
effect
preanalyt
condit
canin
tli
cobalamin
folat
clearli
document
studi
evalu
circadian
variat
canin
tli
cobalamin
folat
concentr
fast
postprandi
condit
plasma
tli
cobalamin
folat
concentr
measur
h
fast
time
everi
h
h
h
healthi
dog
protocol
repeat
feed
sampl
tli
cobalamin
folat
measur
immunoassay
valid
dog
siemen
chang
tli
cobalamin
folat
evalu
gener
linear
model
dunnett
posthoc
test
mean
ae
sd
circadian
tli
concentr
fast
dog
vari
ae
ae
ngml
significantli
lower
p
h
contrast
tli
concentr
affect
feed
folat
concentr
circadian
variat
fast
dog
upper
limit
quantif
ngml
time
point
feed
mean
fast
circadian
cobalamin
concentr
vari
ae
ae
pmolml
significantli
differ
h
p
h
postfeed
cobalamin
concentr
significantli
lower
p
plasma
tli
cobalamin
concentr
signific
circadian
variat
fast
dog
plasma
cobalamin
significantli
decreas
h
feed
plasma
tli
remain
unchang
disclosur
disclosur
report
benoit
rannou
employe
laboratoir
de
biologi
edical
vetagro
sup
univers
lyon
franc
sampl
tli
cobalamin
folat
measur
perform
magnesium
second
abund
intracellular
cation
magnesium
concentr
predominantli
regul
ileum
absorpt
renal
excret
human
medicin
hypomagnesemia
may
accompani
inflammatori
small
bowel
diseas
ibd
affect
treatment
prognosi
aim
studi
evalu
total
serum
magnesium
tmg
cobalamin
cbl
concentr
cat
ibd
small
intestin
neoplasia
reveal
possibl
correl
thirtytwo
client
own
cat
includ
studi
twelv
clinic
healthi
cat
compris
control
group
cat
histopatholog
diagnos
lymphocyticplasmacyt
ibd
cat
small
intestin
lymphoma
small
intestin
adenocarcinoma
blood
serum
tmg
concentr
measur
atom
absorpt
use
perkinelm
analyst
serum
cbl
measur
direct
chemiluminesc
technolog
use
advia
centaur
siemen
mean
sd
tmg
serum
concentr
mgdl
median
mgdl
rang
mgdl
control
group
mgdl
median
mgdl
rang
mgdl
group
mgdl
median
mgdl
rang
mg
dl
ibd
group
mean
sd
cbl
serum
concentr
pgml
median
pgml
rang
pgml
control
group
pgml
median
pgml
rang
pgml
group
pgml
median
pgml
rang
pgml
ibd
group
kruskalw
test
indic
statist
signific
effect
group
median
tmg
valu
v
p
mannwhitney
test
conduct
bonferronidunn
correct
find
signific
differ
among
three
group
also
correl
tmg
cbl
group
nonsignific
r
p
although
signific
differ
concentr
serum
tmg
among
three
group
statist
analysi
fail
verifi
correl
tmg
cbl
concentr
could
attribut
limit
number
anim
disclosur
disclosur
report
esophag
neoplasia
report
dog
regurgit
anecdot
casereport
describ
megaesophagu
associ
gastroesophag
junction
gej
neoplasia
retrospect
case
seri
report
case
megaesophagu
associ
gej
neoplasia
dog
median
rang
age
weight
present
year
kg
respect
case
medium
larg
breed
dog
durat
clinic
sign
rang
day
month
clinic
sign
includ
regurgit
weight
loss
cough
polydipsia
ptyalism
lethargi
cachexia
increas
lung
sound
plain
thorac
radiograph
show
megaesophagu
softtissu
opac
within
caudal
esophagu
sign
aspir
pneumonia
gej
mass
confirm
contrast
esophagogram
two
dog
transabdomin
ultrasonographi
gej
perform
dog
abnorm
dog
endoscopi
perform
case
reveal
protrud
mass
case
ct
imag
perform
case
show
mass
gej
one
dog
treat
gej
stent
result
resolut
clinic
sign
dog
still
aliv
six
dog
euthan
diagnosi
lost
followup
biopsi
esophag
mass
obtain
endoscop
surgic
necropsi
reveal
esophag
leiomyoma
leiomyosarcoma
endoscop
sampl
nondiagnost
consid
long
term
surviv
possibl
case
seri
emphas
import
use
addit
imag
diagnost
procedur
diagnos
idiopath
megaesophagu
disclosur
disclosur
report
resid
program
dr
v
fabr
partli
financ
royal
canin
unrel
subject
matter
abstract
calprotectin
also
refer
protein
complex
involv
acut
chronic
inflammatori
respons
fecal
calprotectin
concentr
demonstr
increas
dog
diagnos
inflammatori
bowel
diseas
ibd
decreas
success
treatment
fecal
calprotectin
concentr
dog
ibd
also
correl
sever
clinic
sign
microscop
inflammatori
lesion
small
intestin
need
aggress
ie
antiinflammatori
immunosuppress
treatment
cutoff
concentr
lgg
inhous
canin
calprotectin
assay
found
also
reliabl
measur
calprotectin
felin
sampl
given
lack
wide
avail
inhous
canin
calprotectin
assay
aim
studi
assess
feasibl
measur
fecal
calprotectin
concentr
dog
cat
commerci
fcal
turbo
immunoassay
use
routin
diagnosi
monitor
ibd
human
medicin
fecal
sampl
obtain
anim
dog
cat
acut
chronic
gastrointestin
diseas
n
diseas
n
clinic
healthi
individu
n
fecal
sampl
collect
calex
cap
stool
extract
devic
extract
dilut
store
frozen
analysi
use
commerci
fcal
turbo
particleenhanc
turbidimetr
immunoassay
statist
analysi
perform
nonparametr
unpair
group
comparison
statist
signific
set
p
fecal
calprotectin
concentr
rang
lgg
median
lgg
studi
fecal
calprotectin
concentr
lgg
anim
lgg
lgg
lgg
significantli
higher
concentr
fecal
calprotectin
detect
dog
acut
chronic
gastrointestin
diseas
median
lgg
n
compar
healthi
control
patient
diseas
local
gastrointestin
tract
median
lgg
n
p
fecal
calprotectin
level
also
higher
cat
acut
chronic
gastrointestin
diseas
median
lgg
n
compar
healthi
control
cat
condit
local
gastrointestin
tract
median
lgg
n
differ
reach
signific
p
result
suggest
fcal
turbo
immunoassay
detect
fecal
calprotectin
dog
cat
separ
anim
gastrointestin
diseas
healthi
control
assay
valid
current
underway
allow
studi
clinic
util
assay
fecal
calprotectin
dog
cat
gastrointestin
diseas
disclosur
disclosur
report
dre
gabri
kock
niederberg
employ
uhlmann
laboratori
ag
turbo
immunoassay
offer
feeforservic
basi
english
cocker
spaniel
ec
suffer
distinct
form
chronic
pancreat
cp
associ
larg
number
duct
veincent
tlymphocyt
histolog
recent
studi
show
predomin
posit
plasma
cell
immunohistochemistri
affect
dog
suggest
diseas
similar
human
diseas
typic
affect
older
men
multipl
organ
particularli
caus
inflammatori
mass
lesion
pancrea
dri
eye
dri
mouth
glomerulonephr
recogn
similar
spectrum
diseas
ecss
present
center
cp
observ
overrepresent
roan
dog
aim
studi
describ
clinic
featur
ec
ecss
cp
present
qvsh
decemb
march
recruit
cp
diagnos
either
pancreat
histolog
n
elev
cpli
abnorm
pancreat
ultrasound
n
one
posit
fine
needl
aspir
cytolog
case
record
search
detail
signal
clinic
clinicopatholog
find
particularli
evid
keratoconjunct
sicca
kc
xerostomia
proteinuria
immunemedi
diseas
ec
present
suspect
cp
dog
fulfil
strict
inclus
criteria
femal
male
median
age
year
rang
year
dog
blue
roan
orang
roan
dog
gastrointestin
sign
pain
dog
tear
check
kc
case
dri
oral
mucou
membran
suggest
xerostomia
dog
proteinuria
urin
protein
creatinin
ratio
rang
case
upc
case
increas
subsequ
visit
glomerulonephr
confirm
post
mortem
one
dog
two
dog
atopi
one
inflammatori
bowel
diseas
one
pemphigu
foliaceu
three
dog
biliari
tract
diseas
one
dog
epilepsi
two
dog
develop
intervertebr
disc
diseas
three
dog
larg
mass
lesion
pancrea
resolv
symptomat
treatment
cp
ecss
show
remark
clinic
similar
human
high
preval
kc
xerostomia
proteinuria
immunemedi
diseas
affect
dog
present
benign
masslik
pancreat
lesion
diseas
appear
common
blue
roan
dog
disclosur
disclosur
report
sought
evalu
feasibl
describ
perfus
pattern
ceu
duodenum
dog
affect
ibd
hypothes
ceu
would
demonstr
chang
perfus
inflam
duodenum
provid
addit
inform
diagnosi
canin
ibd
prospect
enrol
seventeen
dog
ibd
base
canin
inflammatori
bowel
diseas
activ
indexcibdai
endoscop
evalu
histopatholog
assess
duoden
mucosa
sampl
dog
place
left
later
recumb
cranial
portion
duodenum
imag
transvers
plane
endoscopi
dog
receiv
two
bolus
mlkg
iv
contrast
agent
bracco
itali
first
consciou
anesthet
use
anesthet
protocol
duoden
enhanc
pattern
first
evalu
qualit
quantifi
use
dedic
softwar
bracco
itali
dog
duoden
vascular
pattern
character
initi
rapid
enhanc
submucos
layer
follow
gradual
enhanc
mucosa
serosa
musculari
propria
show
poor
enhanc
identifi
pattern
peak
enhanc
complet
enhanc
submucos
mucos
layer
without
subject
demarc
wall
layer
ii
incomplet
enhanc
mucos
layer
nonhomogen
point
streak
appear
dog
similar
perfus
pattern
whether
consciou
anesthet
quantit
analyz
enhanc
anesthet
dog
improv
imag
qualiti
analysi
reveal
reduc
peak
enhanc
intens
reduc
region
blood
flow
reduc
region
blood
volum
dog
cibdai
score
n
dog
show
nonhomogen
point
streak
pattern
howev
found
relationship
perfus
patternsparamet
endoscop
histopatholog
find
studi
demonstr
ceu
duodenum
dog
feasibl
highlight
presenc
differ
vascular
pattern
contrastenhanc
featur
dog
ibd
find
show
associ
dog
higher
clinic
grade
ibd
correl
histopatholog
find
studi
offer
novel
noninvas
imag
modal
diagnosi
monitor
canin
ibd
disclosur
disclosur
report
inflammatori
bowel
diseas
ibd
lymphoma
common
middleag
older
cat
associ
chronic
vomit
weight
loss
diarrhea
includ
chronic
enteropathi
ce
disord
cat
hypoalbuminemia
ce
consid
infrequ
specif
investig
protein
profil
patient
publish
aim
studi
evalu
serum
protein
profil
cat
ibd
lymphoma
compar
clinic
symptom
endoscop
assess
histopatholog
diagnos
fceai
clinic
index
score
cbc
serum
biochem
profil
urinalysi
evalu
cat
affect
ibd
lymphoma
endoscopi
upper
lower
gastrointestin
tract
perform
sever
score
assign
base
wsava
guidelin
histopatholog
diagnosi
base
wsava
guidelin
total
serum
protein
serum
protein
agaros
gel
electrophoresi
albuminglobulin
ratio
ag
evalu
time
diagnosi
cat
rang
year
old
median
femal
european
shorthair
histolog
diagnosi
ibd
lymphoma
common
symptom
vomit
weight
loss
diarrhea
mean
fceai
score
ae
mean
serum
total
protein
ae
gdl
low
total
protein
ae
gdl
occur
cat
hypoalbuminemia
beta
globulin
decreas
cat
gamma
globulin
increas
ag
ratio
significantli
higher
cat
hypoproteinemia
ae
compar
nonhypoproteinem
cat
ae
statist
differ
protein
profil
symptom
fceai
gastrointestin
tract
concern
endoscop
score
type
sever
histolog
pattern
found
despit
hypoproteinemia
rel
frequent
find
work
correl
clinic
variabl
establish
addit
clinic
sever
endoscop
histolog
grade
relat
protein
profil
dysproteinemia
low
beta
globulin
high
gamma
globulin
common
alter
hypoproteinem
cat
ag
higher
nonhypoproteinem
cat
decreas
beta
globulin
could
due
malnutrit
also
iron
metabol
modif
occur
chronic
inflammatori
diseas
reduct
transferrin
ferritin
hypergammaglobulinemia
report
human
medicin
common
featur
ibd
associ
extraintestin
manifest
data
far
avail
preval
clinic
signific
cat
disclosur
disclosur
report
import
obtain
accur
quantif
mitral
regurgit
sever
fact
especi
import
order
identifi
patient
acvim
classificationthat
benefit
start
medic
prevent
congest
heart
failur
vena
contracta
narrowest
portion
jet
downstream
regurgit
orific
object
present
studi
prove
vena
contracta
could
use
criteria
classif
dog
dcmvd
one
hundr
thirteen
dog
suffer
dcmvd
differ
phase
accord
acvim
classif
includ
n
n
c
n
vena
contracta
measur
parastern
left
apic
fourchamb
long
axi
view
three
measur
obtain
dog
averag
obtain
result
show
statist
signific
differ
stage
enddiastol
left
ventricular
index
edvi
endsystol
left
ventricular
index
esvi
vena
contracta
kruskalw
independ
sampl
test
differ
signific
dog
dog
p
c
dog
p
vena
contracta
differ
signific
dog
dog
p
c
dog
p
edvi
differ
signific
dog
dog
p
c
dog
p
esvi
differ
valu
c
dog
vena
contracta
appear
use
differenti
earli
phase
dcmvd
congest
phase
dcmvd
seem
less
use
differenti
dog
c
dog
import
rememb
measur
use
multipl
jet
present
common
dog
dcmvd
vena
contracta
ellipsoid
shape
measur
could
vari
depend
plane
acquisit
due
fact
vena
contracta
usual
small
typic
less
cm
slight
measur
error
could
lead
larg
mistak
misclassif
human
recommend
measur
vena
contracta
right
parastern
long
axi
factor
must
taken
consider
critic
point
view
face
present
result
disclosur
disclosur
report
pulmonari
hypertens
ph
present
approxim
dog
leftsid
congest
heart
failur
lchf
contribut
clinic
sign
outcom
anecdot
evid
suggest
ph
cat
lchf
much
less
frequent
howev
data
preval
ph
cat
lchf
avail
studi
address
gener
hypothesi
ph
secondari
lchf
uncommon
cat
echocardiograph
find
cat
ph
differ
compar
dog
retrospect
observ
studi
includ
healthi
cat
cat
lchf
imag
ohio
state
univers
veterinari
medic
center
key
diagnost
variabl
includ
tricuspid
regurgit
tr
peak
veloc
right
atrial
ra
size
right
ventricular
rv
size
function
rv
wall
thick
pulmonari
arteri
pa
size
dopplerderiv
systol
time
interv
pa
flow
sti
presenc
septal
flatten
variabl
character
left
atrial
size
left
ventricular
size
function
ph
identifi
tr
peak
veloc
msec
estim
systol
pa
pressur
mmhg
parametr
nonparametr
statist
test
procedur
use
compar
normal
cat
cat
lchf
cat
without
ph
tricuspid
regurgit
present
cat
lchf
pulmonari
hypertens
present
cat
lchf
case
ph
associ
cardiomyopathi
case
congenit
heart
diseas
case
caus
cat
ph
subjectivelyassess
rightsid
enlarg
larger
ra
rv
diamet
p
thicker
rv
wall
thick
p
higher
preval
septal
flatten
p
comparison
cat
without
ph
pulmonari
arteri
size
dopplerderiv
sti
statist
differ
cat
without
ph
maximum
right
atrial
diamet
mm
sensit
sn
specif
sp
rv
ventricular
diamet
mm
sn
sp
accur
cutoff
predict
ph
compar
variabl
method
reproduc
measur
variabl
good
coeffici
variat
compar
dog
ph
common
find
cat
lchf
rightsid
enlarg
main
find
cat
ph
rightheart
dimens
use
suspect
ph
tr
absent
difficult
measur
studi
need
identifi
reason
mechan
obviou
differ
dog
cat
disclosur
disclosur
report
dachshund
affect
chronic
mitral
valv
diseas
cmvd
often
heart
diseas
dog
cmvd
develop
mainli
small
anim
chondrodystroph
breed
common
dachshund
predispos
develop
mitral
valv
prolaps
mvp
systol
displac
one
mitral
leaflet
beyond
mitral
valv
annulu
mvp
associ
mark
sinu
arrhythmia
dachshund
hypothesi
adult
healthi
dachshund
dog
predispos
exhibit
mvp
mitral
regurgit
perform
prospect
studi
clientown
anim
screen
physic
examin
thorac
radiographi
electrocardiographi
systol
blood
pressur
measur
echocardiographi
laboratori
test
cbc
biochem
blood
urea
creatinin
pulmonari
hypertens
ph
report
dog
infect
angiostrongylu
vasorum
moder
sever
ph
identifi
small
portion
dog
associ
shorter
surviv
time
retrospect
studi
mild
ph
identifi
experiment
infect
dog
object
studi
determin
preval
sever
ph
dog
present
univers
clinic
vasorum
infect
describ
associ
echocardiograph
chang
dog
dog
present
novemb
februari
confirm
vasorum
infect
base
posit
baerman
coproscopi
ag
detect
blood
pcr
balf
retrospect
includ
diagnosi
ph
base
sole
radiographi
group
plu
echocardiographi
group
group
ph
sever
determin
tricuspid
regurgit
veloc
trmax
pulmon
insuffici
veloc
prmax
regurgit
measur
indirect
sign
ph
right
heart
remodel
main
pulmonari
arteri
dilat
paao
acceler
time
eject
time
atet
tricuspid
annular
plane
systol
excurs
taps
pulmonari
vein
diametertopulmonari
arteri
diamet
ratio
pvpa
taken
account
thirtysix
dog
includ
group
group
median
age
time
diagnosi
year
month
year
chronic
cough
dyspnea
exercis
intoler
main
clinic
complaint
group
dog
sever
ph
display
right
apic
systol
heart
murmur
rightsid
congest
heart
failur
preval
moder
sever
ph
group
two
dog
display
indirect
sign
ph
dog
median
trmax
prmax
respect
msec
msec
median
atet
paao
pvpa
respect
right
ventricular
dilat
observ
dog
consid
sever
dog
sever
ph
howev
taps
within
confid
interv
dog
group
dog
evid
ph
mild
enlarg
pulmonari
arteri
howev
group
two
dog
sever
ph
normal
pulmonari
vasculatur
xray
question
sensit
thorac
radiographi
ph
conclus
base
dopplerechocardiographi
preval
moder
sever
ph
dog
natur
infect
vasorum
seem
import
previous
describ
systemat
ultrasound
scan
dog
infect
vasorum
advis
evalu
presenc
sever
ph
disclosur
disclosur
report
symmetr
dimethylarginin
sdma
produc
protein
metabol
elimin
renal
clearanc
recent
year
use
marker
kidney
diseas
correl
glomerular
filtrat
rate
human
sdma
increas
patient
cardiovascular
diseas
neg
prognost
valu
aim
studi
assess
sdma
dog
myxomat
mitral
valv
diseas
mmvd
variou
diseas
stage
evalu
effect
pulmonari
hypertens
ph
possibl
influenc
cardiovascular
therapi
dog
visit
retrospect
recruit
diagnosi
mmvd
complet
cardiovascular
assess
physic
examin
thorac
radiogram
ecg
transthorac
echocardiographi
cbc
biochemistri
profil
sampl
serum
store
n
control
group
healthi
dog
also
includ
n
dog
mmvd
divid
accord
acvim
guidelin
stage
n
n
cd
n
dog
acvimgroup
subdivid
treat
n
nontreat
n
group
cd
respect
dog
consid
affect
ph
tricuspid
regurgit
peak
veloc
msec
right
ventricl
outflow
tract
obstruct
n
sdma
determin
refer
laboratori
use
routin
avail
immunoassay
select
echocardiograph
cbc
biochem
paramet
sdma
compar
among
acvimgroup
use
kruskalw
test
test
use
assess
combin
effect
therapi
acvimgroup
serum
urea
nitrogen
bun
creatinin
sdma
correl
sdma
echocardiograph
cbc
biochem
variabl
assess
use
pearson
test
manwhitney
test
use
assess
differ
sdma
phgroup
sdma
increas
acvimgroup
cd
compar
group
p
p
bun
increas
group
cd
compar
healthi
p
p
p
creatinin
significantli
differ
among
group
sdma
posit
significantli
correl
bun
r
p
creatinin
r
p
sodium
r
p
leftatrium
aorta
ratio
r
p
mitral
valv
ewav
veloc
r
p
treatment
significantli
affect
sdma
bun
creatinin
acvimgroup
signific
differ
sdma
observ
phgroup
increas
sdma
observ
advanc
stage
canin
mmvd
like
reflect
reduc
renal
function
better
bun
creatinin
therapi
ph
seem
affect
sdma
dog
mmvd
disclosur
disclosur
report
sdma
determin
idexx
laboratori
cost
analysi
partial
reduc
assess
sever
left
ventricular
lv
hypertrophi
human
medicin
consist
three
main
cardiac
paramet
lv
wall
thick
lv
mass
lvm
lv
geometri
latter
assess
either
lvmbodi
surfac
area
bsa
rel
wall
thick
rwt
base
lv
geometri
lv
classifi
normal
lvmbsa
rwt
within
refer
rang
concentr
remodel
normal
lvm
increas
rwt
concentr
hypertrophi
increas
lvm
rwt
eccentr
hypertrophi
normaldecreas
rwt
increas
lvm
data
normal
valu
lvm
rwt
scant
dog
aim
retrospect
studi
determin
normal
valu
lvmbsa
e
rwt
mmode
deriv
healthi
dog
ii
evalu
effect
sex
age
breed
echocardiograph
paramet
iii
compar
lvmbsa
e
rwt
healthi
year
hypertens
dog
clinic
archiv
cardiolog
unit
dimevet
univers
milan
itali
search
dog
complet
echocardiograph
examin
system
blood
pressur
determin
dog
group
healthi
base
cardiac
metabol
renal
diseas
hypertens
accord
acvim
guidelin
digit
store
echocardiograph
mmode
data
lvmbsa
rwt
calcul
lvm
deriv
geometr
formula
index
bsa
rwt
calcul
ratio
posterior
wall
thick
lv
intern
diamet
end
diastol
eightythre
healthi
dog
male
hypertens
dog
includ
studi
mean
sd
lvmbsa
rwt
respect
gm
healthi
dog
differ
sex
age
dog
year
vs
year
found
sighthound
dog
n
show
statist
larger
lvmbsa
gm
vs
gm
p
similar
rwt
nonsighthound
dog
n
vs
p
hypertens
dog
show
otherwis
statist
differ
rwt
vs
p
healthi
dog
similar
lvm
vs
gm
p
result
studi
suggest
echocardiograph
paramet
may
help
routin
classifi
hypertrophi
patternlv
geometri
dog
contrast
human
find
sex
differ
found
lvmbsa
sighthound
dog
tend
show
greater
lvmbsa
valu
like
repres
physiolog
hypertrophi
normal
rwt
increas
lvmbsa
dog
system
hypertens
increas
rwt
normal
lvm
could
repres
first
respons
lv
pressur
overload
disclosur
disclosur
report
recognit
congest
heart
failur
chf
dyspneic
cat
crucial
correct
intervent
pulmonari
vein
pv
pulmonari
arteri
pa
ratio
pvpa
propos
index
might
help
discrimin
dog
chf
never
studi
cat
sought
determin
refer
interv
variou
previous
publish
pv
pa
variabl
healthi
cat
examin
variabl
cat
subclin
clinic
chf
cardiomyopathi
determin
diagnost
util
identifi
chf
prospect
enrol
cat
healthi
cat
subclin
cardiomyopath
cat
cardiomyopath
cat
chf
pv
pa
measur
minim
maxim
diamet
mmode
imag
obtain
modifi
right
parastern
long
axi
view
aorta
left
atrium
measur
right
parastern
short
axi
end
systol
median
pv
min
pa
min
healthi
cat
approxim
pv
max
pa
max
median
distens
vessel
dpa
dpv
sever
variabl
pv
max
pa
max
pv
max
ao
pv
min
ao
increas
increment
group
p
cat
chf
larger
pv
min
pa
min
subclin
healthi
cat
p
evalu
diagnost
perform
variabl
use
cardiomyopath
cat
without
chf
pv
min
pa
min
pv
min
ao
specif
sensit
respect
comparison
laao
specif
sensit
studi
provid
refer
valu
pv
pa
variabl
cat
moreov
pvpa
variabl
perform
better
laao
discrimin
cardiomyopath
cat
without
chf
disclosur
disclosur
report
electrocardiogram
ecg
essenti
tool
diagnos
monitor
cardiac
arrhythmia
veterinari
medicin
howev
lowcost
user
friendli
smartphonebas
electrocardiograph
still
lack
portabl
smartphonebas
devic
stream
trace
via
bluetooth
smartphon
enabl
acquisit
ecg
multipl
lead
current
use
human
cardiolog
aim
studi
determin
accuraci
trace
compar
gold
standard
nonport
electrocardiograph
dog
standard
ecg
ecg
subsequ
acquir
consciou
dog
right
later
recumb
trace
save
anonym
id
two
experienc
observ
independ
imparti
perform
data
analysi
case
disagr
third
imparti
observ
adjud
trace
sampl
describ
continu
variabl
mean
standard
deviat
median
interquartil
rang
iqr
appropri
categor
variabl
proport
concord
ecg
method
assess
weight
kwcohen
index
rel
signific
take
end
point
variabl
standard
ecg
group
blandaltman
method
confid
level
appli
p
pr
qr
qt
interv
measur
sinc
differ
two
measur
follow
normal
distribut
nonparametr
approach
median
valu
iqr
use
determin
limit
agreement
p
valu
consid
signific
level
amplitud
wave
consid
preliminari
analysi
current
softwar
nt
allow
voltag
variat
dog
differ
weight
breed
admit
cardiolog
servic
dimevet
enrol
mean
age
dog
ae
year
intact
male
n
repres
breed
mongrel
n
weight
cohen
kappa
kw
test
ecg
demonstr
excel
concord
p
evalu
heart
rhythm
p
st
segment
morpholog
p
wave
morpholog
concord
among
p
morpholog
assign
p
pr
qr
qt
interv
comparison
blandaltman
method
show
extrem
good
concord
measur
limit
agreement
ae
ms
p
ae
ms
pr
ae
ms
qr
ae
ms
wave
less
concord
result
qt
ae
ms
prove
effect
accur
record
ecg
compar
standard
ecg
open
new
perspect
improv
diagnost
tool
veterinari
cardiolog
disclosur
disclosur
report
effect
teach
method
critic
veterinari
student
learn
complex
subject
cardiolog
graphic
organ
go
visual
spatial
display
tabl
chart
facilit
learn
make
conceptu
relationship
content
appar
hypothes
elect
veterinari
cardiolog
cours
studi
aid
form
go
would
lead
improv
learn
outcom
higher
posttest
score
improv
studi
effici
less
time
spent
studi
higher
student
satisfact
compar
tradit
outlin
format
studi
mixedmethod
prospect
random
crossov
design
studi
particip
n
rd
year
veterinari
student
iowa
state
univers
colleg
veterinari
medicin
enrol
elect
veterinari
cardiolog
cours
particip
complet
comprehens
pretest
random
two
group
b
student
receiv
ident
cardiolog
content
present
instructor
via
live
weekli
inclass
lectur
follow
predesign
experiment
lectur
student
given
instructorprepar
studi
aid
summar
lesson
materi
present
either
go
format
follow
week
student
complet
posttest
content
knowledg
lesson
indic
amount
time
spent
studi
lesson
crossov
occur
group
group
b
altern
receiv
go
experiment
lesson
qualit
data
collect
form
indepth
precours
postcours
survey
group
compar
baselin
term
demograph
data
academ
achiev
precours
survey
result
pretest
score
posttest
score
differ
p
base
type
studi
aid
provid
student
lesson
go
vs
student
spent
averag
min
less
time
studi
per
lesson
use
go
compar
p
student
satisfact
studi
aid
format
high
student
prefer
go
term
studi
effici
p
visual
appeal
p
eas
use
p
likelihood
referenc
studi
aid
futur
p
conclus
elect
veterinari
cardiolog
cours
use
go
compar
format
studi
aid
result
equival
higher
studi
effici
student
satisfact
result
equival
shortterm
learn
outcom
disclosur
disclosur
report
physiolog
heart
murmur
phm
identifi
anim
structur
abnorm
heart
great
vessel
sound
produc
blood
flow
usual
detect
puppi
commonli
observ
healthi
young
adult
dog
phm
may
result
increas
sympathet
tone
possibl
secondari
anxieti
describ
breed
athlet
dog
adulthood
crosssect
studi
perform
healthi
dachshund
includ
male
femal
age
month
yearsold
weight
ae
kg
dog
underw
physic
examin
blood
test
echocardiogram
electrocardiogram
blood
pressur
measur
thorac
radiographi
abnorm
found
systol
heart
murmur
detect
dog
grade
iivi
grade
iiivi
levinefreeman
scale
murmur
mostli
locat
mitral
valv
area
heart
murmur
adult
dog
frequent
indic
patholog
condit
howev
none
dog
structur
heart
abnorm
system
disturb
therefor
studi
show
high
preval
phm
healthi
adult
dachshund
disclosur
disclosur
report
research
new
biomark
bodi
fluid
detect
primari
problem
crucial
human
veterinari
medicin
although
serum
cholin
suggest
emerg
biomark
human
dog
myocardi
ischemia
avail
data
use
cholin
level
predict
cardiac
event
therefor
studi
aim
evalu
use
cholin
concentr
potenti
biomark
distinguish
pleural
effus
due
heart
base
tumor
hbt
dilat
cardiomyopathi
dcm
determin
whether
correl
pleural
serum
cholin
level
dog
dog
pleural
effus
due
dcm
n
hbt
n
use
materi
pleural
effus
diagnos
clinic
radiolog
ultrasonograph
us
examin
along
usguid
thoracentesi
dcm
diagnos
base
sum
score
point
recommend
european
societi
veterinari
cardiolog
taskforc
preoper
diagnosi
hbt
confirm
histopatholog
evalu
show
mesothelioma
chemodectoma
hemangiosarcoma
aortic
bodi
tumor
healthi
ageand
breedmatch
dog
n
use
control
serum
freecholin
concentr
sampl
analyz
high
perform
liquid
chromatographi
triplic
result
express
micromolar
lm
serum
cholin
concentr
dog
median
rang
lm
healthi
dog
lm
dcm
lm
hbt
signific
group
statist
signific
differ
p
cholin
concentr
mean
ae
sem
pleural
fluid
dog
dcm
hbt
ae
lm
ae
lm
respect
cholin
level
higher
p
pleural
fluid
compar
serum
dog
hbt
wherea
statist
signific
differ
dog
dcm
dog
n
cholin
level
pleural
effus
ae
lm
higher
p
serum
level
ae
lm
signific
relationship
pearson
correl
cholin
level
serum
pleural
fluid
dog
dcm
hbt
data
suggest
pleural
fluid
cholin
concentr
rather
serum
concentr
might
use
new
potenti
biomark
distinguish
dcm
hbt
dog
disclosur
disclosur
report
ebstein
anomali
ea
rare
type
congenit
heart
diseas
character
apic
displac
tricuspid
valv
leaflet
right
ventricl
rv
caus
dilat
right
atrium
ra
decreas
function
rv
size
studi
dedic
canin
ea
object
retrospect
studi
character
epidemiolog
clinic
echocardiograph
find
associ
canin
ea
well
surviv
case
record
dog
diagnos
ea
use
echocardiographi
review
studi
popul
consist
dog
ea
median
age
diagnosi
month
iqr
maletofemal
ratio
medium
larg
breed
repres
common
breed
labrador
retriev
eight
dog
hemodynam
compromis
concurr
heart
diseas
n
respiratori
diseas
n
therefor
exclud
subsequ
analysi
right
apic
systol
heart
murmur
median
grade
iqr
detect
dog
dog
present
clinic
sign
relat
ea
dilat
ra
moder
sever
dog
median
ra
left
atrium
la
ratio
sever
echocardiograph
indic
use
human
pediatr
evalu
ea
calcul
includ
displac
index
distanc
hing
point
anterior
mitral
leaflet
delamin
septal
leaflet
divid
bodi
surfac
area
median
mmm
iqr
celermaj
index
ratio
ra
area
sum
area
rv
la
left
ventricl
median
iqr
followup
avail
dog
death
cardiac
origin
report
dog
allcaus
death
dog
median
age
allcaus
death
month
median
time
allcaus
death
month
diagnosi
ea
median
time
cardiac
death
cd
could
calcul
due
high
proport
dog
still
aliv
end
studi
estim
dog
ci
present
cd
month
diagnosi
ea
univari
analys
show
time
diagnosi
cd
associ
presenc
ascit
clinic
sign
ra
la
presenc
right
thrill
celermaj
conclus
ra
enlarg
significantli
associ
decreas
surviv
time
dog
ea
although
may
live
year
may
die
cd
disclosur
disclosur
report
c
poissonni
fondat
un
coeur
vetoquinol
sponsor
clinic
project
unrel
studi
hypertroph
cardiomyopathi
hcm
common
felin
heart
diseas
current
echocardiographi
gold
standard
diagnos
felin
hcm
includ
occult
form
diseas
howev
imag
techniqu
requir
expertis
interpret
data
repres
financi
cost
owner
thu
limit
widespread
use
screen
appar
healthi
cat
therefor
rapidli
assess
biomark
petsid
test
abl
identifi
asymptomat
hcm
cat
would
interest
previou
studi
show
circul
cardiac
biomark
ntermin
probtyp
natriuret
peptid
ntprobnp
significantli
increas
cat
moder
sever
occult
hcm
compar
healthi
cat
aim
prospect
studi
determin
sensibl
se
specif
sp
idexx
snap
felin
probnp
test
diagnos
hcm
asymptomat
adult
cat
materi
method
studi
popul
consist
prospect
recruit
appar
healthi
adult
cat
without
heart
murmur
cat
congenit
heart
diseas
cardiomyopathi
hcm
current
past
diagnosi
congest
heart
failur
gallop
rhythm
includ
studi
cat
underw
complet
physic
examin
blood
pressur
measur
serum
urea
creatinin
measur
convent
echocardiographi
total
also
assess
cat
year
old
plasma
ntprobnp
concentr
measur
use
edtapotassium
sampl
commerci
avail
felin
specif
assay
snap
felin
ntprobnp
also
perform
posit
detect
limit
pmoll
accord
manufactur
instruct
result
studi
popul
consist
appar
healthi
cat
male
femal
median
age
year
bodi
weight
kg
normal
cat
normal
cardiac
auscult
echocardiographi
asymptomat
cat
left
apic
systol
heart
murmur
either
relat
hcm
n
diffus
hcm
form
segment
hcm
form
hypertrophi
subaort
interventricular
septum
minor
mild
mitral
valv
regurgit
without
echocardiograph
abnorm
mvr
n
snap
test
distinguish
asymptomat
hcm
cat
appar
healthi
cat
ie
normal
cat
cat
minor
mild
mvr
sensibl
se
specif
sp
neg
posit
predict
valu
respect
consid
diffus
hcm
form
se
sp
conclus
snap
felin
ntprobnp
test
may
help
identifi
diffus
hcm
form
asymptomat
cat
disclosur
disclosur
report
studi
financ
idexx
laboratori
object
main
object
evalu
effect
addit
shortchain
fructooligosaccharid
scfo
daili
cat
feed
ration
intens
unpleas
odor
cat
fece
secondari
object
evalu
digest
toler
product
cat
owner
satisfact
method
studi
random
doubl
blind
placebo
control
studi
conduct
parallel
arm
experiment
product
dri
cat
food
scfo
tereo
without
scfo
inclus
criteria
healthi
cat
live
naturalist
condit
owner
home
year
old
use
cat
litter
whose
owner
complain
intens
bad
smell
cat
recent
current
treatment
exclud
main
criterion
intens
odor
fece
evalu
owner
likert
scale
odor
unbear
digest
toler
evalu
consist
stool
fecal
score
scale
satisfact
criterion
evalu
likert
scale
criteria
daili
collect
week
begin
studi
day
feed
result
studi
cover
cat
age
ae
among
femal
cat
includ
verum
group
placebo
group
characterist
past
histori
similar
intens
odor
fece
similar
group
inclus
verum
ae
vs
placebo
ae
p
comparison
two
group
show
reduct
fece
odor
greater
verum
group
placebo
group
reduct
describ
absolut
valu
ae
vs
ae
describ
percentag
ae
vs
ae
percentag
owner
satisfi
extrem
satisfi
improv
odor
significantli
greater
verum
group
placebo
group
vs
particular
percentag
satisfi
owner
vs
stool
consist
remain
stabl
group
confirm
scfo
well
toler
cat
conclus
ad
scfo
daili
cat
feed
ration
benefici
order
reduc
unpleas
odor
cat
stool
without
alter
digest
toler
disclosur
disclosur
report
cen
nutrit
anim
receiv
research
grant
tereo
increas
concentr
dietari
polyunsatur
fatti
acid
pufa
eg
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
rel
fa
eg
arachidon
acid
aa
shown
increas
plasma
concentr
epa
dha
reduc
aa
concentr
purpos
studi
investig
effect
increas
dietari
pufa
concentr
urin
characterist
recent
shown
lifespan
cat
nonobstruct
kidney
stone
shorten
compar
control
cat
indic
need
prevent
stone
format
decreas
rate
chronic
kidney
diseas
progress
domest
short
hair
cat
n
mean
age
year
rang
year
random
two
group
fed
one
two
diet
day
cross
diet
anoth
day
protocol
review
approv
institut
anim
care
use
committe
hill
pet
nutrit
inc
day
studi
initi
cat
consum
pretrial
control
food
contain
aa
measur
epa
dha
day
cat
split
two
group
group
continu
eat
control
food
day
group
fed
test
food
day
contain
aa
epa
dha
combin
day
group
cat
fed
test
food
group
cat
fed
control
food
anoth
day
serum
analyz
fa
concentr
baselin
feed
period
concurr
urin
analyz
urin
specif
graviti
usg
calcium
concentr
rel
super
satur
struvit
crystal
addit
urin
calcium
oxal
titrimetr
test
cott
perform
consum
test
food
cat
increas
p
plasma
concentr
aa
epa
dha
compar
cat
consum
control
food
addit
urin
cat
fed
test
food
decreas
usg
p
decreas
calcium
concentr
p
decreas
struvit
super
satur
p
enhanc
titrat
ad
oxal
form
calcium
oxal
crystal
p
resist
oxal
crystal
format
neg
correl
blood
calcium
concentr
r
p
relationship
unaffect
test
food
howev
feed
test
food
decreas
usg
decreas
urin
calcium
concentr
increas
resist
oxal
crystal
format
data
show
could
signific
urinari
tract
benefit
cat
ie
reduc
urin
stone
format
increas
dietari
aa
epa
dha
disclosur
increas
concentr
dietari
polyunsatur
fatti
acid
pufa
eg
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
rel
fa
eg
arachidon
acid
aa
shown
increas
plasma
concentr
epa
dha
reduc
aa
concentr
purpos
studi
investig
effect
enrich
food
bioactiv
ingredi
includ
epa
dha
bodi
composit
concentr
circul
fatti
acid
inflammatori
biomark
prostaglandin
e
pge
domest
short
hair
cat
n
mean
age
year
rang
year
fed
pretrial
food
day
random
three
group
fed
one
three
diet
day
protocol
review
approv
institut
anim
care
use
committe
hill
pet
nutrit
inc
pretrial
food
contain
protein
arachidon
acid
aa
neglig
epa
dha
control
food
contain
protein
aa
epa
dha
test
food
test
food
contain
protein
respect
well
aa
epa
dha
contain
addit
bioactiv
food
factor
broccoli
tomato
oat
pea
increas
bioactiv
ingredi
concentr
compar
serum
analyz
fa
pge
concentr
initi
day
concurr
bodi
composit
determin
dual
energi
xray
absorptiometri
consum
food
day
lean
bodi
mass
lbm
unchang
cat
fed
control
food
ae
g
wherea
cat
fed
ae
g
p
ae
g
p
increas
lbm
bodi
fat
unchang
cat
fed
control
food
ae
g
decreas
cat
fed
ae
g
p
ae
g
p
pge
concentr
decreas
cat
fed
control
tf
posit
correl
ratio
fa
serum
r
p
neg
correl
sum
fa
r
p
cat
consum
food
contain
plant
bioactiv
fish
oil
reduc
concentr
inflammatori
biomark
pge
enhanc
lean
bodi
composit
togeth
may
aid
offset
inflamm
adipos
associ
age
cat
disclosur
bodi
condit
score
bc
method
mani
clinic
veterinarian
adopt
nutrit
assess
method
howev
bc
assess
inconsist
subject
method
therefor
develop
bc
palpat
model
improv
precis
bc
assess
furthermor
studi
new
bc
assess
morphometr
method
improv
precis
bc
assess
bc
assess
measur
bodi
length
current
bodi
weight
method
thirtynin
dog
vari
bc
level
use
breed
gender
age
neglect
select
dog
measur
bodi
fat
percentag
deuterium
water
dilut
method
use
blood
collect
deuterium
water
gkg
subcutan
inject
blood
sampl
collect
h
administr
concentr
deuterium
water
blood
analyz
radio
isotop
massspectrometri
bodi
length
length
scapula
ilium
blsi
scapula
base
tail
blsb
measur
calcul
bodi
weight
correspond
bc
ideal
bodi
weight
ibw
calcul
bodi
weight
bodi
fat
percentag
bodi
weight
correspond
bc
calcul
follow
bc
ibw
bc
ibw
bc
ibw
bc
ibw
bc
ibw
less
result
suggest
correl
coeffici
blsb
ibw
r
p
higher
correl
coeffici
blsi
ibw
mean
measur
length
blsb
accur
measur
length
blsi
result
suggest
ibw
dog
could
estim
measur
blsb
correl
coeffici
blsb
ibw
long
bodi
dog
miniatur
dachshund
welsh
corgi
etc
higher
subject
dog
suggest
better
divid
dog
follow
three
type
standard
shape
long
squar
bodi
dog
morphometr
bc
assess
addit
individu
bc
calcul
estrang
percentag
ibw
current
weight
use
formula
morphometr
method
simpler
object
convent
method
disclosur
disclosur
report
bodi
condit
score
bc
wide
accept
clinic
method
estim
bodi
fat
mass
dog
system
prefer
sinc
visual
characterist
depict
silhouett
imag
singl
breed
assess
visual
characterist
dog
differ
size
bodi
shape
challeng
two
modif
origin
bc
system
develop
refer
imag
archiv
almost
photograph
dog
attend
royal
canin
weight
manag
clinic
univers
liverpool
gant
bmc
veterinari
research
bodi
fat
mass
measur
dualenergi
xray
absorptiometri
dexa
bc
known
dog
owner
gave
written
permiss
use
photograph
first
modif
paperbas
system
use
set
sizespecif
bc
chart
small
medium
larg
giant
breed
respect
written
descript
categori
ident
differ
imag
includ
differ
size
categori
second
computerbas
system
wherebi
visual
characterist
model
onscreen
alter
bodi
shape
differ
zone
chest
abdomen
back
thigh
pelvi
comput
softwar
calcul
bodi
condit
score
automat
use
algorithm
thirti
dog
rang
breed
use
valid
system
refer
surgic
treatment
cranial
cruciat
ligament
diseas
small
anim
teach
hospit
univers
liverpool
owner
consent
particip
separ
research
studi
involv
bodi
fat
measur
dexa
anesthet
use
diagnost
therapeut
procedur
one
author
ws
assess
bc
dog
supervis
second
author
experienc
bodi
condit
score
ajg
comput
system
use
first
follow
paperbas
system
median
bc
median
bodi
fat
rang
strong
posit
correl
bodi
fat
measur
dexa
bc
paper
r
p
computerbas
r
p
system
system
also
correl
strongli
r
p
agreement
almost
perfect
cohen
kappa
p
find
demonstr
modifi
paperbas
computerbas
bc
system
correl
bodi
fat
mass
measur
dexa
consid
use
clinic
case
disclosur
disclosur
report
alex
german
academ
post
fund
royal
canin
author
also
receiv
financi
remuner
gift
provid
educ
materi
speak
confer
consult
work
elodi
morel
marieann
hour
vincent
biourg
employe
royal
canin
renal
sodium
glucos
transport
type
inhibitor
novel
class
drug
develop
manag
diabet
human
inhibit
induc
profound
renal
glucosuria
reduc
blood
glucos
lower
insulin
requir
man
advers
effect
uncommon
drug
evalu
cat
author
knowledg
studi
healthi
cat
sequenti
dose
mg
dapagliflozin
day
per
treatment
week
washout
regimen
cat
hous
individu
cage
hematolog
serum
biochemistri
urinalysi
perform
trial
daili
food
water
intak
urin
product
h
urinari
glucos
excret
measur
durat
trial
data
analyz
use
mix
linear
model
fix
effect
dose
day
random
effect
cat
dapagliflozin
induc
signific
glucosuria
dose
use
persist
day
last
dose
regimen
mg
dose
induc
signific
increas
daili
urin
glucos
output
concomit
decreas
daili
urin
output
one
cat
develop
mild
hyperglobulinemia
leukocytosi
advers
effect
note
cat
lost
weight
trial
one
tout
benefit
drug
human
diabet
polydipsiapolyuria
observ
urinari
tract
infect
detect
trial
conclus
dapagliflozin
appear
safe
effect
induc
glucosuria
disclosur
disclosur
report
adren
ultrasonographi
easili
avail
gener
veterinari
practic
time
endogen
acth
assay
routin
use
differenti
pituitari
adren
depend
diseas
clinic
clinicopatholog
data
obtain
laboratori
submiss
andor
submit
practition
patient
record
total
dog
met
inclus
criteria
confirm
diagnosi
hyperadrenocortic
subset
evalu
age
bodi
weight
sex
breed
lesion
locat
pituitari
vs
adren
median
age
assess
dog
year
median
bodi
weight
kg
sixtyon
percent
dog
femal
male
commonli
affect
breed
crossbr
dog
maltes
maltes
crossbr
maltes
purebr
togeth
compris
studi
popul
commonli
identifi
breed
includ
australian
cattl
dog
jack
russel
terrier
poodl
miniatur
fox
terrier
shi
tzu
bichon
frise
pituitari
depend
hyperadrenocortic
identifi
dog
function
adren
tumor
found
dog
suspect
fourth
dog
result
demonstr
australian
dog
hyperadrenocortic
lower
median
bodi
weight
higher
preval
pituitari
depend
diseas
compar
north
american
data
addit
strike
percentag
studi
popul
maltes
dog
cross
find
implic
investig
therapi
canin
hyperadrenocortic
australia
also
highlight
region
differ
hyperadrenocortic
recogn
veterinarian
worldwid
disclosur
disclosur
report
studi
popul
studi
involv
conflict
interest
author
one
author
bd
employ
accredit
laboratori
sourc
raw
data
one
author
sf
consult
laboratori
studi
independ
collabor
retrospect
studi
perform
commerci
benefit
fund
person
entiti
hyperthyroid
lead
decreas
serum
creatinin
crea
increas
glomerular
filtrat
rate
gfr
decreas
bodi
muscl
mass
mask
concurr
chronic
kidney
diseas
might
becom
evid
onset
treatment
symmetr
dimethylarginin
sdma
novel
earli
renal
biomark
independ
bodi
muscl
mass
therefor
might
use
marker
renal
diseas
hyperthyroid
cat
human
clear
hyperthyroid
state
could
influenc
sdma
aim
studi
evalu
sdma
hyperthyroid
cat
time
diagnosi
treatment
retrospect
observ
studi
nineteen
hyperthyroid
cat
mmoll
normal
crea
mgdl
includ
eighteen
healthi
cat
older
year
normal
crea
mgdl
enrol
control
group
data
physic
exam
emogram
serum
biochemistri
serum
concentr
evalu
sdma
measur
serum
left
previou
analyz
store
sdma
measur
perform
serum
sampl
collect
time
diagnosi
hyperthyroid
methimazol
treatment
normal
day
initi
treatment
followup
avail
hyperthyroid
cat
sdma
measur
use
valid
immunoassay
idexx
sdma
test
hyperthyroid
cat
older
p
lower
weight
p
control
cat
hyperthyroid
cat
crea
diagnosi
posit
correl
sdma
r
p
neg
correl
r
p
correl
found
sdma
diagnosi
p
hyperthyroid
cat
weight
posit
correl
creatinin
r
p
sdma
p
differ
crea
hyperthyroid
cat
control
diagnosi
p
creatinin
significantli
increas
p
treatment
despit
bodi
weight
p
differ
found
compar
sdma
hyperthyroid
control
cat
diagnosi
p
treatment
p
five
hyperthyroid
cat
sdma
valu
higher
refer
rang
diagnosi
followup
treatment
avail
cat
normal
crea
still
normal
sdma
increas
one
cat
show
increas
creatinin
normal
none
high
sdma
diagnosi
base
preliminari
studi
hyperthyroid
seem
influenc
sdma
concentr
disclosur
disclosur
report
feed
biolog
appropri
raw
food
barf
includ
gullet
popular
due
close
anatom
posit
thyroid
gland
respect
muscl
tissu
diet
like
contamin
thyroid
gland
tissu
may
caus
alimentari
thyrotoxicosi
howev
control
studi
miss
unclear
effect
absorb
total
thyroxin
triiodothyronin
may
thyroid
hormon
statu
level
still
routin
check
elderli
dog
commonli
dog
suspici
behavior
issu
would
high
diagnost
interest
potenti
thyroid
gland
feed
may
interfer
diagnost
approach
therefor
present
studi
aim
investig
short
term
effect
thyroid
gland
feed
thyroid
hormon
concentr
dog
bovin
thyroid
gland
slaughterhous
gkg
bodi
weight
fed
h
fast
togeth
complet
dri
diet
blood
sampl
taken
day
experi
order
verifi
euthyroid
healthi
beagl
dog
n
day
feed
experi
blood
taken
h
well
day
feed
sampl
free
thyroid
stimul
hormon
tsh
well
thyroglobulin
autoantibodi
tgaa
measur
either
use
autom
chemiluminesc
immunoassay
system
siemen
diagnost
usa
commerci
avail
tgaa
assay
oxford
laboratori
mi
usa
dog
tgaa
feed
thyroid
gland
increas
fold
basal
level
free
serum
concentr
serum
level
return
basal
level
h
howev
three
five
dog
show
ft
concentr
refer
rang
h
day
singl
control
thyroid
gland
feed
tsh
level
suppress
feed
h
none
dog
show
clinic
symptom
hyperthyroid
feed
thyroid
tissu
healthi
dog
result
distinct
effect
thyroid
hormon
blood
concentr
initi
singl
feed
thyroid
gland
lead
consider
higher
level
afterward
also
lower
ft
concentr
therefor
euthyroid
diagnos
administr
dog
food
contain
thyroid
gland
care
rule
last
seven
day
disclosur
disclosur
report
creactiv
protein
crp
major
acut
phase
protein
marker
system
inflamm
dog
creactiv
protein
indirectli
innat
immun
system
previous
evalu
dog
hypoadrenocortic
ha
accordingli
aim
studi
investig
dog
ha
abl
mount
acut
phase
respons
assess
elev
crp
medic
record
review
patient
newli
diagnos
hypoadrenocortic
may
march
dog
consid
ha
preand
post
acth
stimul
cortisol
nmoll
dog
exclud
newli
diagnos
ha
receiv
treatment
either
hypoadrenocortic
hyperadrenocortic
crp
measur
around
time
diagnosi
three
hundr
twentytwo
medic
record
dog
acth
stimul
perform
screen
seventeen
dog
ha
identifi
nine
dog
hypoadrenocortic
includ
retrospect
case
seri
median
age
time
present
year
includ
three
intact
male
two
neuter
male
two
intact
femal
two
spay
femal
preval
clinic
sign
includ
vomit
weight
loss
diarrhea
dog
least
one
clinic
sign
six
nine
dog
azotemia
mean
crp
mgl
inter
quartil
rang
mgl
refer
mgl
seven
nine
dog
elev
crp
interestingli
two
dog
normal
crp
nonazotem
clinic
stabl
time
present
conclus
dog
hypoadrenocortic
abl
induc
crp
product
could
indic
least
part
innat
immun
respons
function
dog
ha
often
normal
neutrophil
count
make
neutrophil
unreli
marker
inflamm
ha
creactiv
protein
could
therefor
use
biomark
acut
inflamm
patient
ha
marker
inflamm
reliabl
disclosur
disclosur
report
hypertens
diabet
human
common
preval
relat
hyperglycemia
durat
diseas
sever
complic
diabet
cat
previou
studi
shown
hypertens
present
uncommon
aim
studi
determin
preval
hypertens
felin
diabet
mellitu
dm
potenti
relat
differ
paramet
age
bodi
condit
score
bc
bc
previou
diagnosi
sex
glycem
control
time
sinc
diagnosi
concurr
diseas
chronic
corticoid
treatment
diabet
neuropathi
remiss
thirti
diabet
cat
assess
first
time
veterinari
teach
hospit
complutens
januari
april
systol
blood
pressur
sbp
measur
use
doppler
methodolog
hypertens
defin
mm
hg
subclassifi
follow
acvim
consensu
isfm
guidelin
bc
categor
ideal
weight
cat
receiv
antihypertens
treatment
age
rang
year
male
femal
neuter
except
one
male
diagnosi
cat
underweight
previou
diagnosi
cat
underweight
fact
overweight
preval
hypertens
sever
hypertens
mm
hg
concurr
diseas
known
associ
hypertens
present
cat
hypertens
sbp
valu
correl
age
time
sinc
diagnosi
sex
glycem
control
corticoid
excess
remiss
diabet
neuropathi
bc
previou
diagnosi
neg
correl
sbp
p
none
overweight
cat
previou
diagnosi
hypertens
p
also
underweight
cat
diagnosi
shown
higher
preval
hypertens
respect
p
preval
hypertens
differ
diabet
cat
without
concurr
diseas
diabet
cat
diseas
associ
hypertens
diseas
known
increas
sbp
p
remiss
present
cat
median
time
ae
month
remiss
posit
correl
presenc
diabet
neuropathi
first
visit
p
hypertens
seem
infrequ
diabet
cat
previous
report
posit
correl
concurr
diseas
associ
hypertens
neg
correl
bc
diagnosi
relat
hypertens
obes
diabet
cat
similar
observ
human
hypertens
diabet
cat
recommend
search
diseas
caus
elev
blood
pressur
disclosur
disclosur
report
relationship
diabet
mellitu
dm
hypertens
complex
human
dm
associ
hypertens
inform
blood
pressur
diabet
dog
scarc
report
diabet
dog
male
dog
longer
durat
diabet
higher
blood
pressur
bp
valu
furthermor
obes
associ
increas
bp
varieti
speci
role
dog
unclear
aim
studi
identifi
frequenc
hypertens
dog
dm
character
relationship
hypertens
age
sex
reproduct
statu
durat
dm
bodi
condit
score
concurr
diseas
treatment
corticoid
medic
record
diabet
dog
present
intern
medicin
servic
veterinari
teach
hospit
complutens
madrid
juli
march
review
bp
use
doppler
devic
assess
first
visit
hypertens
defin
systol
blood
pressur
sbp
mm
dog
receiv
antihypertens
medic
moment
exclud
follow
acvim
guidelin
hypertens
anim
subclassifi
accord
risk
target
organ
damag
antihypertens
treatment
administ
deem
appropri
good
control
dm
consid
fructosamin
valu
micromol
glucos
curv
valu
rang
mgdl
absenc
dm
clinic
sign
fiftythre
dog
includ
femal
intact
neuter
male
intact
neuter
age
rang
year
first
visit
hospit
dog
good
control
dm
twentyf
dog
consid
hypertens
hypertens
significantli
posit
correl
age
p
signific
correl
hypertens
sex
reproduct
statu
concurr
diseas
time
sinc
dm
diagnosi
obes
observ
hypertens
significantli
correl
control
dm
howev
none
dog
consid
good
control
diabet
sever
hypertens
p
hypertens
significantli
associ
chronic
corticoid
excess
due
hyperadrenocortic
exogen
administr
p
hypertens
present
diabet
dog
similar
preval
report
previou
studi
age
corticoid
excess
significantli
relat
obes
diabet
dog
relat
hypertens
observ
non
diabet
dog
disclosur
disclosur
report
dog
receiv
treatment
hypoadrenocortic
typic
monitor
analysi
serum
sodium
na
potassium
k
concentr
na
k
ratio
alongsid
clinic
sign
desir
veterinarian
abl
measur
concentr
inhous
allow
day
dose
chang
oppos
wait
result
refer
laboratori
aim
studi
compar
electrolyt
concentr
na
k
ratio
obtain
two
inhous
electrolyt
analyz
idexx
catalyst
idexx
refer
laboratori
olympu
cohort
dog
hypoadrenocortic
case
n
prospect
enrol
clinic
trial
compar
fludrocortison
docp
treatment
hypoadrenocortic
dog
multipl
electrolyt
measur
taken
variou
time
point
treatment
total
sampl
test
refer
laboratori
use
olympu
analyz
sampl
also
test
use
catalyst
analyz
analyz
sampl
test
use
three
analyz
catalyst
show
good
correl
olympu
na
k
concentr
na
k
ratio
catalyst
r
respect
p
r
p
mean
differ
blandaltman
plot
na
mmoll
standard
deviat
catalyst
mmoll
mean
differ
standard
deviat
k
mmoll
respect
catalyst
mmoll
final
mean
differ
standard
deviat
na
k
ratio
respect
catalyst
inhous
analyz
display
good
correl
refer
laboratori
electrolyt
measur
howev
analyz
persist
record
higher
na
concentr
analysi
k
concentr
closer
refer
laboratori
effect
increas
na
result
na
k
ratio
also
higher
could
clinic
signific
effect
manag
dog
hypoadrenocortic
care
taken
use
target
rang
base
refer
analyz
use
result
inhous
electrolyt
measur
disclosur
disclosur
report
lead
author
posit
studi
jointli
fund
dechra
ltd
univers
glasgow
spontan
hypercortisol
cush
syndrom
dog
due
pituitari
tumor
pt
adrenocort
tumor
concurr
pt
also
report
object
retrospect
studi
analyz
clinic
comput
tomograph
ct
imag
data
larg
group
dog
diagnos
spontan
hypercortisol
report
concurr
pt
clinic
record
dog
spontan
hypercortisol
refer
author
institut
review
diagnosi
base
physic
biochem
chang
suggest
hypercortisol
confirm
endocrin
function
test
endocrin
test
reveal
dexamethason
resist
combin
endogen
plasma
acth
concentr
ngml
interpret
function
dog
preand
postcontrast
ct
pituitari
gland
adren
gland
perform
pituitarybrain
pb
ratio
interpret
enlarg
consist
pt
heterogen
adren
structur
asymmetr
shape
adren
width
mm
consist
adren
expans
blood
vessel
greatli
support
diagnosi
dog
suppress
hypercortisol
dog
show
enlarg
pituitari
gland
median
pb
ratio
rang
ct
two
dog
diagnos
concurr
remain
dog
suppress
hypercortisol
pituitari
microadenoma
median
pb
ratio
rang
diagnos
nonsuppress
group
dog
enlarg
pituitari
gland
median
pb
ratio
rang
dog
concurr
present
remain
dog
group
pituitari
gland
enlarg
median
pb
ratio
rang
among
pituitari
microadenoma
diagnos
dog
dog
at
bilater
unilater
diagnos
confirm
plasma
acth
concentr
ngml
case
histopatholog
case
conclud
concurr
adren
pituitari
lesion
present
mainli
dog
nonsuppress
hypercortisol
result
studi
show
ct
evalu
pituitari
adren
gland
alway
includ
diagnost
workup
dog
hypercortisol
provid
optim
treatment
prognosi
disclosur
disclosur
report
age
rang
year
femal
male
intact
neuter
durat
clinic
sign
diagnosi
rang
month
mean
ae
month
clinic
sign
bodi
condit
score
bc
concurr
diseas
bodi
weight
totalthyroxin
freethyroxin
thyroid
stimul
hormon
tsh
cholesterol
level
record
neurolog
sign
present
dog
seizur
common
dog
present
ns
vestibular
deficit
megaesophagu
head
bob
syndrom
peripher
neuropathi
associ
observ
seizur
age
sex
bc
durat
sign
diagnos
level
reproduct
statu
ns
mean
plasma
tsh
dog
without
seizur
ae
ngml
significantli
higher
dog
without
ns
ae
ngml
p
among
dog
present
seizur
normocholesterolemia
hypercholesterolemia
includ
one
dog
plasma
cholesterol
level
mgdl
howev
group
dog
without
seizur
present
normal
cholesterol
level
hypercholesterolemia
includ
plasma
cholesterol
level
mgdl
p
preval
seizur
diagnosi
higher
dog
clinic
evid
myxedema
compar
dog
without
clinic
sign
p
neurolog
sign
describ
occur
hypothyroid
dog
howev
present
studi
hypothyroid
dog
ns
among
present
seizur
probabl
diagnost
protocol
use
convuls
patient
thyroid
hormon
test
alway
includ
anticonvuls
treatment
administ
relat
find
differ
mechan
propos
explain
develop
ns
hypothyroid
dog
includ
alter
axon
transport
ischemia
hypercholesterolemia
atherosclerosi
consequ
hypoxia
central
nervou
system
observ
propos
caus
ns
howev
present
studi
hypercholesterolemia
definit
relat
seizur
clinic
evid
myxedema
though
seem
relat
seizur
disclosur
disclosur
report
sampl
obtain
non
anem
dog
pcv
anem
dog
pcv
divid
three
glycem
rang
high
mgdl
medium
mgdl
low
mgdl
pair
measur
glucos
zhydroxybutyr
capillari
venou
blood
sampl
determin
use
two
devic
compar
result
refer
method
enzymat
hexokinas
respect
obtain
autom
chemistri
analyz
beckmancoult
linear
regress
bland
altman
plot
park
error
grid
analysi
eg
use
assess
accuraci
pcv
interfer
glucos
measur
assess
compar
differ
pbgm
read
refer
method
valu
anem
nonanem
dog
assess
withinrun
precis
glucos
concentr
obtain
sampl
belong
three
glycem
rang
measur
time
within
min
betweenday
precis
assess
test
manufactur
glucos
control
solut
consecut
day
p
consid
signific
mean
differ
mgdl
measur
pbgm
capillari
venou
blood
valu
measur
refer
method
gc
ae
ae
ae
ae
respect
posit
signific
correl
pair
sampl
found
devic
r
howev
neither
pbgm
fulfil
iso
requir
glucos
valu
measur
respect
capillari
venou
blood
use
gc
fell
zone
ab
eg
glucos
valu
measur
respect
capillari
venou
blood
fell
zone
ab
eg
withinrun
betweenday
precis
adequ
effect
pcv
signific
higher
result
lower
pcv
observ
correl
capillari
venou
refer
r
r
respect
mean
differ
capillari
venou
refer
method
respect
withinrun
precis
adequ
result
show
gc
suffici
accur
safe
clinic
use
dog
disclosur
disclosur
report
devic
test
strip
provid
manufactur
wellionvet
canin
hypothyroid
associ
decreas
glomerular
filtrat
rate
gfr
serum
creatinin
scr
concentr
rare
increas
refer
interv
ri
hypothyroid
dog
symmetr
dimethylarginin
sdma
consid
biomark
earli
detect
renal
dysfunct
result
strongli
correl
gfr
dog
human
sdma
significantli
higher
hypothyroid
compar
healthi
peopl
aim
studi
evalu
sdma
concentr
popul
hypothyroid
dog
hd
time
diagnosi
treatment
fourteen
dog
affect
spontan
hypothyroid
healthi
dog
control
group
includ
diagnosi
hypothyroid
base
consist
clinic
sign
laboratori
find
includ
serum
total
ctsh
concentr
ri
respect
dog
normal
ctsh
rhtsh
stimul
test
perform
confirm
diagnosi
scr
measur
diagnost
checkup
purpos
sdma
measur
afterward
surplu
serum
store
hd
measur
perform
day
median
treatment
levothyroxin
h
po
sdma
measur
use
valid
immunoassay
idexx
sdma
test
hd
median
age
year
median
bodi
weight
bw
kg
male
castrat
femal
spay
signific
differ
regard
signal
bw
hd
control
group
median
sdma
concentr
ri
dl
healthi
dog
hd
respect
sdma
concentr
significantli
higher
hd
comparison
healthi
dog
p
hd
p
among
hd
sdma
ri
hd
scr
ri
mgdl
scr
concentr
significantli
higher
hd
compar
hd
p
one
dog
scr
ri
signific
correl
observ
sdma
sdma
scr
hd
studi
show
hd
sdma
concentr
frequent
ri
diagnosi
normal
treatment
gfr
modif
present
canin
hypothyroid
may
better
detect
sdma
compar
scr
disclosur
disclosur
report
numer
portabl
blood
glucos
meter
pbgm
develop
last
decad
major
design
use
human
recent
one
glucomet
gluco
calea
wellionvet
gc
one
glucoseketon
meter
belua
wellionvet
develop
use
veterinari
medicin
aim
studi
assess
accuraci
precis
devic
felin
venou
capillari
blood
sampl
base
iso
evalu
pack
cell
volum
pcv
interfer
sampl
obtain
non
anem
cat
pcv
anem
cat
pcv
divid
three
glycem
rang
high
mgdl
medium
mgdl
low
mgdl
pair
measur
glucos
zhydroxybutyr
capillari
venou
blood
sampl
determin
use
two
devic
compar
result
refer
method
enzymat
hexokinas
respect
obtain
autom
chemistri
analyz
beckmancoult
linear
regress
bland
altman
plot
park
error
grid
analysi
eg
use
assess
accuraci
pcv
interfer
glucos
measur
assess
compar
differ
pbgm
read
refer
method
valu
anem
nonanem
cat
assess
withinrun
precis
glucos
concentr
obtain
sampl
belong
three
glycem
rang
measur
time
within
minut
betweenday
precis
assess
test
manufactur
glucos
control
solut
consecut
day
p
consid
signific
mean
differ
mgdl
measur
pbgm
capillari
venou
blood
valu
measur
refer
method
gc
ae
ae
ae
ae
respect
posit
signific
correl
pair
sampl
found
devic
r
howev
neither
pbgm
total
fulfil
iso
requir
glucos
valu
measur
venou
blood
use
fell
zone
ab
eg
withinrun
betweenday
precis
adequ
effect
pcv
signific
higher
result
lower
pcv
correl
capillari
venou
refer
r
r
respect
mean
differ
capillari
venou
refer
method
respect
withinrun
precis
adequ
result
show
gc
suffici
accur
superior
perform
support
clinic
use
cat
disclosur
disclosur
report
devic
test
strip
provid
manufactur
wellionvet
consider
variat
report
total
cell
count
concentr
biochem
marker
due
variabl
recoveri
pulmonari
epitheli
line
fluid
pelf
bronchoalveolar
lavag
bal
fluid
number
chronic
respiratori
condit
difficult
diagnos
definit
account
dilut
pelf
may
allow
us
better
differenti
respiratori
diseas
differenti
variou
chronic
respiratori
diseas
may
made
via
analysi
bal
fluid
use
urea
concentr
bal
rel
blood
urea
concentr
marker
dilut
pelf
assess
cell
count
adjust
dilut
may
allow
differenti
primari
diseas
process
dog
present
respiratori
sign
clientown
dog
present
investig
respiratori
diseas
includ
dog
bal
perform
bal
cell
count
correct
use
urea
marker
dilut
comparison
urea
blood
urea
bal
fluid
final
diagnosi
respiratori
diseas
made
retrospect
analysi
diagnost
investig
respons
treatment
seventi
two
bal
sampl
total
dog
analyz
thirteen
primari
caus
respiratori
diseas
identifi
base
diagnost
investig
includ
bal
cell
cytolog
treatment
respons
respiratori
diseas
also
assign
inflammatori
noninfecti
infecti
upper
respiratori
tract
respiratori
neoplasia
categori
base
diseas
diagnos
statist
differ
adjust
total
cell
count
bal
fluid
balf
dog
differ
respiratori
diseas
diseas
group
mycoplasma
spp
effect
total
cell
count
dog
chronic
bronchiti
studi
suggest
total
cell
count
bal
fluid
correct
dilut
urea
concentr
use
distinguish
differ
respiratori
diseas
larger
number
case
cross
section
respiratori
diseas
may
identifi
signific
differ
total
differenti
cell
count
variou
differ
diseas
disclosur
studi
fund
australian
companion
anim
health
foundat
support
australian
new
zealand
colleg
veterinari
scientist
research
grant
amanda
paul
jason
stayt
also
indic
affili
financi
involv
organ
entiti
financi
interest
financi
competit
subject
matter
materi
discuss
articl
aim
investig
report
radiograph
preval
djd
physic
chang
appendicular
skeleton
clinic
relev
matur
indoor
cat
one
hundr
sixteen
appar
healthi
matur
clientown
cat
includ
age
year
cat
kept
exclus
indoor
owner
report
lame
observ
cat
last
six
month
cat
underw
full
physic
examin
orthoped
evalu
appendicular
axial
skeleton
sign
pain
instabl
effus
crepitu
perform
assessor
bodi
condit
score
bc
system
also
assess
cat
gentli
restrain
radiograph
examin
without
sedat
radiograph
shoulder
elbow
carpi
coxofemor
joint
stifl
tarsi
evalu
among
cat
cat
least
one
appendicular
joint
affect
radiograph
osteoarthr
preval
djd
shoulder
elbow
carpi
coxofemor
joint
stifl
tarsi
respect
result
multivari
gener
linear
model
analys
indic
djd
elbow
coxofemor
joint
associ
bc
p
p
respect
djd
hock
associ
bc
gender
neuter
p
sixti
six
cat
decreas
mobil
discrimin
analysi
indic
decreas
mobil
associ
presenc
djd
hock
p
wherea
cat
hesit
jump
discrimin
analysi
indic
hesit
jump
associ
presenc
djd
elbow
p
presenc
djd
decreas
mobil
associ
age
bodi
weight
base
investig
djd
highli
preval
indoor
cat
front
limb
joint
commonli
affect
djd
live
environ
exclus
indoor
floor
materi
limit
access
exercis
might
contribut
high
preval
djd
cohort
studi
selffund
author
declar
compet
interest
studi
carri
accord
code
research
ethic
offic
nation
taiwan
univers
ethic
approv
need
trial
therapi
test
medicin
involv
studi
owner
cat
whose
case
includ
studi
sign
written
consent
agreement
particip
research
studi
carica
papaya
leaf
extract
use
oral
recov
platelet
count
control
bleed
human
patient
dengu
fever
activ
compon
papaya
carica
extract
prove
earlier
inhibit
immun
mediat
platelet
destruct
possibl
bone
marrow
suppress
fasten
natur
cours
recoveri
increas
platelet
count
report
studi
effect
caprica
papaya
treatment
infecti
thrombocytopenia
dog
oneyear
period
thrombocytopen
dog
ehrlichiosi
babesiosi
andor
leptospirosi
refer
madra
veterinari
colleg
teach
hospit
studi
mild
platelet
sever
platelet
thrombocytopenia
evid
bleed
addit
coagul
profil
buccal
mucos
bleed
time
salin
agglutin
test
spherocyt
review
direct
coomb
direct
antiglobulin
test
von
willebrand
factor
assay
plateletassoci
antibodi
psab
assay
bone
marrow
aspir
cytolog
dea
type
determin
plateletrich
plasma
fresh
whole
blood
transfus
case
sever
platelet
thrombocytopenia
andor
anemia
dog
receiv
doxycyclin
prednison
ehrlichiosi
leptospirosi
imidocarb
babesiosi
carica
papaya
leaf
extract
administ
ml
per
kg
bodi
weight
twice
day
week
platelet
count
increas
significantli
faster
dog
receiv
carica
papaya
day
compar
receiv
treatment
also
bleed
sign
appear
improv
rapidli
carica
papaya
side
effect
observ
conclus
carica
papaya
may
inexpens
easili
avail
thrombopoiet
supplement
rapidli
control
thrombocytopenia
bleed
dog
hemoprotozoan
diseas
along
transfus
specif
infecti
diseas
immunosuppress
disclosur
disclosur
report
methemoglobin
carri
oxygen
due
oxid
iron
may
accumul
cytochrom
reductas
system
overwhelm
toxin
genet
dysfunct
report
diagnost
studi
hereditari
methemoglobinemia
dog
novel
longterm
treatment
juvenil
male
mix
breed
present
lethargi
exercis
intoler
aggress
cyanosi
tachycardia
tachypnea
observ
persist
oxygen
supplement
arteri
blood
ga
analysi
cooximetri
indic
increas
methemoglobin
concentr
normal
normal
arteri
oxygen
tension
initi
intraven
methylen
blue
mb
mgkg
administr
dog
treat
longterm
oral
mb
mgkg
h
reduc
methemoglobinemia
resolv
clinic
sign
observ
period
erythrocyt
cytochrom
reductas
activ
measur
nadhferricyanid
reductas
assay
low
compar
control
cytochrom
c
reductas
activ
normal
whole
genom
sequenc
dog
contain
two
heterozyg
missens
mutat
serin
glycin
substitut
predict
codon
leucin
isoleucin
substitut
predict
codon
missens
mutat
like
deleteri
suggest
inherit
differ
parent
contribut
recess
methemoglobinemia
compound
heterozyg
state
first
molecular
genet
report
variant
longterm
manag
oral
mb
hereditari
methemoglobinemia
dog
cytochrom
reductas
defici
studi
affect
dog
progress
disclosur
disclosur
report
abnorm
gait
result
musculoskelet
andor
neuromuscular
condit
pug
breed
predispos
specif
orthoped
condit
neuromuscular
problem
pug
breed
becom
increasingli
recogn
last
year
lame
result
musculoskelet
problem
spinal
cord
disord
character
paresi
ataxia
report
british
studi
versu
pug
attend
primari
veterinari
care
preval
spinal
cord
disord
present
unit
kingdom
poorli
correspond
swedish
insur
data
report
suggest
sevenfold
increas
mortal
rate
ataxia
paresi
collaps
pug
compar
breed
ad
attent
wobbl
pug
given
internet
suggest
need
investig
preval
gait
abnorm
pug
systemat
way
aim
prospect
studi
investig
preval
gait
abnorm
cohort
swedish
pug
use
ownerbas
questionnair
target
sign
gait
abnorm
video
footag
show
gait
studi
also
aim
evalu
associ
condit
abnorm
gait
includ
health
disord
preval
breed
owner
report
gait
aberr
pug
preval
increas
increas
age
ad
pug
report
show
indirect
sign
gait
abnorm
wear
nail
dorsal
aspect
skin
paw
increas
preval
gait
abnorm
breed
result
suggest
gait
abnorm
signific
health
problem
previous
report
inde
singl
list
common
caus
deatheuthanasia
report
owner
gait
abnorm
conclus
gait
abnorm
common
find
pug
breed
wear
nail
andor
skin
dorsum
paw
predomin
thorac
limb
frequent
found
compar
young
age
result
questionnair
video
analysi
suggest
neurolog
disord
predomin
respons
high
preval
gait
abnorm
pug
breed
preval
abnorm
gait
significantli
associ
age
dyspnea
gait
abnorm
associ
overt
sign
pain
associ
reluct
go
walk
disclosur
disclosur
report
develop
bronchiectasi
irrevers
dilat
bronchi
wellestablish
complic
bacteri
viral
pneumonia
human
lead
defect
mucociliari
clearanc
predispos
develop
new
bacteri
respiratori
infect
describ
dog
varieti
respiratori
diseas
connect
recurr
bacteri
infect
fulli
establish
breed
predisposit
acut
bacteri
pneumonia
bp
describ
irish
wolfhound
iwh
etiolog
larg
undiscov
high
resolut
comput
tomographi
hrct
perform
iwh
recurr
bp
median
age
year
rang
year
median
number
previou
bp
rang
dog
examin
clinic
healthi
receiv
antibiot
hrct
find
compris
mild
sever
bronchiectasi
dog
mild
moder
local
bronchointerstiti
pattern
mild
local
interstiti
pattern
parenchym
band
local
thicken
pleura
subpleur
band
bronchiectasi
detect
singl
lung
lobe
lung
lobe
lung
lobe
dog
left
right
cranial
lobe
right
middl
lobe
often
involv
studi
commonli
detect
iwh
recurr
bp
develop
like
postinfecti
consequ
previou
bp
presenc
may
facilit
develop
new
respiratori
infect
may
therefor
act
predispos
caus
recurr
bp
disclosur
disclosur
report
sinonas
aspergillosi
sna
commonli
affect
middleag
dolichocephal
dog
character
destruct
rhiniti
sinus
absenc
fungal
deeper
tissu
invas
pathogenesi
diseas
date
fulli
understood
uncontrol
detriment
inflammatori
respons
commens
fungal
colon
nasal
caviti
sinus
suggest
human
role
bacteri
microbiota
regul
host
immun
respons
fungi
hypothes
therefor
object
present
studi
identifi
character
microbiota
present
nasal
caviti
clientown
dog
diagnos
sna
compar
healthi
age
breedmatch
nonaffect
dog
nine
larg
breed
dolichocephal
dog
diagnos
sna
male
femal
mean
age
year
healthi
ageand
breedmatch
dog
male
femal
mean
age
year
includ
dna
extract
steril
swab
introduc
distal
third
right
nasal
caviti
gener
anesthesia
metagenet
analysi
perform
hypervari
region
rdna
total
bacteri
dna
extract
nasal
specimen
sequenc
miseq
illumina
sequenc
taxonom
assign
microbiota
commun
analysi
done
mothur
otu
cluster
distanc
differ
popul
abund
group
assess
use
multipl
test
holmsidak
multitest
correct
signific
sequenc
reveal
proteobacteria
firmicut
two
predomin
phyla
group
repres
togeth
almost
total
bacteri
abund
remain
compos
bacteroidet
fusobacteria
diseas
dog
actinobacteria
almost
exclus
healthi
dog
famili
level
significantli
higher
abund
lactobacillacea
found
sna
dog
moraxellacea
significantli
predomin
control
analysi
divers
metric
reveal
bacteri
speci
rich
divers
significantli
higher
sna
dog
compar
control
conclus
result
present
studi
demonstr
presenc
nasal
microbiota
alter
dog
affect
sna
associ
increas
bacteri
divers
howev
whether
chang
caus
consequ
diseas
unknown
warrant
investig
disclosur
disclosur
report
primari
immunemedi
hemolyt
anemia
pimha
common
immunehematolog
diseas
dog
yet
still
repres
prognost
therapeut
challeng
mani
veterinarian
far
limit
number
prognost
indic
outcom
score
accept
consist
influenc
treatment
initi
refer
veterinarian
clinicopatholog
featur
diseas
sever
followup
surviv
time
investig
time
present
referr
center
month
post
present
chao
tokyo
sever
score
appli
case
compar
diseas
outcom
furthermor
sever
clinicopatholog
sign
studi
prognost
factor
time
discharg
veterinari
hospit
td
day
day
discharg
thirtythre
case
pimha
accord
standard
clinic
clinicopatholog
criteria
collect
februari
includ
data
regard
histori
blood
urin
laboratori
test
immunosuppress
treatment
collect
patient
divid
two
group
patient
previous
treat
refer
vet
group
untreat
group
b
statist
compar
group
platelet
count
p
serum
concentr
alkalin
phosphatas
p
significantli
higher
group
b
group
b
serum
concentr
total
protein
p
globulin
p
creactiv
protein
p
lactat
dehydrogenas
p
urinari
paramet
pigmenturia
p
bilirubinuria
p
significantli
higher
group
mannwhitney
test
chao
sever
score
predict
outcom
tokyo
sever
score
day
odd
ratio
respect
addit
clinicopatholog
sign
statist
relat
wors
prognosi
urea
concentr
mg
dl
td
hyperbilirubinemia
mgdl
number
nucleat
rbc
wbc
thrombocytopenia
l
td
group
b
dog
higher
mortal
rate
group
dog
week
p
kaplanmei
curv
conclus
previou
immunosuppress
treatment
refer
veterinarian
may
weaken
clinician
abil
properli
assess
patient
prognosi
studi
confirm
literatur
inform
regard
diagnosi
prognosi
surviv
time
dog
suffer
imha
add
addit
prognost
factor
urea
concentr
hyperbilirubinemia
circul
nucleat
rbc
thrombocytopenia
disclosur
disclosur
report
concentr
differ
bile
acid
determin
total
bile
acid
tba
concentr
calcul
sum
tba
minimum
detect
limit
cipf
bp
cb
ebp
ld
dog
healthi
dog
bile
acid
balf
detect
less
commonli
iwh
eb
beagl
healthi
whwt
result
suggest
occur
variou
canin
respiratori
diseas
healthi
dog
bile
acid
detect
whwt
could
associ
breed
predisposit
cipf
disclosur
disclosur
report
lungworm
infect
potenti
lifethreaten
parasit
infect
canin
speci
common
clinic
present
respiratori
distress
cough
neurolog
manifest
dic
also
report
aim
studi
report
clinic
laboratori
alter
dog
diagnos
lungworm
infect
mean
age
month
month
dog
male
intact
neuter
dog
femal
intact
spay
seven
dog
mixedbre
other
belong
differ
breed
fifteen
dog
histori
risk
exposur
main
durat
clinic
sign
day
day
cough
dog
dyspnea
main
symptom
five
dog
acut
occurr
neurolog
sign
one
dog
develop
neurolog
sign
day
diagnosi
thorac
radiograph
character
mild
diffus
moder
sever
mix
alveolarbronchialinterstiti
pattern
cbccount
perform
dog
show
anemia
leukocytosi
neutrophilia
eosinophilia
monocytosi
basophilia
lymphocytosi
low
plt
count
biochemistri
perform
dog
show
increas
total
protein
count
globulin
count
cpk
amylas
creactiv
protein
phosphoru
urea
protein
serum
electrophoresi
avail
dog
show
increas
fraction
fraction
dog
respect
urinalysi
avail
four
dog
pucu
increas
two
dog
coagul
profil
perform
dog
suggest
dic
dog
eleven
dog
mean
hematocrit
twenti
dog
posit
fecal
examin
two
neg
one
dog
posit
angiostrongylu
vasorum
idexx
angiodetecttest
twentytwo
dog
posit
idexx
angiodetecttext
one
neg
posit
fecal
examin
lungworm
type
submit
one
dog
diagnos
bal
three
dog
diagnos
post
mortem
two
vasorum
infect
dog
mix
infest
vasorum
filaroid
osleri
overal
seven
dog
die
other
recov
lungworm
infect
includ
differenti
diagnosi
dog
present
respiratori
diseas
acut
onset
neurolog
sign
though
hematolog
alter
nonspecif
presenc
dic
increas
globulin
count
increas
b
fraction
awar
clinician
possibl
undergo
lungworm
infect
disclosur
disclosur
report
presenc
least
recogn
risk
factor
tti
report
cat
result
neg
fiv
felv
wherea
posit
fcov
antibodi
use
rapid
test
pcr
neg
test
microorgan
except
cat
posit
hemoplasma
dna
one
felv
proviru
howev
latter
result
posit
sensit
pcr
protocol
appli
other
sinc
differ
gl
recommend
differ
protocol
differ
classifi
candid
donor
suitabl
harmon
recommend
especi
main
tti
screen
choic
best
sensit
serolog
molecular
test
possibl
variat
accord
local
epidemiolog
situat
would
advis
improv
gener
level
veterinari
blood
safeti
moreov
consid
profil
high
risk
tti
blood
donor
consequ
cost
time
procedur
guarante
blood
safeti
tool
select
donor
low
risk
develop
appropri
recruit
strategi
current
consid
gl
questionnairebas
risk
profil
educ
cours
owner
possibl
establish
perman
group
safe
blood
donor
could
improv
identif
suitabl
donor
reduc
necess
perform
wide
screen
disclosur
disclosur
report
urolithiasi
common
caus
felin
lower
urinari
tract
diseas
flutd
common
felin
urolith
calcium
oxal
struvit
dietari
dissolut
safe
effect
erad
steril
struvit
urolith
cat
rich
moistur
andor
sodium
andor
protein
order
increas
water
intak
thu
increas
diuresi
urinari
flow
frequenc
micturit
may
vari
commerci
diet
prospect
multicent
random
doubl
blind
clinic
trial
evalu
efficaci
safeti
two
new
high
proteinlow
carbohydr
dri
diet
steril
struvit
urolithiasi
cat
sign
nonobstruct
flutd
cat
enrol
studi
randomli
assign
either
diet
formul
achiev
dissolut
prevent
struvit
urolith
diet
b
formul
dissolv
struvit
urolith
cat
follow
day
urolith
dissolv
latest
ae
physic
examin
urinalysi
abdomin
ultrasound
perform
weekli
analys
perform
use
softwar
version
signific
threshold
set
twosid
thirtythre
case
recruit
suppli
diet
n
diet
b
n
accord
random
procedur
mean
time
struvit
dissolut
day
day
respect
diet
diet
b
ns
mean
time
disappear
least
one
urinari
sign
day
diet
day
diet
b
p
cat
group
cat
group
b
urinari
sign
p
mean
urinari
ph
decreas
group
b
end
studi
ae
ae
respect
compar
ae
ae
respect
group
b
urin
specif
graviti
significantli
decreas
p
ae
end
studi
ae
group
urin
specif
graviti
decreas
signific
two
cat
group
b
respect
exhibit
transitori
advers
event
possibl
relat
diet
mild
diarrhea
mild
vomit
event
resolv
spontan
lead
exclus
cat
new
high
proteinlow
carbohydr
test
diet
effect
dissolut
felin
struvit
urolithiasi
disclosur
disclosur
report
studi
found
virbac
three
coauthor
employe
virbac
quantit
bacteri
cultur
qbc
gold
standard
diagnos
urinari
tract
infect
uti
current
guidelin
recommend
qbc
perform
within
h
collect
urin
unpreserv
store
transport
refriger
temperatur
howev
temperaturecontrol
transport
expens
may
alway
feasibl
veterinari
practic
indic
need
altern
storag
method
aim
studi
investig
effect
storag
temperatur
boric
acid
preserv
qbc
canin
urin
hypothesi
urin
store
nonpreserv
refriger
cool
preserv
commerci
avail
urin
preserv
swab
contain
boric
acid
copan
uriswab
tm
roomtemperatur
baroom
h
respect
would
noninferior
refer
qbc
ii
would
signific
differ
sensit
specif
two
storag
method
canin
urin
sampl
receiv
veterinari
microbiolog
laboratori
ucph
februari
march
prospect
includ
studi
initi
refer
qbc
urin
sampl
split
three
aliquot
two
aliquot
store
room
temperatur
copan
uriswab
tm
one
aliquot
store
refriger
unpreserv
microfug
tube
h
h
respect
signific
bacteriuria
determin
regard
urin
collect
method
accord
current
recommend
noninferior
conclud
lower
limit
onesid
confid
interv
mcnemar
v
test
perform
compar
sensit
specif
two
storag
method
total
sampl
dog
includ
signific
bacteriuria
found
sampl
accord
refer
qbc
overal
accuraci
storag
condit
noninferior
refer
qbc
except
baroom
h
inferior
sensit
howev
signific
differ
sensit
two
method
two
time
point
p
result
show
boric
acid
preserv
room
temperatur
valid
altern
refriger
reliabl
qbc
obtain
storag
canin
urin
h
method
disclosur
disclosur
report
copan
uriswab
tm
kit
kindli
donat
copan
italia
microalbuminuria
mau
associ
underli
renal
system
diseas
dog
glomerular
diseas
proteinuria
common
dog
natur
experiment
infect
dirofilaria
immiti
preval
mau
dog
experiment
infect
heartworm
diseas
higher
healthi
anim
dirofilaria
repen
caus
agent
subcutan
canin
dirofilariasi
consid
emerg
zoonosi
mani
part
europ
repen
infect
usual
associ
minor
clinic
sign
dog
known
whether
repen
capabl
produc
similar
glomerular
lesion
proteinuria
caus
heartworm
infect
purpos
studi
determin
preval
mau
urinari
albumin
creatinin
ratio
uac
proteinuria
urinari
protein
creatinin
ratio
upc
dog
natur
infect
repen
blood
urin
sampl
taken
clinic
healthi
beagl
kept
two
close
coloni
similar
hous
feed
condit
extens
laboratori
work
use
reveal
underli
diseas
distinguish
repen
infect
occult
heartworm
diseas
incl
modifi
knotttest
two
differ
agelisa
test
dirofilaria
speci
specif
real
time
pcr
urin
obtain
cystocentesi
albumin
measur
formerli
valid
commerci
human
immunoturbidimetr
method
exclus
criteria
sever
laboratori
alter
posit
immiti
test
posit
urin
cultur
older
otherwis
elig
repen
infect
dog
also
exclud
older
anim
without
infect
age
match
two
group
exclus
remain
repen
infect
noninfect
beagl
statist
signific
differ
two
group
respect
age
weight
sex
ratio
significantli
dog
mau
repen
infect
group
compar
noninfect
beagl
vs
p
also
proteinur
dog
infect
group
vs
yield
signific
differ
p
studi
show
preval
mau
dog
infect
repen
higher
observ
noninfect
dog
kept
condit
studi
need
determin
whether
dog
infect
repen
mau
progress
develop
overt
proteinuria
renal
failur
disclosur
disclosur
report
research
partli
support
bayer
hungari
symmetr
dimethylarginin
sdma
propos
sensit
specif
renal
biomark
whose
concentr
increas
earlier
serum
creatinin
scr
glomerular
filtrat
rate
decreas
sdma
promis
paramet
diagnosi
manag
chronic
kidney
diseas
ckd
includ
intern
renal
interest
societi
iri
guidelin
aim
studi
assess
use
singl
determin
sdma
evalu
renal
statu
dog
risk
affect
ckd
evalu
correl
scr
paramet
renal
function
ninetyf
dog
consecut
select
within
patient
refer
univers
veterinari
hospit
milan
first
clinic
examin
dog
underw
physic
examin
hematolog
blood
chemistri
includ
serum
sdma
scr
urinalysi
urinari
protein
creatinin
ratio
upc
perform
case
ultrasound
examin
done
dog
dog
stage
accord
iri
guidelin
statist
analysi
perform
jmp
softwar
sa
institut
inc
cari
usa
sdma
show
expect
signific
correl
scr
urin
specif
graviti
usg
upc
ratio
p
iri
stage
accord
scr
result
follow
dog
includ
stage
stage
stage
stage
stage
sdma
evalu
modifi
iri
stage
dog
sdma
increas
dog
sdma
equal
cutoff
valu
lgdl
high
sdma
case
scr
mgdl
other
alreadi
one
alter
decreas
usg
case
increas
upc
ratio
case
ultrasound
featur
suggest
ckd
case
sdma
alter
paramet
dog
sdma
normal
creatinin
slightli
increas
dog
sdma
use
reliabl
paramet
diagnosi
manag
ckd
evalu
marker
renal
function
diagnost
imag
essenti
order
correctli
approach
patient
diagnost
therapeut
point
view
especi
first
clinic
present
furthermor
patient
normal
scr
alter
sdma
requir
evalu
confirm
develop
ckd
disclosur
disclosur
report
ultrasound
guid
renal
biopsi
essenti
diagnost
method
facilit
histopatholog
examin
increas
accuraci
differenti
diagnosi
acut
chronic
nephropathi
help
clinician
perform
etiolog
diagnosi
issu
prognosi
orient
therapi
major
parenchym
nephropathi
due
rel
invas
potenti
advers
effect
use
renal
biopsi
limit
among
practition
studi
evalu
intens
renal
damag
induc
renal
cortex
sampl
clinic
consequ
procedur
examin
dog
mix
breed
variabl
age
male
femal
refer
clinic
underw
ultrasound
guid
renal
biopsi
order
establish
definit
diagnosi
patient
present
varieti
diffus
nephropathi
kidney
lymphoma
glomerulonephr
tubulointerstiti
nephriti
nephrocalcinosi
acut
kidney
failur
chronic
renal
patient
type
sever
renal
lesion
correl
chang
urinari
nag
index
inag
specif
serum
renal
damag
marker
urea
creatinin
phosphoru
ioniz
calcium
quantifi
side
effect
percutan
renal
biopsi
magnitud
post
biopsi
hematuria
chang
urinari
inag
activ
evalu
result
indic
signific
post
biopsi
increas
urinari
inag
activ
patient
underw
procedur
ae
ug
prebiopsi
inag
vs
ae
ug
postbiopsi
inag
p
suggest
intensif
renal
tubular
damag
consecut
kidney
punctur
sampl
transitori
macroor
microhematuria
constant
find
dog
underw
ultrasound
guid
renal
biopsi
magnitud
extent
could
associ
plt
l
aptt
pt
level
patient
resolv
h
without
therapeut
intervent
percutan
ultrasound
guid
renal
biopsi
rel
safe
minim
invas
diagnost
procedur
induc
seri
deleteri
effect
kidney
structur
function
consid
correctli
obtain
tissu
sampl
high
diagnost
valu
greater
import
complic
associ
sampl
procedur
disclosur
disclosur
report
first
object
studi
investig
capac
variou
speci
cell
line
support
infect
replicationselect
oncolyt
vv
second
object
assess
replic
potenc
cell
line
thymidin
kinas
ribonucleotid
reductas
genesdelet
vv
express
green
fluoresc
protein
gfp
design
non
tumor
canin
felin
crfk
porcin
human
cell
line
use
well
tumor
canin
human
hela
cell
line
suscept
evalu
h
infect
use
fluoresc
microscopi
flow
cytometri
multipl
infect
moi
test
viru
titer
evalu
day
infect
moi
standard
plaqu
form
assay
cultur
medium
cell
lysat
experi
perform
triplic
gfp
express
detect
fluoresc
microscopi
h
infect
cell
line
even
low
infect
dose
flow
cytometri
allow
assess
dose
depend
infect
cell
cell
line
cell
infect
moi
equival
percentag
infect
notic
hela
moi
hand
lower
infect
assess
crfk
moi
higher
percentag
infect
observ
other
less
cell
infect
tumor
statu
cell
line
nt
seem
influenc
suscept
interestingli
h
infect
prove
effect
lytic
potenc
cell
line
lytic
potenc
import
higher
viral
dose
replic
factor
determin
day
infect
cell
line
except
felin
cell
line
tumor
statu
cell
line
nt
seem
influenc
replic
factor
studi
prove
canin
porcin
human
cell
line
support
infect
high
replic
factor
comparison
suscept
replic
potenc
lower
felin
cell
line
vitro
lytic
potenc
also
notic
promis
result
support
use
replicationselect
oncolyt
vv
canin
tumor
disclosur
disclosur
report
studi
support
transgen
fouryearold
femal
neuter
jack
russel
terrier
present
oneyear
histori
hematochezia
intermitt
diarrhea
respond
dietari
chang
antibiot
present
dog
bright
alert
good
bodi
condit
rectal
examin
reveal
multipl
nodular
mass
approxim
mm
diamet
rectum
remaind
examin
unremark
bloodwork
reveal
hypocobalaminemia
pmoll
ref
hypofolatemia
nmoll
ref
consist
diffus
small
intestin
diseas
hematolog
biochemistri
unremark
gastrointestin
endoscopi
document
multipl
small
mass
rectum
colon
total
mass
present
last
cm
larg
intestin
mucosa
around
mass
appear
irregular
swollen
ileum
appear
mildli
irregular
histopatholog
mass
identifi
popul
larg
cell
granular
cytoplasm
multifoc
expand
lamina
propria
gland
consist
granular
cell
tumor
also
mild
aggreg
lymphocyt
plasma
cell
spars
eosinophil
colic
mucosa
mass
minim
lacteal
dilat
ileum
evid
inflamm
addit
stain
yield
signific
inform
bacteri
fungal
cultur
colic
biopsi
neg
diet
chang
hypoallergen
diet
purina
ha
parenter
cobalamin
supplement
led
resolut
diarrhea
recent
followup
one
year
diagnosi
dog
still
clinic
well
hypoallergen
diet
owner
report
intermitt
hematochezia
occasion
tenesmu
rectal
examin
similar
initi
visit
granular
cell
tumor
uncommon
predominantli
benign
neoplasm
human
tumor
develop
gastrointestin
tract
endoscop
surveil
usual
suffici
small
asymptomat
tumor
surgic
excis
recommend
larg
malign
multifoc
tumor
endoscop
resect
also
recent
report
surgic
excis
attempt
dog
given
multipl
mass
absenc
signific
clinic
sign
knowledg
first
descript
multipl
granular
cell
tumor
affect
gastrointestin
tract
dog
appear
benign
clinic
cours
disclosur
disclosur
report
observ
multicent
studi
aim
assess
outcom
dog
neoplast
spirocercosi
undergo
endoscopicguid
ablat
n
surgeri
n
identifi
prognost
indic
paramet
evalu
includ
age
weight
bodi
condit
score
diagnosi
gender
durat
clinic
sign
hematolog
biochemistri
tumor
size
placement
percutan
endoscopicallyplac
gastrostomi
tube
histopatholog
mitot
indic
day
discharg
chemotherapi
administr
kaplan
meier
surviv
curv
show
differ
surviv
ablat
surgeri
median
day
rang
vs
day
respect
p
dog
surviv
first
day
ablat
surgeri
evalu
signific
surviv
borderlin
day
vs
day
respect
p
none
paramet
measur
associ
surviv
advantag
intratreatmentgroup
surviv
analysi
identifi
surviv
advantag
chemotherapi
within
surgic
group
p
becam
insignific
p
latter
evalu
ht
p
white
cell
count
l
present
p
associ
improv
outcom
ht
present
dog
show
signific
hazard
ratio
p
p
respect
clear
benefit
identifi
surgeri
ablat
technic
possibl
prognost
indic
use
dog
surviv
first
day
postsurgeri
chemotherapi
postintervent
made
differ
surviv
disclosur
disclosur
report
inflammatori
mammari
cancer
imc
specif
type
local
advanc
mammari
cancer
dog
uncommon
tumor
aggress
type
mammari
cancer
femal
dog
extrem
poor
surviv
rate
effect
treatment
report
dog
imc
surgeri
indic
first
option
base
differ
molecular
featur
highli
angiogen
cancer
new
therapi
focus
specif
target
propos
aim
studi
evalu
surviv
time
dog
diagnos
imc
treat
multimod
therapi
base
drug
firocoxib
tyrosin
kinas
inhibitor
toceranib
androgen
receptor
inhibitor
flutamid
ten
dog
diagnos
imc
present
veterinari
teach
hospit
complutens
madrid
includ
diagnosi
base
clinic
featur
edema
erythema
warmth
firm
mammari
gland
histopatholog
confirm
immunohistochem
analysi
index
ckit
androgen
receptor
perform
five
dog
receiv
palli
treatment
antibiot
corticoid
control
group
cg
dog
treat
combin
firocoxib
flutamid
toceranib
treatment
group
tg
one
dog
tg
refus
treatment
toceranib
due
economi
matter
surviv
time
defin
time
imc
diagnosi
euthanasia
death
dog
age
time
imc
diagnosi
reproduct
statu
previou
histori
mammari
tumor
evolut
imc
treatment
also
analyz
pair
student
ttest
perform
statist
analysi
parametr
variabl
alpha
error
chi
squar
test
parametr
variabl
mean
surviv
time
dog
tg
significantli
higher
cg
ae
ae
day
respect
p
age
time
imc
diagnosi
ae
year
tg
ae
year
cg
reproduct
statu
immunohistochem
profil
significantli
differ
group
tg
complet
remiss
obtain
one
case
stabl
diseas
dog
progress
diseas
tg
grade
n
grade
n
toxic
observ
week
increas
qualiti
life
refer
case
initi
treatment
despit
poor
prognosi
multimod
therapi
increas
surviv
time
dog
diagnos
imc
adequ
qualiti
life
disclosur
disclosur
report
radiat
therapi
consid
treatment
choic
mani
brain
tumor
dog
like
glioma
intracrani
meningioma
retrospect
studi
carri
inform
patient
treat
veterinari
referr
hospit
goal
set
evalu
efficaci
therapeut
approach
search
associ
differ
epidemiolog
clinic
diagnost
therapeut
featur
tumor
type
surviv
time
studi
includ
dog
diagnos
intracrani
meningioma
glioma
undergon
radiat
therapi
clinic
report
analyz
two
surviv
time
calcul
overal
ost
posttreat
ptst
diagnosi
end
radiat
respect
death
end
studi
period
sex
contrast
enhanc
exhibit
statist
signific
associ
p
tumor
diagnosi
result
show
sexual
predisposit
male
glial
type
femal
mening
type
greater
specif
contrast
enhanc
observ
mri
meningioma
found
breed
sex
prognost
factor
significantli
associ
p
surviv
time
boxer
labrador
retriev
breed
femal
sex
consid
surviv
benefit
patient
median
valu
day
tspt
day
tst
surviv
rate
respect
thu
radiat
therapi
effect
treatment
option
neoplast
case
better
result
therapeut
approach
disclosur
disclosur
report
whole
transcriptom
nextgener
sequenc
ng
perform
illumina
system
tissu
sampl
examin
histolog
nine
diagnos
malign
nine
classifi
nonneoplast
cytolog
examin
usfna
possibl
case
eleven
diagnos
normal
hyperplast
three
specimen
classifi
prostat
carcinoma
rna
concentr
detect
sampl
rang
rna
quantiti
suffici
start
materi
ng
transcriptom
analys
sampl
rin
valu
success
data
set
differenti
express
gene
deg
summar
princip
compon
analysi
show
major
varianc
deg
nonneoplast
malign
sampl
minor
differ
usfna
tissu
compar
diagnosi
globin
gene
identifi
significantli
upregul
usfna
sampl
base
isol
total
rna
concentr
integr
residu
cell
diagnost
usfna
canin
prostat
consid
adequ
sampl
sourc
gene
express
studi
biomark
research
potenti
tool
advanc
diagnost
canin
prostat
diseas
disclosur
disclosur
report
histiocyt
sarcoma
hs
aggress
neoplasm
dog
overrepresent
document
sever
breed
includ
bernes
mountain
dog
flatcoat
retriev
golden
retriev
rottweil
purpos
retrospect
studi
describ
seri
miniatur
schnauzer
ms
diagnos
hs
uk
assess
whether
overrepres
compar
hospit
popul
medic
record
ms
cytolog
histopatholog
diagnosi
hs
januari
march
review
breed
predisposit
assess
odd
ratio
use
total
number
hospit
admiss
breed
without
hs
admit
studi
period
control
also
perform
two
case
hs
record
particular
breed
ten
ms
diagnos
hs
studi
period
make
overrepres
among
hospit
popul
odd
ratio
ci
seven
diagnos
primari
pulmonari
hs
base
presenc
larg
pulmonari
mass
without
evid
intrathorac
metastasi
abdomin
involv
though
five
exhibit
overt
respiratori
sign
patient
solitari
hs
five
patient
treat
chemotherapi
lomustin
epirubicin
aggress
clinic
cours
found
patient
median
surviv
time
patient
day
rang
day
sever
previous
report
breed
also
note
predispos
hs
ms
addit
previous
report
breed
overrepres
amongst
dog
hs
patient
popul
primari
pulmonari
involv
common
patient
present
advanc
diseas
though
patient
overt
respiratori
sign
prognosi
appear
poor
despit
chemotherapi
disclosur
disclosur
report
canin
leishmaniosi
life
threaten
zoonot
diseas
wide
distribut
allopurinol
parasitostat
drug
use
longterm
fashion
treatment
retrospect
report
indic
xanthinuria
deposit
appear
secondari
prolong
therapi
allopurinol
dog
purpos
prospect
studi
evalu
incid
characterist
time
appear
urinari
advers
effect
dog
leishmaniosi
treat
allopurinol
moreov
dog
xanthin
deposit
clinic
respons
low
purin
diet
also
evalu
studi
includ
dog
new
diagnosi
leishmaniosi
allopurinol
treatment
h
month
dog
evalu
time
diagnosi
one
six
twelv
month
diagnosi
treatment
allopurinol
addit
dog
also
evalu
month
clinic
evalu
includ
follow
test
physic
exam
abdomin
ultrasound
upc
ratio
urinalysi
hematolog
biochem
panel
leishmania
serolog
dog
unremark
urinari
ultrasound
without
urinari
sediment
treatment
onemonth
control
dog
xanthinuria
miner
pelvic
recess
mpr
vesic
urolithiasi
threemonth
control
xanthinuria
bilater
mpr
urolithiasi
locat
renal
pelvi
bladder
dog
bladder
control
dog
xanthinuria
bilater
mpr
urolithiasi
locat
renal
pelvi
bladder
dog
renal
pelvi
two
control
dog
xanthinuria
bilater
mpr
urolithiasi
locat
bladder
dog
renal
pelvi
dog
suffer
xanthinuria
renal
miner
urolithiasi
treat
low
purin
diet
reduct
xanthinuria
urolith
size
observ
dog
compliant
owner
strict
diet
treatment
mpr
persist
conclus
present
studi
describ
elev
prompt
incid
urinari
advers
effect
associ
allopurinol
treatment
closer
followup
includ
urinalysi
abdomin
ultrasound
mandatori
dog
treat
allopurinol
moreov
accord
result
low
purin
diet
seem
option
reduc
xanthin
deposit
studi
requir
evalu
efficaci
dietari
treatment
accord
author
knowledg
first
prospect
studi
confirm
previou
suspicion
urinari
advers
effect
allopurinol
treatment
dog
leishmaniosi
disclosur
disclosur
report
previou
studi
demonstr
leishmania
infantum
infect
colon
sampl
histiocyt
lymphoplasmacyt
inflamm
seroposit
sick
dog
howev
studi
investig
presenc
l
infantum
infect
dog
diagnos
inflammatori
bowel
diseas
ibd
clinic
histopatholog
examin
object
studi
retrospect
investig
presenc
leishmania
infect
immunohistochemistri
ihc
archiv
canin
colon
biopsi
previous
diagnos
ibd
area
endem
canin
leishmaniosi
well
describ
main
histopatholog
find
total
case
canin
coliti
retrospect
retriev
archiv
biopsi
servei
de
diagn
ostic
de
patologia
universitat
aut
onoma
de
barcelona
inform
regard
clinicopatholog
data
includ
signal
histolog
result
diagnost
test
detect
leishmania
infect
leishmania
ihc
stain
compil
select
case
lymphoplasmacyt
n
histiocyt
n
lymphoplasmacyt
mild
eosinophilicneutrophil
compon
n
coliti
diagnos
januari
septemb
perform
endoscop
colon
biopsi
interestingli
leishmania
ihc
carri
colon
sampl
confirm
exclud
leishmania
infect
base
diagnost
databas
diagnos
granulomat
lymphoplasmacyt
coliti
four
biopsi
classifi
posit
two
unclear
result
due
unspecif
background
stain
rest
neg
leishmania
ihc
leishmania
ihc
perform
remain
colon
sampl
diagnosi
lymphoplasmocyt
histiocyt
inflamm
previous
test
confirm
exclud
infect
due
econom
restrict
colon
sampl
retriev
could
investig
one
colon
biopsi
examin
classifi
posit
ihc
total
dog
diagnos
leishmania
infect
two
dog
present
intens
histiocyt
inflamm
three
dog
show
mild
intens
lymphoplasmacyt
inflamm
number
amastigot
per
microscop
field
view
assess
ihc
variabl
rang
countless
conclus
leishmania
infect
includ
list
differenti
inflammatori
colon
biopsi
leishmania
amastigot
commonli
visual
routin
histolog
stain
therefor
ihc
leishmania
routin
use
diagnost
tool
endem
area
leishmaniosi
exclud
confirm
infect
parasit
patient
diagnosi
ibd
disclosur
disclosur
report
previous
shown
canin
leishmaniasi
canl
caus
sever
myocardi
damag
lead
elev
troponin
ctni
also
previous
shown
myocardi
damag
like
primarili
associ
sever
protozo
diseas
degre
azotemia
anemia
system
arteri
hypertens
remain
determin
howev
whether
myocardi
damag
directli
correl
cardiac
parasit
load
damag
primarili
indirect
mechan
system
inflamm
aim
studi
evalu
compar
concentr
ctni
histopatholog
sever
plasma
creatinin
concentr
cr
parasit
load
within
cardiac
tissu
sampl
cohort
dog
canl
ethic
approv
grant
univers
extremadura
committe
five
dog
without
previou
histori
cardiac
diseas
sever
canl
renal
azotemia
stage
iv
leishvet
scheme
includ
studi
dog
underw
full
physic
examin
hematolog
biochemistri
urinalysi
includ
proteincreatinin
ratio
elisa
serolog
l
infantum
ctni
measur
blood
pressur
abdomin
ultrasound
electrocardiographi
thorac
radiograph
echocardiograph
examin
dog
euthan
due
sever
diseas
underw
postmortem
examin
myocardi
sampl
taken
histopatholog
test
l
infantum
realtimepcr
rtpcr
detect
quantif
kinetoplast
minicircl
dna
elev
ctni
dog
ngml
dog
ngml
dog
ngml
dog
ngml
dog
ngml
median
ngml
iqr
ngml
normal
ngml
cr
dog
mgdl
dog
mgdl
dog
mgdl
dog
mgdl
dog
mgdl
median
mgdl
iqr
mgdl
normal
mgdl
detect
dog
sever
lymphoplasmacyt
myocard
observ
myocardi
sampl
l
infantum
dna
detect
myocardi
tissu
five
dog
rtpcr
assay
perform
sampl
estim
parasit
load
dog
parasitesmg
dog
parasitesmg
dog
parasitesmg
dog
parasitesmg
dog
parasitesmg
median
parasit
mg
iqr
parasitesmg
posit
strong
correl
observ
ctni
parasit
load
p
correl
p
observ
ctni
cr
concentr
result
studi
show
first
time
associ
sever
myocardi
damag
canin
leishmaniasi
sever
myocardi
parasit
load
disclosur
disclosur
report
aim
prospect
studi
investig
bacteremia
puppi
enter
attribut
canin
parvoviru
infect
blood
sampl
obtain
cultur
puppi
parvovir
enter
group
age
month
prior
treatment
admiss
time
hour
later
time
day
sudden
deterior
discharg
time
thirteen
healthi
puppi
group
age
month
select
control
sampl
blood
cultur
dog
elig
inclus
group
accord
clinic
clinicopatholog
abnorm
incomplet
vaccin
canin
parvovir
enter
presenc
cpv
antigen
rapid
immunoassay
dna
realtim
pcr
fece
group
dog
healthi
physic
examin
complet
blood
count
serum
biochemistri
urinalysi
abdomin
ultrasonographi
buffi
coat
cytolog
test
neg
cpv
antigen
dna
fece
anim
receiv
antimicrobi
week
prior
inclus
studi
blood
sampl
dog
asept
obtain
jugular
vein
timepoint
place
pediatr
cultur
bottl
ship
laboratori
immedi
blood
cultur
perform
bactec
blood
cultur
instrument
becton
dickinson
use
pediatr
ped
bottl
isol
posit
blood
cultur
identifi
speci
level
vitek
autom
system
biomerieux
franc
standard
treatment
includ
intraven
administr
fluid
maropit
metoclopramid
ampicillin
enrofloxacin
group
dog
surviv
discharg
escherichia
coli
isol
dead
dog
klebsiella
pneumonia
blood
cultur
neg
nine
survivor
blood
cultureneg
present
asymptomat
bacteremia
day
discharg
k
pneumonia
enterobact
cloaca
respect
repeat
blood
cultur
latter
day
postdischarg
antimicrobi
administ
neg
median
durat
hospit
group
day
rang
day
blood
cultur
group
neg
limit
data
exist
regard
blood
cultur
result
puppi
natur
infect
e
coli
enterobact
spp
k
pneumonia
previous
report
cultur
intraven
cathet
dog
parvovir
enter
e
coli
also
recov
blood
case
best
knowledg
first
prospect
studi
monitor
bacteri
blood
cultur
longitudin
dog
disclosur
disclosur
report
data
serum
proteom
clinic
anim
modif
proteom
thu
aim
present
studi
identifi
potenti
serum
biomark
diagnosi
anaplasmosi
lyme
diseas
use
proteom
approach
pool
serum
sampl
dog
natur
infect
phagocytophilum
b
burgdorferi
infect
agent
collect
treatment
compar
control
group
anaplasmosi
lyme
diseas
diagnos
base
specif
igg
igm
antibodi
titer
serum
creactiv
protein
ferritin
level
infect
dog
higher
p
control
twodimension
electrophoresi
pool
sampl
run
triplic
imag
analysi
show
differenti
express
spot
infect
anim
control
compar
healthi
control
vitamin
dbind
protein
decreas
haptoglobin
ig
chain
differ
spot
increas
diseas
serum
level
decreas
dog
lyme
express
differenti
dog
anaplasmosi
dual
infect
concentr
vitamin
dbind
protein
albumin
decreas
wherea
alpha
glycoprotein
haptoglobin
ig
chain
increas
compar
control
studi
result
show
mani
protein
might
chang
vbd
could
use
biomark
diagnosi
pathophysiolog
treatment
strategi
understand
role
protein
mani
biolog
process
acut
phase
respons
immunolog
reaction
transport
oxid
stress
apoptosi
calcium
iron
lipid
metabol
blood
coagul
cascad
provid
advantag
diagnost
therapeut
approach
clinic
set
disclosur
disclosur
report
distemp
infecti
canin
hepat
parvovirosi
lifethreaten
diseas
due
respect
canin
distemp
viru
cdv
canin
adenoviru
viru
cav
canin
parvoviru
cpv
mainten
serolog
respons
post
vaccin
often
use
evalu
protect
statu
dog
howev
live
vaccin
stimul
mainli
cellmedi
pathway
immun
system
method
may
underestim
real
durat
efficaci
vaccin
studi
aim
evalu
efficaci
attenu
cdv
cav
cpv
strain
multival
canigen
tm
dhppil
vaccin
virbac
franc
experiment
infect
perform
three
year
first
annual
booster
forti
seven
spf
beagl
puppi
male
femal
particip
studi
puppi
alloc
either
vaccin
group
group
n
unvaccin
group
group
n
puppi
group
receiv
canigen
tm
dhppil
vaccin
formul
minimum
titer
live
compon
primari
vaccin
two
inject
threeweek
interv
respect
week
age
first
annual
booster
blood
sampl
taken
sever
occas
serolog
followup
cdv
antibodi
titer
measur
seroneutr
test
sn
vaccin
sn
antibodi
titer
cdv
variant
consid
posit
three
year
first
annual
booster
dog
group
administ
either
pathogen
cdv
n
n
n
strain
follow
appear
typic
sign
relat
diseas
day
vaccin
dog
lowest
sn
titer
select
receiv
pathogen
agent
group
puppi
seroconvert
primari
vaccin
cours
year
first
annual
booster
sn
antibodi
still
present
dog
dog
cdv
experiment
infect
typic
sign
distemp
infecti
hepat
lead
death
observ
respect
nonvaccin
dog
none
vaccin
dog
respect
n
n
typic
sign
parvovirosi
includ
cpv
viral
shed
observ
nonvaccin
dog
conclus
experiment
studi
demonstr
protect
distemp
infecti
canin
hepat
parvovirosi
last
least
three
year
annual
vaccin
booster
canigen
tm
dhppil
vaccin
disclosur
disclosur
report
author
employe
virbac
aim
studi
compar
kill
canin
urinari
pathogen
antimicrobi
agent
clinic
relev
drug
concentr
approxim
coloni
form
unitsmillilit
canin
isol
strain
escherichia
coli
ec
enterobact
faecali
ef
proteu
mirabili
pm
staphylococcu
pseudintermediu
sp
expos
maximum
serum
c
max
maximum
urin
u
max
concentr
drug
lt
percent
kill
measur
minut
drug
exposur
measur
triplic
averag
data
point
base
averag
valu
ie
triplic
strain
exposur
ec
c
max
cp
tmxsmx
mr
pr
result
lt
lt
ly
lt
kill
follow
minut
drug
exposur
u
max
lt
growth
lt
lt
lt
kill
follow
minut
drug
exposur
follow
minut
drug
exposur
u
max
kill
seen
cp
growth
tmp
smx
exposur
pm
c
max
cp
tmpsmx
mr
pr
result
kill
growth
respect
follow
min
drug
exposur
u
max
kill
observ
follow
min
drug
exposur
exposur
sp
c
max
cp
tmpsmx
mr
pr
result
kill
follow
minut
drug
exposur
u
max
kill
seen
respect
follow
minut
drug
exposur
exposur
ef
u
max
tmpsmx
mr
pr
result
growth
kill
respect
follow
minut
drug
exposur
kill
bacteri
pathogen
necessari
clinic
cure
rapid
complet
kill
influenc
durat
therapi
mr
pr
rapidli
complet
kill
urinari
pathogen
cp
tmpsmx
observ
may
import
clinic
empir
antimicrobi
treatment
canin
urinari
tract
infect
consist
antimicrobi
stewardship
goal
disclosur
disclosur
report
unrestrict
research
grant
bayer
anim
health
canin
monocyt
ehrlichiosi
cme
major
tickborn
diseas
worldwid
diagnosi
cme
challeng
patient
may
present
variabl
often
nonspecif
clinic
sign
associ
differ
stage
infect
coinfect
ehrlichia
cani
etiolog
agent
diagnosi
cme
gener
support
detect
e
cani
antibodi
either
indirect
questionnair
use
studi
clinic
relat
factor
might
influenc
amu
companion
anim
veterinarian
antimicrobi
usag
data
convert
number
defin
daili
dosag
ddd
standard
dutch
databas
built
purpos
number
ddd
specifi
period
mostli
year
repres
number
day
period
averag
dog
cat
rabbit
clinic
treat
ddd
differenti
first
select
esbl
second
might
select
esbl
third
choic
critic
import
public
health
ie
thirdand
fourthgener
cephalosporin
fluoroquinolon
result
show
amu
decreas
last
year
signific
decreas
use
third
choic
antimicrobi
statist
analys
perform
explor
associ
ddd
clinic
characterist
eg
number
veterinarian
work
clinic
rural
versu
urban
clinic
number
dog
cat
rabbit
treat
clinic
disclosur
disclosur
report
studi
fund
zonmw
netherland
organ
health
research
develop
project
number
campylobact
jejuni
c
jejuni
common
caus
clinic
campylobacteriosi
peopl
denmark
incid
human
campylobacteriosi
constant
despit
signific
reduct
food
born
case
last
coupl
year
indic
role
sourc
infect
aim
studi
follow
examin
preval
c
jejuni
famili
dog
younger
year
age
copenhagen
denmark
identifi
risk
factor
associ
carriag
c
jejuni
examin
associ
carriag
c
jejuni
clinic
sign
diarrhea
crosssect
studi
dog
younger
year
present
univers
hospit
companion
anim
univers
copenhagen
denmark
carri
may
novemb
sampl
collect
rectal
swab
store
charcoal
medium
maximum
h
cultur
posit
sampl
verifi
use
phase
contrast
microscopi
whole
genom
sequenc
dog
owner
complet
questionnair
regard
manag
dog
data
analyz
use
chisquar
test
multivari
analys
spss
statist
p
consid
signific
dog
includ
preval
c
jejuni
primari
feed
bone
raw
food
barf
p
regular
feed
dri
meat
p
signific
risk
factor
campylobact
carriag
dog
younger
year
age
fed
barf
andor
dri
meat
greater
risk
carri
campylobact
dog
older
year
age
feed
routin
associ
posit
c
jejuni
statu
concurr
diarrhea
swim
sea
lake
water
abroad
live
pet
children
famili
dog
act
reservoir
c
jejuni
raw
feed
increas
risk
carriag
c
jejuni
dog
may
pose
zoonot
risk
human
disclosur
disclosur
report
depart
veterinari
clinic
scienc
univers
copenhagen
grant
dkr
euro
danish
food
administr
perform
studi
hospit
acquir
infect
hai
import
caus
morbid
potenti
mortal
increas
concern
role
multidrug
resist
mdr
organ
hai
surfac
includ
stethoscop
could
act
fomit
howev
current
consensu
decontamin
protocol
furthermor
increas
concern
regard
develop
bacteri
resist
topic
appli
antisept
agent
lead
evalu
innov
decontamin
method
purpos
project
evalu
type
bacteri
contamin
stethoscop
referr
hospit
set
compar
effect
three
decontamin
protocol
studi
prospect
intervent
base
upon
avail
inform
sampl
size
thirti
stethoscop
per
group
calcul
adequ
determin
differ
protocol
three
decontamin
protocol
use
crossov
design
across
six
week
period
decontamin
protocol
includ
isopropyl
alcohol
quaternari
ammonium
biguanid
disinfect
anistel
exposur
uv
light
nm
diaphragm
membran
stethoscop
sampl
use
steril
cottontip
swab
moisten
pb
coloni
number
determin
bacteri
identif
perform
collect
time
point
stethoscop
regular
clinic
circul
group
comparison
deltachang
valu
coloni
count
determin
stethoscop
differ
group
analyz
use
nonparametr
analysi
varianc
kruskalw
test
differ
return
group
posthoc
analysi
dunn
multipl
comparison
method
perform
identifi
differ
occur
varieti
bacteri
type
cultur
across
cours
studi
mdr
bacteria
isol
differ
delta
chang
valu
comparison
made
decontamin
protocol
p
referr
set
stethoscop
contamin
mdr
bacteria
present
differ
group
regard
expect
reduct
bacteri
coloni
count
uv
light
appear
equival
topic
solut
reduc
contamin
rate
stethoscop
disclosur
disclosur
report
canin
babesiosi
tickborn
protozo
diseas
affect
dog
worldwid
accord
previou
studi
b
cani
consid
main
speci
involv
canin
babesiosi
recent
year
studi
show
exist
babesia
gibsoni
infect
dog
europ
romania
b
gibsoni
infect
dog
mainli
describ
american
pit
bull
terrier
although
signific
breed
predisposit
yet
fulli
understood
howev
possibl
bloodtoblood
transfer
transplacent
infect
consid
possibl
modal
host
contamin
year
old
femal
american
staffordshir
terrier
refer
clinic
previous
diagnos
babesia
cani
infect
treat
one
dose
imidocarb
dipropion
three
day
prior
dog
present
fever
pale
mucou
membran
hemoglobinuria
complet
blood
count
reveal
sever
anemia
hct
hg
gdl
rbc
l
thrombocytopenia
plt
l
mild
leukocytosi
neutrophilia
coomb
test
alvedia
rapid
test
dirofilaria
immiti
antigen
ehlichia
cani
antigen
borrelia
burgdoferi
antigen
anaplasma
phogocytophilumanaplasma
plati
antibodi
rapid
test
kit
bionot
show
neg
result
giemsastain
blood
film
posit
small
pleomorph
inclus
babesia
spp
dna
detect
polymeras
chain
reaction
pcr
assay
molecular
character
sampl
show
involv
babesia
gibsoni
macrogen
europ
amsterdam
follow
molecular
identif
babesia
gibsoni
combin
therapi
initi
clindamycin
mgkg
po
bid
doxycyclin
mgkg
po
bid
metronidazol
mgkg
po
bid
fourteen
day
therapi
hb
hct
rbc
plt
valu
increas
blood
sampl
test
posit
b
gibsoni
pcr
therapi
ceas
week
hct
reach
pcr
show
complet
bgibsoni
infect
steril
patient
blood
sampl
test
three
six
month
initi
treatment
remain
neg
b
gibsoni
sinc
femal
week
postpartum
time
babesiosi
diagnost
establish
four
sampl
two
differ
litter
pup
test
found
neg
bgibsoni
although
transplancet
transmiss
possibl
bgibsoni
infect
accur
diagnosi
import
dog
present
hemolyth
anemia
bgibsoni
resist
tradit
antibabesi
therapi
combin
therapi
may
effici
order
reduc
elimin
parasitemia
disclosur
disclosur
report
cytauxzoon
feli
emerg
ticktransmit
protozoan
parasit
domest
wild
felid
cytauxzoonosi
typic
fatal
clinic
case
without
aggress
treatment
combin
treatment
atovaquon
azithromycin
along
support
care
improv
surviv
rate
contrast
surviv
rate
imidocarb
dipropion
parasit
resist
atovaquon
via
cytochrom
b
parasit
gene
cytb
mutat
identifi
protozoan
concern
c
feli
specif
mutat
amino
acid
posit
put
atovaquon
bind
site
cytb
associ
resist
aim
character
atovaquon
bind
region
cytb
sampl
c
felisinfect
domest
cat
remain
parasitem
despit
treatment
atovaquon
azithromycin
approxim
nineyear
femal
spay
domest
shorthair
present
adopt
assess
cat
anem
persist
despit
fenbendazol
doxycyclin
treatment
comprehens
infecti
diseas
test
detect
c
feli
via
microscopi
polymeras
chain
reaction
pcr
atovaquon
mgkg
po
h
day
azithromycin
mgkg
po
h
day
treatment
administ
pcv
improv
cat
remain
persist
infect
c
feli
sequenc
atovaquon
bind
region
cytb
cours
infect
pre
posttreat
sampl
would
reveal
transit
wildtyp
isoleucin
valin
two
four
month
post
treatment
repeat
treatment
cours
use
increas
atovaquon
dose
mgkg
po
h
day
would
fail
clear
c
feli
infect
mutat
persist
wildtyp
cytb
detect
posttreat
sampl
day
first
document
resist
c
feli
atovaquon
associ
cytb
mutat
addit
carrier
cat
appear
first
chronic
c
felisinfect
felid
persist
anemia
case
suggest
parasit
mutat
cytb
select
impart
resist
treatment
even
face
increas
atovaquon
dose
disclosur
disclosur
report
orthopoxviru
opxv
genu
famili
poxvirida
subfamili
chordopoxvirina
includ
sever
virus
infect
human
anim
among
ectromelia
viru
ectv
infect
mice
cowpox
viru
cpxv
recogn
wild
rodent
reservoir
sever
speci
includ
human
cat
consid
incident
host
report
case
lethal
infect
cat
caus
put
novel
opxv
display
intermedi
posit
cpxv
ectv
genom
level
cat
european
male
present
wide
alopec
erythemat
area
face
paw
day
skin
lesion
spread
area
bodi
ulcer
appear
tongu
palat
diagnosi
opxv
infect
cat
treat
antivir
famciclovir
subsequ
aciclovir
initi
improv
anim
rapidli
worsen
euthan
bioptic
sampl
collect
intravitam
skin
lesion
process
histolog
virolog
investig
histopatholog
leukocyt
infiltr
eosinophil
cytoplasm
inclus
bodi
evid
skin
punch
differ
pcr
approach
detect
character
poxvirus
show
collect
sampl
contain
poxviru
unabl
assign
definit
viru
speci
within
genu
orthopoxviru
opxv
strain
isol
african
green
monkey
kidney
cell
also
embryon
egg
demonstr
develop
typic
pock
chorioallanto
membran
larg
amount
typic
brickshap
virion
approxim
nm
size
morpholog
relat
genu
orthopoxviru
observ
neg
stain
electron
microscopi
nearli
fulllength
genom
viru
obtain
nextgener
sequenc
approach
carri
isol
viru
sequenc
phylogenet
analysi
select
genom
region
commonli
use
classifi
opxv
isol
proven
form
separ
cluster
cpxv
ectv
extens
epidemiolog
surveil
cat
wild
anim
includ
rodent
assess
whether
felin
opxv
circul
domest
cat
popul
whether
cat
incident
host
repres
main
reservoir
viru
disclosur
disclosur
report
dissemin
esbl
carbapenemas
produc
klebsiella
pneumonia
worldwid
concern
multidrugresist
mdr
k
pneumonia
uti
companion
anim
rais
great
concern
regard
role
reservoir
spread
bacteria
aim
studi
evalu
withinhousehold
share
esblproduc
mdr
k
pneumonia
uti
infect
cat
antimicrobi
suscept
test
uropathogen
bacteria
conduct
microdilut
method
accord
clsi
screen
presenc
ctxm
esbl
perform
pcr
sequenc
fecal
sampl
infect
cat
icat
cohabit
pet
collect
detect
quantif
colon
infect
k
pneumonia
strain
environ
swab
anim
foodwat
bowl
bed
also
collect
sampl
serial
dilut
cultur
macconkey
agar
plate
contain
lg
ml
cefotaxim
ctx
neg
sampl
grown
enrich
media
prior
plate
detect
low
level
colon
posit
five
k
pneumonia
coloni
obtain
analysi
uniqu
clone
resolv
pfgexbai
macrorestrict
use
diceupgma
cluster
analysi
cat
histori
urolithias
underw
subcutan
ureter
bypass
system
sub
implant
sub
mainten
uti
k
pneumonia
diagnos
k
pneumonia
produc
mdr
phenotyp
fecal
sampl
infect
cat
icat
posit
ctxresist
k
pneumonia
sampl
prior
icat
treatment
neg
thu
colon
detect
regard
one
sampl
collect
possibl
icat
treatment
yet
reveal
high
fecal
burden
ctxresist
e
coli
k
pneumonia
pfgexbai
analysi
show
similar
index
ctxresist
k
pneumonia
fece
k
pneumonia
icat
urin
thu
prove
colonizationtransf
furthermor
similar
ctxresist
k
pneumonia
also
detect
cat
bed
best
knowledg
first
studi
report
share
mdr
k
pneumonia
infect
healthi
pet
household
samespeci
transfer
mdr
k
pneumonia
like
due
share
litterbox
bed
thu
special
control
measur
implement
environ
high
colon
enterobacteriacea
cohabit
healthi
cat
increas
spread
mdr
k
pneumonia
acknowledg
assess
liver
fibrosi
major
import
treatment
prognosi
canin
chronic
liver
diseas
panel
blood
score
current
use
human
medicin
combin
sever
biochem
paramet
proprietari
algorithm
test
help
clinician
stage
monitor
liver
diseas
therebi
decreas
need
liver
biopsi
alreadi
built
blood
score
use
train
set
dog
score
use
alanin
aminotransferas
alkalin
phosphatas
total
bilirubin
potassium
gamma
glutamyl
transferas
blood
score
sensit
specif
respect
auroc
ci
aim
present
studi
valid
blood
score
perform
new
popul
follow
ethic
committe
approv
inform
owner
consent
clientown
dog
year
old
underw
liver
biopsi
investig
abnorm
liver
enzym
activ
includ
exclus
criteria
focal
liver
lesion
andor
extrahepat
cholestasi
abdomin
ultrasound
previou
medic
extrahepat
comorbid
diseas
could
influenc
liver
enzym
activ
diagnosi
neoplasia
histolog
examin
fast
blood
sampl
collect
day
liver
biopsi
liver
fibrosi
evalu
accord
criteria
world
small
anim
veterinari
associ
guidelin
canin
liver
patholog
dog
classifi
follow
portal
fibrosi
group
bridg
fibrosi
cirrhosi
group
thirtyeight
dog
recruit
femal
male
group
group
valid
popul
blood
score
discrimin
dog
signific
fibrosi
auroc
curv
valid
protocol
demonstr
similar
perform
train
valid
popul
blood
score
develop
studi
design
help
clinician
screen
dog
liver
fibrosi
order
guid
investig
test
provid
accur
reliabl
result
fast
simpl
costeffect
manner
extern
valid
protocol
need
assess
robust
test
disclosur
disclosur
report
author
declar
potenti
conflict
interest
compani
echosen
develop
blood
score
describ
studi
echosen
support
part
resid
fund
present
author
increas
serum
bile
acid
sba
expect
hepat
biliari
portal
disord
limit
hepat
portal
blood
flow
hepatocellular
uptak
best
clinicopatholog
test
detect
disord
remain
controversi
result
pair
sba
preand
postfeed
retrospect
review
sampl
obtain
anim
undergo
bile
acid
ba
test
suspect
liver
diseas
two
veterinari
hospit
aim
determin
frequenc
alter
valu
fast
postprandi
pair
sba
evalu
clinic
approach
would
differ
depend
select
test
sba
sent
outsid
laboratori
idexx
barcelona
measur
spectrophotometri
normal
fast
valu
lmoll
differ
cutoff
lmoll
also
evalu
postprandi
valu
lmoll
studi
includ
sampl
dog
cat
femal
male
median
age
year
three
felin
breed
canin
breed
includ
twohundr
fiftytwo
pair
sba
test
consid
abnorm
among
fast
sampl
show
valu
lmoll
sampl
lmol
sampl
lmoll
postprandi
sampl
lmoll
test
one
ba
valu
alter
abnorm
valu
detect
fast
valu
test
postprandi
valu
test
patient
fast
postprandi
valu
increas
among
anim
fast
valu
rang
increas
postprandi
valu
test
fast
valu
lower
postprandi
valu
test
show
higher
fast
ba
valu
author
recent
suggest
fast
ba
use
screen
test
straten
studi
corrobor
higher
valu
pair
sba
purpos
previous
confirm
other
center
fast
ba
perform
higher
cut
select
lmoll
suggest
author
case
fast
valu
rang
abnorm
postprandi
valu
would
miss
therefor
normal
fast
valu
lmoll
seem
appropri
moreov
postprandi
valu
increas
often
fast
valu
therefor
one
ba
perform
postfeed
could
prefer
test
fast
valu
exceed
postprandi
sampl
occur
shown
test
studi
although
spontan
gall
bladder
contract
may
respons
valu
abnorm
hepat
abnorm
suggest
lawrenc
disclosur
disclosur
report
